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Abstract 
Muscular dystrophy (MD) is a set of progressive muscle wasting conditions characterised by 
progressive muscle weakness and limited range of motion (ROM). Current evidence of these 
clinical features, their associations and impacts on quality of life (QoL) are however, largely 
focussed on children with Duchenne MD (DMD). By comparison, quantified evidence of these 
features remains limited in adults with Becker’s MD (BMD), Limb-Girdle MD (LGMD) and 
Facioscapulohumeral MD (FSHD), and unreported in adults with DMD. Current guidance on 
living with MD encourages physical activity (PA) and physiotherapy as methods to maintain 
health and function, however the understanding of PA and the effectiveness of 
physiotherapy, remains limited in its reporting in adults with MD. Therefore, the aim of this 
thesis was to quantify lower limb strength and ankle ROM in adults with MD, identify the 
associations of these clinical features and the impact of muscle weakness on QoL, measure 
the effectiveness of physiotherapy on ROM, and quantify the progression of muscle 
weakness, in adults with MD. Healthy adult controls (CTRL) were shown to have greater 
maximal voluntary contraction (MVC) of plantar-flexion (PFMVC) and knee extension 
(KEMVC), ROM measures of passive ROM (ROMPassive) and active ROM (ROMActive) than adults 
with DMD (75%, 92%, 66%, 82%), BMD (51%, 41%, 34%. 55%), LGMD (58%, 53%, 45%, 60%) 
and FSHD (35%, 25%, 35%, 56%). KEMVC and PFMVC were positively associated with 10m 
walk time in ambulant adults with MD (r= 0.484 and r= 0.502), and PFMVC was associated 
with ROMActive in all adults with MD (r= 0.376-.750). Strength (KEMVC) was positively 
associated with only two domains of QoL, in BMD (r= 0.544 and r= 0.609). By comparison, 
activities of daily living (positively), self-efficacy (positively), pain (negatively) and fatigue 
(negatively) were more consistently associated with QoL in adults with MD. The stiffness 
properties of the Gastrocnemius Medialis (r= -0.494) and muscle tendon unit (MTU) (r= -
xv 
 
0.464) were both negatively associated with ROMPassive in BMD and DMD, respectively. 
Physiotherapy was shown as effective for acutely improving ROMPassive (19%) and decreasing 
MTU stiffness (-27%), in adults with DMD. PA was shown to explain both the variance in 10m 
walk time in ambulant adults with MD (R2 = 0.540), and the change in lower limb strength 
over 12 months in adults with BMD (PFMVC, R2 = 0.585; KEMVC, R2 = 0.532). Change in lower 
limb muscle strength in adults with DMD was reported as -19% PFMVC and -14% KEMVC per 
year. Evidence from this thesis suggests in ambulant adults with MD PA is an important 
measure to promote to help maintain lower limb strength and function. While in non-
ambulant adults with MD a shift in focus to measures of pain and fatigue is required, and that 
there is some benefit from physiotherapy on the ROMPassive of the ankle in DMD, likely due to 
reductions in the stiffness properties of the MTU. 
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Chapter 1 
An Introduction to Muscular Dystrophy 
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1.1 Introduction 
Muscular dystrophy (MD) is an umbrella term for a set of myopathic conditions characterised 
by their progressive muscle wasting nature, leading to loss of ambulation, impaired muscle 
strength and range of motion (ROM) (Huml, 2015). An estimated 70,000 people in the UK are 
classified as having a form of MD (Emery, 1991). There are 9 main forms of MD, which are 
classified dependant on their genetic defect, however characterised on the extent and 
distribution of muscle weakness, age of onset, rate of progression and severity (Emery, 1991; 
Emery, 2002). This thesis focusses on four of the most common classifications of MD, 
Duchenne MD (DMD), Becker’s MD (BMD), Limb-Girdle MD (LGMD) and Facioscapulohumeral 
MD (FSHD). These four classifications of MD, represent the MDs that influence the proteins 
expressed in the sarco-glycan complex (Huml, 2015). In comparison to the sarco-glycan 
dystrophies investigated in the present thesis, other MDs are asosociated with genetic defects 
affecting the muscle nuclear envelope (Emery-Dreyfus MD)(Bonne et al., 1999), or nuclear 
structure (Congential MD) (Barateau et al., 2017), or only effect the eyes, with no influence 
on appendicular skeletal muscle function (oculopharengeal MD) (Victor et al., 1962). 
Myotonic dystrophy (DM), which is the most common form of MD (Emery, 1991), is however 
not dicussed during this thesis. DM has been extensively researched (Johnson et al., 1995; 
Harper, 2009; Lindeman et al., 1998). Genetically, DM is associated with the expression of 
protein kinase and not impairments of the sarco-glycan complex (Brook et al., 1992), and DM 
uniquely presents with myotonia unlike any of the other forms of MD presented in this thesis 
(Turner and Hilton-Jones, 2010; Moxley III et al., 2007). In addition, other forms of MD than 
those addressed in this thesis (DMD, BMD, LGMD and FSHD, see table 1.1) are less common, 
and it would have been impossible to recruite sufficent samples sizes from these rare forms 
of MD. 
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1.2 Incidence, Genetic Presentation and Classification of Conditions 
DMD, incidence 3:100,000 (Table 1.1 (Deenen et al., 2015)) and BMD, incidence 2:100,000 
(Table 1.1 (Deenen et al., 2015)), are both caused by a deletion or mutation in the coding for 
the Dystrophin protein, a large structural protein associated with sarcolemma stability 
(Deconinck and Dan, 2007). Mutations resulting in non-functional dystrophin lead to DMD, 
while partly functional proteins of abnormal size or shape result in BMD (Emery et al., 2015). 
The degeneration of muscle from dystrophin deficiency remains unclear, however current 
theories suggest loss of dystrophin results in increased mechanical stress from sarcolemma 
destabilisation (Ervasti et al., 1990; Petrof, 1998) and increased calcium influx, causing 
proteases such as calpains to become activated (Deconinck and Dan, 2007; Morandi et al., 
1990). DMD is typically diagnosed by the age of 5 through muscle biopsy and genetic testing, 
following presentation of symptoms such as a lack of co-ordination and abnormal gait; most 
individuals become non-ambualtory by the age of 10 (C. McDonald, R. Abresch, et al., 1995). 
BMD is typically identified at a later age than DMD, with some less severe individuals not 
identified until adulthood (C. M. McDonald et al., 1995). Muscle weakness is throughout the 
whole body in DMD and BMD, and progressive by nature, with DMD typically the fastest and 
most progressive MD condition (Huml, 2015). BMD is slower progressing, with the rate of 
decline dependant on the extent of dystrophin protein present (Bello et al., 2016).  
LGMD, incidence 3:100,000 (Table 1.1 (Deenen et al., 2015)), is the most heterogenous form 
of MD, with various different genetic types. Despite the genetic sub-classifications of LGMD, 
all are charecterised by weakness of the hip and shoulder girdles (Bushby, 1999). LGMDs are 
numbered by their inheritance pattern, as either autosomal dominant (LGMD1) or autosomal 
recessive (LGMD2), then subcategorised further into an alphabetical system, of order of 
discovery (eg. LGMD1A was mapped before LGMD1B) (Guglieri et al., 2008). It is worth 
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nothing that as physical manifestations and functional impairments are described as similar 
for all LGMDs (Emery, 2002), and for the sake of ensuring consistency with previous 
descriptions of LGMD (C. McDonald, R. Johnson, et al., 1995; Morse, 2016; Morse et al., 2018), 
for this thesis sub-classifcations of LGMD have been grouped, and hereafter are referred to 
as LGMD only. 
FSHD, incidence 4:100,000 (Table 1.1 (Deenen et al., 2015)), is a classification which is named 
after the muscles that are first affected, i.e. the facial and shoulder girdle muscles, with 
muscle weakness progressing to proximal muscles (Padberg, 2009). Similar to LGMD, FSHD 
can be split into autosomal dominant (FSHD1) and autosomal recessive (FSHD2) (Sacconi et 
al., 2015). Both FSHD1 and FSHD2 result from incorrect expression of DUX4 in differentated 
tissues, however the pathophysiological mechanism remains undefined (Tawil, 2008). As with 
LGMD, for this thesis FSHD1 and FSHD2 have been grouped, and hereafter are termed FSHD. 
Table 1.1 Mean prevalance rate of muscular dystrophy classifications. 
 
 
 
 
Table 1.1. Mean prevalance rate of Muscular Dystrophy classifications. MD = Muscular 
Dystrophy (Deenen et al., 2015) 
Condition Mean prevalence rate (per 
100,000) 
Duchenne MD 3 
Becker’s MD 2 
Facioscapulohumeral MD 4 
Limb-Girdle MD 3 
Emery Dreifuss Dystrophy 0.3 
Oculopharyngeal MD 0.1 
Myotonic Dystrophy 10 
Congenital MD 0.8 
Non-dystrophic myotonia 1 
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1.3 Clinical and functional presentation of the MD conditions, the 
classical perspective. 
The following sections briefly outline some of the key outcome measures commonly used to 
describe the severity and progression of MD. These outcome measures are described in 
further detail throughout the thesis where relevant. 
1.3.1 Muscle Strength 
The degenerative nature of MD is commonly associated with progressive muscle weakness 
and limited ROM (Bakker et al., 2002; Yılmaz et al., 2004; Gaudreault et al., 2009; Hyde et al., 
2000). Emery (2002) presented the classical understanding of muscle weakness in MD, with 
muscle weakness presented as whole body in DMD and BMD, while FSHD and LGMD by 
definition presented with muscle weakness affecting the face/scapula/calves and limb girdles, 
respectively (Figure 1.1: A = DMD and BMD, B = LGMD, C = FSHD). Ambulation is typically lost 
from the age of 12 in DMD and between the ages of 20-40 in BMD, while the severity, 
progression and age of onset typically determining ambulatory status in FSHD or LGMD (C. M. 
McDonald et al., 1995; C. McDonald, R. Abresch, et al., 1995; C. McDonald, R. Johnson, et al., 
1995; Kilmer et al., 1995). The progressive muscle weakness and muscle wasting observed in 
all of these conditions results in an impaired ability to perform functional tasks such as the 
10m walk, rise from the floor and stair climbing (Mathur et al., 2010; Alfano et al., 2013). PA 
is promoted as a measure to maintain muscle mass and function within MD (Muscular 
Dystrophy Campaign, 2014). Muscle strength is presented cross-sectionally in Chapter 4 and 
longitudinally in Chapter 8 as a primary outcome measure, and in chapters 5-7 as a secondary 
outcome measure, due to its significance as a defining clinical feature of MD.  
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Figure 1.1. Classical Presentation of Muscle Weakness in MD. A = DMD and BMD, B = LGMD, 
C = FSHD. (Emery, 2002). 
1.3.2. Muscle Morphology 
As with progressive muscle weakness, the patterns of muscle mass loss are reflected and 
consistent (and commonly described) as in Figure 1.1. The patterns of muscle mass loss 
depicted in Figure 1.1 however are reflective of contractile tissue loss, as the size of the 
muscle mass (volume of material within the muscle membrane) may not match the decline 
of the contractile area. Within DMD for example, there is evidence of whole-body loss of 
muscle mass with ageing, consistent with the condition being described as “muscle wasting” 
(Shimizu-Fujiwara et al., 2012). Within the calf muscles of children with DMD however, is an 
increased muscle size with no relative increase in muscle strength termed psuedohypertrophy 
(Mathur et al., 2010; Vohra et al., 2015; Jones et al., 1983). Psuedohypertrophy, and the 
presentation of increased size of the calf muscles, is one of the most defining clinical features 
B C 
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associated with DMD, and in accordance with abnormal gait, is one of the earliest indicators 
of DMD (Huml, 2015). Psuedohypertrophy has been attributed to increased muscle damage, 
necrotic processes of muscle degeneration leads to the muscle trying to repair itself, and an 
inflammatory response (Deconinck and Dan, 2007) resulting in increased calf size (Beenakker 
et al., 2002). These necrotic and degenerative processes within the muscle lead to a 
replacement of contractile tissue with non-contractile tissue (Akima et al., 2012). Increased 
calf size has also been reported in BMD (Jacques et al., 2017), and described as common in 
LGMD (Bushby, 1999), however it is not seen as a classic presentation in FSHD. Scapular 
winging however is a common characteristic within FSHD, resultant from weakness of the 
Serratus Anterior (Giannini et al., 2006). It should be noted, that despite pseudohypertrophy 
being reported at the whole muscle level in DMD and BMD, reductions in contracile area with 
an accumulation of non-contractile material have been reported in children with DMD (Vohra 
et al., 2015; Jones et al., 1983) and adults with BMD, LGMD and FSHD (Gerevini et al., 2016; 
Løkken et al., 2016). Given that muscle morphology is a clinical feature identified within 
children with DMD, but also as a limitation of ROM in healthy adults, within this thesis muscle 
morphology is investigated in Chapter 4, 6 and 8. 
1.3.3 Physical Activity 
PA and exercise within the general population are recommended in order to maintain and 
improve muscle strength, general wellbeing and quality of life (QoL) (Chastin et al., 2011; Bize 
et al., 2007). Historically, individuals with MD had been advised to avoid PA, for fear of 
exacerbating muscle damage and increasing progression of the conditions (Siciliano et al., 
2015). This was due to primary studies into exercise in animal models, specifically MDX mice, 
which showed increased muscle damage following exercise (Brussee et al., 1997). More 
recently, individuals with MD have been advised to partake in low-intensity PA in order to 
8 
 
maintain muscle integrity (Campaign, 2014). Therefore, although recommended, the 
implications of PA and sedentary behaviour (SB) in adults with MD are currently poorly 
understood and are investigated in Chapters 4 and 8. 
1.3.4 Range of Motion 
Limited passive ROM (ROMPassive) is often present within MD, especially in children with DMD 
(Archibald and Vignos Jr, 1959), however it has been argued whether limited ROM is a direct 
characteristic of DMD, or as a direct result from decreased muscle strength (C. McDonald, R. 
Abresch, et al., 1995). Loss of ability to actively move through joint ROM (ROMActive), as well 
as static positioning of joint and fibrotic changes in muscle tissue have all been proposed as 
causes of ROM loss (Bushby et al., 2010). Similarly, following immobilisation and/or muscle 
weakness, joints such as the ankle can adapt to “gravity-assisted” positions and therefore stay 
in plantar-flexion (PF) and display limited dorsi-flexion (DF) capabilities, commonly termed 
equinus deformity (Williams et al., 1984). Within less severe conditions, FSHD, LGMD, and 
some forms of BMD, limited ROM has been reported following the loss of ambulation (Kilmer 
et al., 1995; C. M. McDonald et al., 1995; C. McDonald, R. Johnson, et al., 1995). Limited ROM 
has previously been shown to increase fall risk in ambulant individuals, and cause pain, impair 
sleep quality, and therefore QoL, in other clinical conditions. Therefore it is important to 
understand the presentation and limitations of ROM in adults with MD. Limited ROM, as a 
clinical feature of MD, is investigated in Chapter 6, along with its associations with muscle 
morphology, stiffness and weakness.  
1.3.5 Quality of Life 
QoL represents an individual’s perception of their physical, mental and social functioning 
(Brazier et al., 1992), and is a meaningful measure of how a clinical condition may impact an 
individual. Given the declining muscle strength, and typical loss of independence, associated 
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with MD, it is theorised that QoL would likely decrease with condition progression, as is shown 
in children with DMD (McDonald et al., 2010). It is therefore important to understand the 
impact of muscle weakness on QoL. Reports of QoL in adults with MD however is limited and 
therefore investigated in Chapter 5, alongside the implications of muscle weakness on QoL. 
1.3.6 Physiotherapy in DMD 
Thayer et al. (2017) reported a 10-fold increase in healthcare costs in DMD compared to age 
matched CTRL, with a particular increase post the age of 16 and into adulthood, primarily due 
to hospital admissions. No cure for MD is currently available; yet steroid and drug therapy is 
a primary focus to maintain and improve functional impairments (Daftary et al., 2007; Hawker 
et al., 2005). Therapeutic techniques however, are a priority for those living every day with 
this range of conditions. Physiotherapy sessions are currently promoted and actively 
encouraged by Muscular Dystrophy UK (MDUK) (MDUK, 2016), however data regarding its 
effectiveness remains unreported. It is therefore important to understand if physiotherapy is 
an effective non-pharmaceutical intervention in adults with DMD, and to provide further 
guidance for physiotherapists. Physiotherapy as an effective intervention and mechanistic 
changes to improve ROM, in DMD is investigated in Chapter 7. 
1.3.7 Natural History 
Natural history is the term used to describe the progression of a condition or a disease over 
a period of time, typically 12 months or longer. DMD and BMD are progressive muscle wasting 
conditions, therefore loss of muscle strength and muscle tissue is likely with clinical 
progression (Huml, 2015). The natural history of strength changes in children with DMD is 
well described and reported (C. McDonald, R. Abresch, et al., 1995; Henricson et al., 2013), 
and DMD is historically recognised as the most progressive MD (Brooke et al., 1989). BMD by 
comparison is seen as a relatively milder condition, with descriptions of longitudinal changes 
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limited (C. M. McDonald et al., 1995). Given the progressive nature of MD, it is important to 
understand the natural progression of these conditions. One year changes in muscle strength, 
body composition and muscle morphology, of adults with DMD and BMD, is investigated in 
Chapter 8. 
1.4 The Neuromuscular Centre 
The Neuromuscular Centre (NMC) is a nationally recognised centre of excellence for adults 
with neuromuscular conditions. The NMC was established in 1989 by two physiotherapists 
from a nearby specialist school, who aimed to continue the management and physiotherapy 
practice that is readily available for children with neuromuscular conditions. For adults with 
neuromuscular conditions however, provision of services have been commonly reported as 
lacking (Hill and Phillips, 2006).The NMC does not receive any funding from the NHS, 
therefore is an established charity, requiring over £1 million annually to run (ref). 
Since its establishment in 1989, The NMC has grown to now have more than 700 adults with 
Neuromuscular Disorders registered. The NMC was originally set up for the provision of 
physiotherapy for adults with neuromuscular disorders, for which the department has now 
expanded to employ 5 fulltime physiotherapists specialising in clinical/neuromuscular 
conditions, and 4 fulltime physiotherapy assistants. Physiotherapy is provided to attendees 
on a weekly, bi-weekly or monthly basis, following a referral to the centre by a clinician. 
Regularity of physiotherapy is typically determined by severity of condition (more severe 
conditions typically attend more frequently), and locality to the centre (more local individuals 
typically attend more frequently than non-locals). Physiotherapy sessions are typically one 
hour long, and consist of passive stretching and active-assisted movements (these are 
outlined in more detail in Chapter 3 and 7), depending on the condition (i.e. more severe 
conditions will typically focus on passive stretching, while less severe conditions will be a 
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combination of passive and active-assist movements. Whilst individuals may attend the NMC 
through referral for physiotherapy and condition management, the unique sense of 
community and meeting other adults with neuromuscular conditions is key to The NMC, with 
the psychosocial, as well as physical benefits reported by its users (Hartley and Stockley, 2013; 
Hartley et al., 2011; Campaign, 2008). These psychosocial benefits are likely enhanced by the 
dedication by the NMC to its service users, whereby the NMC offers employment to up to 20 
adults with neuromuscular conditions, in addition to providing training for web design.  
1.5 This Thesis 
The aims of this thesis are to provide information on strength, physical activity, passive and 
active ROM and QoL measures in adults with MD, with comparisons across 4 different 
classifications of MD (DMD, BMD, LGMD, and FSHD) and a healthy CTRL GROUP. In addition, 
as well as measurement of typical MD clinical features, this thesis aims to identify associations 
and mechanisms of identified impairments. In addition, this thesis will assess the acute 
responses of muscle strength and flexibility to physiotherapy, and the longitudinal changes in 
body composition, strength and physical activity. 
The subsequent literature review will outline the extant research that describes the above 
identified presentation of muscle strength, ROM, QoL, physiotherapy interventions and 
natural history in adults with MD. The aim of which is to provide an overview of the current 
evidence, in support of and contrasting to, the classical understanding of MD presented here.  
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Chapter 2 
Literature Review 
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2.1 Introduction 
MD is a varied yet unique set of conditions, generalised by progressive muscle weakness and 
development of contractures (Huml, 2015). This literature review will first comment on the 
limitations of DMD research, then explore and discuss, within the MD classifications identified 
in Chapter 1, the extant evidence in agreement and contrast with the ‘Classical Perspective’ 
presented in Chapter 1, of muscle weakness, muscle morphology, QoL, ROM, natural history 
and physiotherapy. This literature review is a selective, narrative review (Ressing et al., 2009), 
presenting MD data with CTRL comparisons only for discussion. This approach was conducted 
as there are insufficient studies with which to conduct a meta-analysis approach of the 
outcome measures (These are addressed individually below e.g. 2.2). Throughout the course 
of the thesis (Oct 2015-July 2018) literature reviews were conducted using Google Scholar, 
Pubmed, Scopus and ScienceDirect, using search terms using the group (MD, FSHD, DMD, 
BMD, LGMD) and outcome measure of interest (MVC, ROM, QoL etc.). As limited study data 
is available from adult populations with MD, there are instances where examples had to be 
considered from children, again rendering this approach incompatible with that of a meta-
analysis. Where relevant this is discussed in the subsequent thesis. 
2.2 DMD Research  
MD research is heavily centred on DMD, specifically in children, with a recent commentary 
identifying the need for research in adults with DMD (McDonald and Mercuri, 2018; Pandya 
et al., 2018). Three primary reasons have been proposed for this, which are as follows (Bettolo 
et al., 2016; Rahbek et al., 2005; Pandya et al., 2018; Eagle et al., 2002; Bachasson et al., 2014; 
Lott et al., 2014): 1) Life expectancy has historically been up to the age of approximately 20 
years old, and has only improved in the last few decades due to greater respiratory and 
cardiac care. 2) There is better access to paediatric groups of DMD due to the provision of 
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support for attendance at specialist treatment centres. Once approaching adulthood, 
individuals with MD typically lose funding and care through National Health Service (NHS), 
and so access to large enough samples becomes difficult. 3) Interventions are typically 
implemented while participants still have a relative maintenance of function.  
The subsequent sections of this literature review will assess the relevant literature across 
DMD, BMD, LGMD and FSHD when possible. Given the severity and focus of research on DMD, 
the majority of current literature is within paediatric populations with DMD. 
2.3 Lower Limb Muscle Size 
Despite there being sites of weakness symptomatic for each of the four MDs under 
consideration, all are characterised by a decline in functioning muscle mass (Kilmer et al., 
1995; C. M. McDonald et al., 1995; C. McDonald, R. Abresch, et al., 1995; C. McDonald, R. 
Johnson, et al., 1995). As described in Chapter 1 and reviewed previously (Emery, 2002), the 
patterns of muscle loss are presented as whole-body within DMD and BMD, and largely 
consistent, although not limited to, the body regions within the names of LGMD (hip and 
shoulder girdles) and FSHD (face, scapula and upper arms). Despite these often reviewed and 
reported declines in muscle mass, the presented research describing these changes are 
somewhat lacking. Within DMD for example, despite muscle wasting being characteristic of 
the condition, in children there is “pseudohypertrophy” of the calf area. This increase in 
muscle size with no relative increase in strength (Mathur et al., 2010; Vohra et al., 2015; 
Wokke et al., 2014) is associated with an inflammatory response from the breakdown of 
muscle and replacement with non-contractile tissue (Jones et al., 1983). Consistent with the 
description of the progressive nature of DMD, within adults there is only lower limb 
comparative data from the Gastrocnemius Medialis (GM) (Morse et al., 2015) and Tibialis 
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Anterior (TA) (Morse, 2016), which both report much smaller muscle size than CTRL 
comparisons.  
Unlike children with DMD, lower limb muscle size in BMD is greatly under reported. Despite 
a historical description of psuedohypertrophy of the calves (C. M. McDonald et al., 1995; 
Bradley et al., 1978), only two papers having previously reported lower limb muscle size in 
adults with BMD (Jacques et al., 2017; Løkken et al., 2016). Løkken et al. (2016) reported no 
difference in muscle size of the triceps surae compared to healthy CTRL. In contract, Jacques 
et al. (2017) reported increased GM anatomical cross sectional area (ACSA) in adults with 
BMD compared to healthy age matched CTRL, however upon further analysis; increased GM 
ACSA was only evident in non-ambulatory adults. This is likely reflective of the milder and 
slower nature of this condition, but also suggests that exercise and PA in ambulant adults with 
BMD may help maintain contractile muscle mass, delaying the onset of psuedohypertrophy. 
In FSHD psuedohypertrophy is not described as a typical characteristic (Kilmer et al., 1995). In 
comparison, psuedohypertrophy of the calf has been described as common in LGMD (Bushby, 
1999), the only reported measurement of triceps surae in LGMD however, did not report an 
increase in muscle size compared to CTRL (Løkken et al., 2016). 
Current reports of quantified muscle size of the four dystrophic conditions of this thesis with 
CTRL comparisons are presented in Figure 2.1. For clarity, muscles have been presented as 
either plantar-flexor (PF) or dorsi-flexor (DF) muscle groups, dependant on the movement 
they are associated with. This highlights the termed psuedohypertrophy within children with 
DMD, and the limited reports of muscle size in adults with DMD. 
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Figure 2.1. Muscle size of DF and PF muscles in DMD, BMD, LGMD and FSHD, presented as 
percentage comparisons relative to CTRL participants. Data is presented as the mean age of 
participants groups (X axis) to show the lifespan comparisons, and muscle size as percentage 
of CTRL (Y axis). PF = Muscles associated with plantar-flexion, DF = Muscles associated with 
dorsi-flexion. D = Duchenne muscular dystrophy; B = Becker’s muscular dystrophy; LG = Limb-
Girdle muscular dystrophy; F = Facioscapulohumeral muscular dystrophy’ (Mathur et al., 2010; 
Vohra et al., 2015; Forbes et al., 2013; Wokke et al., 2014; Jones et al., 1983; Huml, 2015; 
Morse, 2016; Morse et al., 2015; Jacques et al., 2017; Løkken et al., 2016) 
2.4 Strength in MD 
2.4.1 Measurement of Strength in MD 
Measurement of muscle strength in MD, given its progressive nature, has been a focus of 
research for a long time (C. M. McDonald et al., 1995; C. McDonald, R. Abresch, et al., 1995; 
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Kilmer et al., 1993). Within MD, these descriptions of strength are often reported using 
physiotherapist assessment scales, such as the Manual Muscle Test (MMT) and the adapted 
MMT by Medical Research Council (MRC%) (Florence, 1984). MMT and MRC% are based on 
an individual’s resistance to movements from an assessor, typically a physiotherapist, and 
rated weak to strong on a 5-point scale (MMT), or converted to a 10 point scale and expressed 
as a percentage of the maximum score possible (MRC%) (Mendell and Florence, 1990; 
Florence et al., 1992). MMT and MRC% have the benefit of not requiring any equipment, 
however, both rely on subjective judgement and have therefore been questioned for 
reliability, validity and sensitivity to change (Cuthbert and Goodheart, 2007; Bohannon, 2005; 
Mayhew et al., 2007) and are better classified as muscle strength assessments, rather than 
muscle strength measures. 
Myometry, the use of a handheld dynamometer to quantify the force of a movement, is an 
alternative measure of muscle strength (Schwartz et al., 1992). Myometry requires a 
practitioner to provide the resistive force to a movement while holding the handheld 
dynamometer, which measures the force produced by the participant, and can be used to 
measure force from up to 13 muscle groups (Van der Ploeg et al., 1991). Myometry is a more 
sensitive measure of muscle strength than MMT and MRC%, and due to its accessibility is 
commonly used in clinical randomised CTRL trials and longitudinal studies (C. M. McDonald 
et al., 1995; McDonald et al., 2013). Issues have been noted however, for the reliability (ICC 
= 0.72-.91) and validity of myometry. Limitations include a maximum attainable force in many 
handheld dynamometers, limiting its possible use to some of the more less-abled conditions 
(Stuberg and Metcalf, 1988). In addition, Sloan (2002) and Bohannon (1999), in children and 
adults respectively, reported issues of stabilisation, as well as myometry being dependent 
upon resistance from an assessor.  
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Quantative Muscle Testing (QMT) is a measurement system typically using a force transducer 
or strain gauge with straps to a mechanical ‘anchor’. The use of a mechanical ‘anchor’ in QMT, 
which the force transducer is attached to, to provide resistance, provides a more objective 
measure than resistance from an assessor as seen in myometry. QMT has been shown to be 
a reliable measure of muscle force across 9 strength measures, with high ICC for CTRL (0.91-
.96) and FSHD participants (0.86-.96), as well as Intrarater Class Coefficients (0.91-.99) in the 
FSHD participants (Personius et al., 1994). Furthermore, QMT was shown to be more reliable 
than MMT, as the same study reported MMT Interrater Class Coefficients = 0.5-1 and 
Intrarater Class Coefficients = 0.79-.98 (Personius et al., 1994). Similarly, Brussock et al. (1992) 
utilised a similar method of QMT, using an electronic strain gauge, which reported a high ICC 
(0.88-.99) across 8 muscles in children with DMD. QMT has become a common method of 
strength measurement for use in populations that exhibit a wide range of muscle strength, 
such as FSHD (Janssen et al., 2014; Wokke et al., 2014; Wilson et al., 2018). Primarily the use 
of mechanical resistance allows for more accurate and reliable measurements in stronger and 
more functional individuals than myometry (Personius et al., 1994), as well as in lower 
strength and less functional individuals (Brussock et al., 1992).  
Measurement of lower limb strength using wholly mechanical QMT systems, rather than the 
strain gauges and straps associated with typical QMT (Personius et al., 1994), is limited within 
the literature to more able bodied and ambulant MDs, such as children with DMD or younger 
and milder forms of other MDs (Mathur et al., 2010; Løkken et al., 2016; Lerario et al., 2012). 
These strength measurements are also typically limited to one or two movements (usually 
associated with the knee or ankle). This is primarily due to difficulties in mobility and 
mechanics of positioning to allow such testing in the more severely affected individuals. More 
specifically, this would require the use of a hoist, and difficulties in body positioning and self-
19 
 
support, given the nature of whole body contractures in some participants (Johnson et al., 
1992). Testing of only ambulant, or more able-bodied individuals, is unrepresentative of these 
populations, where many result in eventual reliance upon wheelchairs and/or walking aids 
(Bushby et al., 2010; Pegoraro and Hoffman, 2012; Pandya et al., 2008). This highlights the 
requirement for greater adaptability in the procedures and techniques used to assess muscle 
strength, such as QMT, or adaptations thereof.  
2.4.2 Lower Limb Muscle Strength Comparisons 
Progressive muscle weakness is a defining clinical feature of MD, with impaired MVC of knee 
extension (KEMVC) and plantar flexion (PFMVC) influencing QoL in children with DMD, and 
the ability to perform functional measures in children with DMD and adults with BMD (Alfano 
et al., 2013; Bendixen et al., 2014; Mathur et al., 2010). Emery (2002) presented areas of 
predominant areas of weakness in MD (Figure 1.1), presenting DMD and BMD as whole body 
progressive muscle weakness conditions, LGMD with weakness associated with the hip and 
shoulder girdles, and FSHD with weakness focussed on shoulder girdles and dorsi-flexors. 
Below describes evidence of muscle weakness in MD in comparison with healthy CTRL, and is 
summarised in Figure 2.2. 
As noted previously, extensive research has examined muscle strength in children with DMD, 
where KEMVC was 72-87% lower than CTRLs across six studies (Akima et al., 2012; Lott et al., 
2014; Mathur et al., 2010; Skalsky et al., 2009; Wokke et al., 2014; Lerario et al., 2012). 
Furthermore, PFMVC was 54-65% lower than CTRLs across four studies in children 
comparisons (Lott et al., 2014; Mathur et al., 2010; Wokke et al., 2014; Vohra et al., 2015). To 
date, no lower limb muscle strength has been reported for adults with DMD.  
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Across the three other MD classifications identified for this thesis, one paper reported PFMVC 
as 52% and 38% lower than CTRL in BMD and LGMD, respectively (Løkken et al., 2016). PFMVC 
in adults with FSHD however has not been compared to CTRL. Comparatively, KEMVC was 
reported as 45-65% lower than CTRL in adults with FSHD within three studies (Bachasson et 
al., 2014; Skalsky et al., 2008; Wilson et al., 2018). KEMVC has not been reported against CTRL 
in either adults with BMD or LGMD, despite previous recognition of the relationship between 
KEMVC and functional tasks in adults with BMD (Alfano et al., 2013). 
In summary, lower limb muscle strength with CTRL comparisons is only reported in children 
with DMD, while in adult populations of BMD, LGMD and FSHD, there are no CTRL 
comparisons of specifically KEMVC in adults with BMD and LGMD, and PFMVC in adults with 
FSHD. Current MD lower limb strength comparisons to CTRL are summarised in Figure 2.2. 
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Figure 2.2. Percentage muscle strength of PFMVC and KEMVC in DMD, BMD, LGMD and FSHD, 
based on comparisons relative to CTRL participants. Data is presented as the mean age of 
participants groups (X axis) to show the lifespan comparisons, and muscle strength as 
percentage of CTRL (Y axis). PF = Plantar-flexion maximal voluntary contraction; KE = Knee-
extension maximal voluntary contraction D = Duchenne muscular dystrophy; B = Becker’s 
muscular dystrophy; LG = Limb-Girdle muscular dystrophy; F = Facioscapulohumeral muscular 
dystrophy’ CTRL = Control. (Bachasson et al., 2014; Forbes et al., 2013; Lott et al., 2014; Akima 
et al., 2012; Mathur et al., 2010; Skalsky et al., 2008; Skalsky et al., 2009; Wilson et al., 2018; 
Lerario et al., 2012; Løkken et al., 2016; Vohra et al., 2015; Wokke et al., 2014) 
2.5. Physical Activity and Sedentary Behaviour 
PA is commonly defined as the expenditure of energy greater than 1.5 Metabolic Equivalent 
Tasks (METs), while SB is defined as 1.5 METs or less (Tremblay et al., 2010; D. J. Ryan et al., 
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2018). Healthy adults are suggested to participate in 30 minutes of moderate PA (3-6 METs) 
five days a week or 20 minutes of vigorous PA (6+ METs), 3 days a week, in order to maintain 
and promote health (Haskell et al., 2007). Higher PA and lower SB are linked to better 
musculo-skeletal and cardio-metabolic health in the general population (Peterson et al., 2013; 
Gianoudis et al., 2015; Tremblay et al., 2010; Henson et al., 2013). The clinical progression 
and progressive muscle weakness may predispose those with MD to higher levels of SB and 
limit PA, with recent evidence of increased obesity reported in non-ambulant adults with BMD 
compared to ambulant adults (Jacques et al., 2017). PA is promoted by Muscular Dystrophy 
UK (MDUK) (Campaign, 2014) as a method to maintain health and function when possible, 
however there is currently limited research in PA levels in neuromuscular conditions, and 
more specifically, MD (Jimenez-Moreno et al., 2017).  
PA assessments have been presented in children with DMD using subjective methods such as 
questionnaires (Baecke Physical activity questionnaire (Hawker et al., 2005); Short-Form 36 
Health Assessment (SF36: however the SF36 does not contain a PA domain, more likely this 
study has used the Physical Function domain of the SF36 to represent PA)(Abresch et al., 
2002); Self developed Physical activity questionnaire (Heutinck et al., 2015)), all reporting 
reduced PA in DMD groups. McDonald et al. (2005) and Davidson et al. (2015) both used 
objective measures of step count activity in children and adolescents with DMD, both 
reporting significantly reduced step count in DMD. Davidson et al. (2015) remains currently 
the only paper linking PA (step count) with functional measures, with a strong correlation 
between PA and the 6 minute walk distance (6MWD) (r= 0.80). Objective measures of PA 
using accelerometry (Jeannet et al., 2011; Ferguson et al., 2016) (DMD and FSHD) and doubly 
labelled water (Elliott et al., 2015) (DMD) have both been used in MD, however the DMD 
studies were in children, and no CTRL group was used in either study. While objective 
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measures of PA has only been reported in ambulant children with DMD, PA remains possible 
even following the loss of ambulation, such as through the use of adapted exercise 
equipment, which has previously been shown to maintain muscle function in DMD (Jansen et 
al., 2013). All current reports to date have focussed on PA, SB however can be an independent 
predictor of impaired health and wellbeing (Park, 2017; D. Ryan et al., 2018), and remain 
prevalent even when PA guidelines are met (Craig et al., 2009; Ryan et al., 2015). No study 
has yet examined SB in adults with MD, nor evaluated its impact on measures of function and 
wellbeing. 
Only two papers have reported PA in adults with MD with a healthy CTRL comparison, both 
using the Bone and Physical Activity Questionnaire (BPAQ), Jacques et al. (2017) reported 
lower current PA levels in adults with BMD compared to healthy age matched CTRL. While 
Morse et al. (2016) reported significantly reduced PA history (using BPAQ) in all MD conditions 
compared to CTRL, as well as DMD being lower compared to BMD, LGMD and FSHD groups. 
The use of questionnaire and self-report methods to determine PA however have previously 
been shown to over-estimate PA and lack objectivity (D. J. Ryan et al., 2018). 
Despite the relationships long recognised between lower limb muscle strength and functional 
outcomes in MD (Alfano et al., 2013; Mathur et al., 2010; McDonald et al., 2013), the 
relationships between PA and muscle strength in MD remains relatively unexplored, with 
Morse et al. (2016) reporting a correlation between the Physical Activity Scale for Individuals 
with Physical Disabilities (PASIPID) and grip strength. Given the lack of PA comparisons in MD, 
ageing populations can be a useful comparison, particularly as sarcopenia, the loss of muscle 
size and strength from ageing, becomes prevalent (Morse et al., 2005; Thom et al., 2005). 
Foong et al. (2015) reported positive associations of PA intensity with lean body mass (LBM) 
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and lower limb strength in an ageing population, exhibiting a dose-response like relationship, 
as those that participate in more PA are likely to maintain more muscle strength and 
contractile tissue. Similarly, Morie et al. (2010) reported positive associations of muscle 
strength and PA levels in healthy elderly, while Goodpaster et al. (2006) showed that 
increased PA in elderly populations increased muscle strength and delayed fatty infiltration 
into the muscles. The association between PA and maintained muscle strength and contractile 
tissue in ageing populations has also been shown in adults with FSHD, where PA as an 
intervention reduced fatty infiltrations into muscles, as well as reducing fatigue (Ferguson et 
al., 2016; Voet et al., 2014). No PA or SB data, measured through accelerometry and with a 
CTRL comparison, is currently available in adults with MD. Presentation of such findings could 
provide greater understanding of functional and health impairments, and inform future 
intervention strategies. Furthermore, understanding of PA and SB will help to further 
substantiate current guidance in adults with MD. 
2.6 Quality of Life (QoL) 
QoL is a measure of an individual’s perceptions of their own well-being, and is becoming 
increasingly prominent in clinical assessment and monitoring processes, as a universal 
method of assessment beyond, but also including, the physical implications of the condition 
(Graham et al., 2011). 
Some of the earliest work into QoL in MD assessed the QoL construct using extremely broad 
methods of participant recruitment, often assessing QoL in MD as a single combination of 
classifications (Nätterlund and Ahlström, 2001; Ahlström and Sjöden, 1996), rather than 
specific classifications. Typically QoL was lower in those with MD, and was associated with 
disability, impairment and pain (Ahlström and Gunnarsson, 1996; Abresch et al., 2002). The 
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variations in mutative-genetic cause (Emery, 2002), function (Lue et al., 2009) and clinical 
progression (Kilmer et al., 1995; C. M. McDonald et al., 1995; C. McDonald, R. Abresch, et al., 
1995; C. McDonald, R. Johnson, et al., 1995) of each condition however, strongly suggests 
that each classification should be recognised and assessed independently. 
Within DMD, QoL has been extensively measured in children, typically showing lower QoL, 
which has been associated with measures of physical function such as the 10m walk time 
(Messina et al., 2016), KEMVC (McDonald et al., 2010), functional scales (Bray et al., 2010) 
and 6MWD (Henricson et al., 2013). Associations between clinical outcome measures and QoL 
however have been shown to reduce with age (Henricson et al., 2013; Messina et al., 2016). 
Beyond changes in function, the Emotional domain of QoL has been reported as comparable 
in children with DMD to CTRLs (Bendixen et al., 2012), while Uzark et al. (2012) reported 
higher Psychosocial domain in older boys with DMD than younger boys, possibly indicating 
improved coping mechanisms with clinical progression. In adults with DMD however, QoL has 
only been reported in three studies, the first identifying lower QoL in adults with DMD 
compared to CTRL except for domains of Mental Health and Role Emotional, which acts as 
further evidence of improved coping mechanisms with clinical progression (Pangalila, Van 
Den Bos, Bartels, Bergen, Kampelmacher, et al., 2015). While the second study identified 
factors of fatigue, pain, anxiety and depression to significantly influence QoL in adults with 
DMD (Pangalila, Van Den Bos, Bartels, Bergen, Stam, et al., 2015). The third study looked at 
the associations between QoL in children and adults with DMD (aged 8-33 years old), Kohler 
et al. (2005) however showed no association between QoL and respiratory function, a clinical 
measure known to decline with age in DMD and recognised as influenced by clinical 
progression (Phillips et al., 2001; Brooke et al., 1989). Therefore, further investigation is 
required to understand QoL in adults with DMD, but also to see if functional impairment 
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impacts QoL in adults with DMD as seen in children, or if there is a shift to perceptive 
measures, such as fatigue and pain.  
Within FSHD QoL has similarly been assessed across three studies, in which QoL has been 
shown to be lower than CTRL in domains associated with Physical Function, and shown to be 
associated with walking function (Aprile et al., 2012). In addition, pain has previously been 
described as symptomatic of FSHD (Bushby et al., 1998), and has been associated with QoL in 
adults with FSHD (Morís et al., 2017; Padua et al., 2009). Only one study has compared 
different MD classifications, and is the only study to include adults with BMD and LGMD 
(Grootenhuis et al., 2007). BMD were shown to have better QoL on some domains compared 
to other adults with MD (Grootenhuis et al., 2007), which was suggested to be due to the 
relatively milder nature of the BMD participants within the study. This study however was 
largely descriptive of differences in QoL between MD classifications and age (Young vs Old), 
and therefore offered no mechanistic measure of function, or any other possible co-variates, 
to associate with higher or lower QoL scores. 
To date, comparisons of QoL between different classifications of MD remain limited, with 
most research containing multiple classifications grouping them together into a single MD. In 
addition, the impact on QoL of progressive muscle weakness, seen as a defining clinical 
feature of MD, similarly needs assessing, in comparison to other previously identified QoL 
associates such as pain and fatigue. 
2.7 Range of Motion (ROM) 
There are a number of measurements encompassed within the term “flexibility”; in general, 
it refers to the passive ROM (ROMPassive) around a joint. For example, the ROMPassive from 
maximum PF to maximum DF is a measure of flexibility within the muscle-tendon unit (MTU) 
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of the triceps surae. Alternatively, it is possible to describe the stiffness of the elements of 
the MTU. For example, the passive torque generated during the passive angle change of the 
joint provides MTU stiffness (N.m.deg-1) (Morse et al., 2008). Whereas, tracking the 
elongation of the myotendinous junction (MTJ) allows for the calculation of the GM stiffness 
(N.m.cm-1) (Morse, 2011). Clinically, limitations in ROM are often referred to as 
“contractures”, this however does not distinguish the mode or region within the MTU that is 
being assessed, and often lacks quantitative assessment.  
The flexibility of the joint, especially the ankle, when stretched to end ROM has been 
historically recognised as limited in MD (Archibald and Vignos Jr, 1959). Hereafter ROM will 
refer to ankle ROM, in the sagittal plane from maximum plantar flexion (PF) to maximum 
dorsiflexion (DF). Limited ROM is reported as a characteristic in children with DMD (Bushby 
et al., 2010), and reported in adults with BMD, LGMD and FSHD following the loss of 
ambulation (Kilmer et al., 1995; C. M. McDonald et al., 1995; C. McDonald, R. Johnson, et al., 
1995). Within MD, the loss of maximum passive PF (Max PFPassive) to maximum passive 
dorsiflexion (Max DFPassive) ROM (ROMPassive) at the ankle has been reported in children with 
DMD (13.6 years) and adults with BMD (20.7 years), LGMD (44.8 years) and FSHD (48.6 years) 
as 44°, 15°, 47° and 28°, respectively, where values represent a decrease from CTRL, whom 
typically report a ROMPassive of 60° (Johnson et al., 1992). These reports however lack 
population homogeneity, with a wide age range of ages within LGMD (9-82) and DMD (1-30 
years). In children with DMD, ankle ROMPassive has been associated with lower limb functional 
status (Archibald and Vignos Jr, 1959). Limited ROMPassive has been reported as rare in 
ambulant children with DMD but becomes more prevalent in wheelchair users (Ringel et al., 
1977), and is often described as associated with levels of muscle weakness in LGMD and FSHD 
(Kilmer et al., 1995; C. McDonald, R. Johnson, et al., 1995). While ROMPassive has been reported 
28 
 
in MD (Johnson et al., 1992), ROMActive, the ROM that an individual is able to independently 
move their ankle to, remains unreported. ROMActive is likely to be a more important measure 
given its likely influence of function and fall risk (Menz et al., 2006; Menz et al., 2005), 
however remains unreported in adults with MD. 
Mechanistic causes of limited ROM have been proposed as fibrotic changes to the muscle, 
reduced muscle strength to actively move through ROM, and static positioning of the ankle 
in PF. Investigation into these factors however remains largely unreported (Dubowitz, 1964; 
Brooke et al., 1989; Hsu and Furumasu, 1993). In animal models, a significant relationship has 
been identified between collagen content (non-contractile tissue) of the gastrocnemius and 
level of contracture in dystrophin deficient animal models, specifically MDX mice (Garlich et 
al., 2010). Conversely, increased collagen content of Soleus in MDX mice has been reported 
as having no relationship with muscle stiffness (the passive torque produced with the soleus 
under stretch) (Smith and Barton, 2014). Muscle stiffness has been shown to be higher in 
children with DMD than CTRL, measured by ultrasound (Supersonic Shear Imaging) 
(Lacourpaille et al., 2015). Muscle stiffness however has not been quantified in lower limb 
muscles of adults with MD, nor has its association with ROM been explicitly reported in 
human models. 
Limited ROM has previously been shown to cause pain (Dalyan et al., 1998; Willig et al., 1995), 
increase fall risk (Menz et al., 2006), impair sleep quality (Oztura and Guilleminault, 2005), 
and therefore reduce QoL (Katalinic et al., 2010). The current presentation of limited ROM in 
MD is restricted to paediatrics with DMD, and in adults with BMD, LGMD and FSHD, however 
the broad age ranges used previously limits its comparability. Furthermore, while speculated, 
determinants of ROM remain unquantified in adults with MD.  
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2.8 Acute Response to Physiotherapy 
Physiotherapy, which in MD is typically limited to passive stretching and mobility exercises, is 
currently encouraged by MDUK as a method of maintaining health and function (MDUK, 
2016). Other clinical conditions, such as cerebral palsy, which display muscle weakness 
(Hussain et al., 2014) and increased stiffness (Hussain, 2013), have reported positive 
responses to physiotherapy and passive stretching, with outcomes such as decreased muscle 
stiffness (Pin et al., 2006; Zhao et al., 2011). Within MD however, quantified effects of passive 
stretching and physiotherapy on ROM is limited, therefore clinical practice is typically guided 
by expert clinical opinion (Radford et al., 2006). 
Hyde et al. (2000) reported ankle ROM reduced with age, synonymous with the progressive 
nature of the condition, even whilst receiving passive stretching in children with DMD. No 
specific measure of ROM was reported however, nor was there a non-treatment group 
against which to compare passive stretching. Hyde et al. (2000) did however report that the 
progression of ROM loss was reduced in participants receiving a combination of passive 
stretching and night splints, in comparison to just passive stretching. Similarly, individuals 
receiving passive stretching as part of multi-component care have been reported to maintain 
ROM and ambulation for up to 2 years longer than those not receiving care (Vignos and 
Archibald, 1960; Vignos et al., 1963). 
Longitudinal studies have shown some, albeit limited, benefit of stretching in MD. Given the 
progressive and degenerative nature of DMD, it is important to assess the effectiveness of 
physiotherapy in adults with DMD, who have developed further limited ROM and weakness, 
likely from muscle degeneration and increased non-contractile tissue, compared to children 
with DMD (Willcocks et al., 2014). Furthermore, it is unclear whether changes in ROM with 
stretching can be attributed to the MTU or the muscle i.e. whether the non-contractile 
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component limits stretch hence no adaptation to the muscle. At present however, there are 
no descriptions of the acute outcomes of passive stretching in adults with MD. Therefore 
further guidance is required as to the effectiveness of physiotherapy as a non-pharmaceutical 
treatment in adults with DMD. 
2.9 Natural History Studies 
The progressive nature of DMD means it has been a focus of a wide range of studies to 
quantify the condition progression, but also as a reference for the effectiveness of steroid 
treatment (Akima et al., 2012; Bendixen et al., 2014; Elliott et al., 2012; Jansen et al., 2013; 
Kohler et al., 2005; C. McDonald, R. Abresch, et al., 1995). Natural history studies (the 
description of disease progression over time) have shown a maintenance of strength in 
children younger than 7 years old, and a decline in strength in children over the age of 7 
(Lerario et al., 2012). Consistent with this, a 15% decline in KEMVC has been shown over a 48 
week period, in ambulant children with DMD (Mean age= 8.3) (McDonald et al., 2013). Clinical 
trials and longitudinal studies have typically used ‘clinical endpoints’ as a measure of function, 
typically a 6-minute walk test (Mayhew et al., 2007; McDonald et al., 2010; McDonald et al., 
2013). Children with DMD typically lose ambulation by the age of 12 however, therefore 
clinical endpoint measures of function become redundant (Morse et al., 2018). Two studies 
have reported annual changes in adolescents/adults with DMD, reporting 1.2-2% decline in 
KEMVC (13-24 years) (C. McDonald, R. Abresch, et al., 1995; Steffensen et al., 2002), however 
these studies used MMT and MRC% methods of assessment, previously described as not 
sensitive to report changes in muscle strength (Chapter 2.4.1). Given the improvements in 
health care, particularly cardiac and respiratory, life-expectancy is increasing in DMD, with 
many now living well into adulthood (Bettolo et al., 2016; Rahbek et al., 2005). Comparatively, 
only one study has assessed change in muscle strength longitudinally in adults with BMD, 
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however MRC% was used as measure of muscle strength (C. M. McDonald et al., 1995). 
Therefore further understanding of the progression of these conditions is required. 
2.10 Thesis Aims 
Based upon the presented literature, sub-classifications of MD have many clinical features, 
such as progressive muscle weakness, increased muscle size of the calves and limited ROM. 
Current evidence of these clinical features, their associations and impacts are however largely 
focussed on children with DMD. By comparison, quantified evidence of these features, their 
associations and impacts, remains limited in adults with BMD, LGMD and FSHD, and 
unreported in adults with DMD. Furthermore, current guidance on living with MD encourages 
PA and physiotherapy as methods to maintain health and function, however the 
understanding of PA, and the effectiveness of physiotherapy, remains limited in its reporting 
in adults with MD. Therefore, the aims of thesis are: 
Chapter 4:  To investigate the relationship between muscle strength and size; establish the 
relationship between muscle size and strength with objective measures of physical activity, 
with implications for the maintenance of muscle function in MD. 
Chapter 5: Compare the self-reported QoL of adults with DMD, BMD, LGMD and FSHD, and a 
non-MD CTRL group; Present and compare between groups measures of Muscle Strength, 
Activities of Daily Living, Fatigue, Pain, Self-Efficacy and BMI; Identify associations between 
QoL domains and Muscle Strength, Activities of Daily Living, Fatigue, Pain, Self-Efficacy and 
BMI. 
Chapter 6: Compere ROMActive and ROMPassive in adults with MD and CTRL; Compare levels of 
MTU and GM stiffness in adults with MD and CTRL; Identify associations of ROM with 
measures of muscle weakness, stiffness and muscle length. 
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Chapter 7: Quantify the acute effect of physiotherapy on 1) Range of Motion Measures, 2) 
Stiffness Properties Associated with the ankle as identified in Chapter 7 and 3) Muscle 
Strength, in adults with DMD.  
Chapter 8: Quantify changes, from a one year follow up, in body composition, muscle 
morphology, muscle strength and physical activity levels in adults with DMF and BMD; Identify 
the impact of changes in physical activity on body composition and muscle strength in adults 
with BMD and DMD. 
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Chapter 3 
Methods 
3.1 Participants 
All MD participants were recruited from The NMC (Winsford), which was described in Chapter 
1. This thesis has utilised The NMC to overcome the limitations of participant recruitment, 
discussed in Chapter 2, whereby the lack of healthcare provision has previously limited 
accessibility to large populations of adults with neuromuscular disorders. Similarly, this thesis 
has formed part of a broader partnership between The NMC and Manchester Metropolitan 
University, whereby research questions from individuals with, or practitioners working with, 
neuromuscular disorders can be answered. Previous work has identified an end of 
psuedohypertrophy in adults with DMD (Morse et al., 2015), impaired bone health in adults 
with MD (Morse, 2016) and calculations for resting energy expenditure as a basis for 
nutritional guidelines in adults with BMD (Jacques et al., 2017). 
In line with this thesis the principal investigator was based at The NMC 5 days a week, where 
all MD participant recruitment and data collection took place. Therefore, all protocols and 
data collection techniques were designed to be made around participant’s regular 
physiotherapy appointments, and with the least inconvenience to the participants, but also 
to not impact on their regular physiotherapy. 
3.1.1 Sample Size 
Prior to participant recruitment a priori power analysis was used (G Power 3.1, Germany), 
based on previous means and SD for PFMVC (Løkken et al., 2016), between CTRL and BMD 
(effect size = 1.28), and CTRL and LGMD (effect size = 2.15), the estimated sample size would 
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be BMD n = 6, and LGMD n = 14. In addition, based on previous means and SD for KEMVC 
(Bachasson et al., 2014), between CTRL and FSHD (effect size = 1.60), the estimated sample 
size for FSHD would be n = 10. Therefore sample sizes of MD and CTRLS are comparable, or 
indeed higher than those suggested by the power analysis. Furthermore, the comparable 
participant sample sizes of independent MD and CTRL groups are largely consistent with 
previous research into these conditions, for example previous participant numbers have been  
CTRL n = 14, FSHD n = 17(Skalsky et al., 2008); CTRL n = 13, n = 21(Mathur et al., 2010); in  
CTRL n = 19, FSHD n = 19(Bachasson et al., 2014). 
3.1.2 Recruitment 
MD participants were recruited from the NMC, for which all were male, as DMD and BMD are 
x-linked conditions, to therefore allow cross- condition comparisons. Participants were 
typically recruited during their standard physiotherapy session. Due to the variety of 
neuromuscular disorders that utilise the services of The NMC, the physiotherapists with 
access to diagnosis were often the first point of recruitment. Whereby physiotherapists were 
briefed by the principal investigator of the criteria of participants (Male, aged 18-55, 
conditions of DMD, BMD, LGMD or FSHD, attend the NMC a minimum of once a month). 
Participants were often offered the chance to take part in research during their standard 
physiotherapy session, following a briefing session from the principal investigator. If an 
individual expressed an interest in taking part in the research, the principal investigator was 
at the centre to discuss the research, give the participant an information sheet (Appendix 1) 
and answer any questions. In addition to recruitment through physiotherapists, the principal 
investigator also actively recruited through interaction with individuals during their visits to 
the NMC. The healthy CTRL group were recruited using poster advertisements (Appendix 2) 
at Manchester Metropolitan University.  
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A total of 77 adult males volunteered for the studies within this thesis, of which 61 were adults 
had been previously diagnosed with a type of MD on referral to the NMC. Table 3.1, below, 
presents the numbers of individuals in each of the MD classifications relevant to this thesis 
that attend the NMC, that are male and those that were recruited out of the potential NMC 
and estimated national populations. In addition, participant’s frequency of physiotherapy 
(median and range) is included, which as stated previously, is typically dependant on the 
severity of condition and locality to The NMC. Note: This thesis has only recruited adults that 
visit the NMC at least once a month as to improve reliability of measures. 
In terms of co-morbidities, of the MD participants, 4 participants were prescribed with beta 
blockers, all of which had BMD. ACE inhibitors were used by 3 of 18 with BMD, 2 of 13 with 
LGMD, and 2 of 14 with FSHD. There was no use of ACE inhibitors or beta-blockers within the 
DMD participants. Regarding cardiac dysfunction, 2 of those with BMD had previously been 
diagnosed with cardiac myopathy. There is no evidence that these medications or co-
morbidities would impact the outcome measures reported in the present thesis. 
Table 3.1. Participant Recruitment.  
 DMD BMD LGMD FSHD 
NMC Total 20 44 55 64 
NMC Total Males 20 44 24 31 
Recruited 16 18 13 14 
% of possible recruits 80% 41% 54% 45% 
Estimated % of National Population 1.3% 0.75% 1.8% 1.4% 
Physiotherapy Frequency (Monthly 
Visits) 
3 (1-4) 2 (1-2) 2 (1-2) 2 (1-2) 
Table 3.1. NMC = The Neuromuscular Centre; DMD = Duchenne Muscular Dystrohpy; BMD = Beckers 
Muscular Dystrophy; LMD = Limb-Girdle Muscular Dystrophy; FSHD = Facioscapulohumeral. 
3.1.3 Age Differences 
Given the condition onset from birth in DMD and in adulthood in FSHD (Emery, 2002), 
differences were expected between MD groups and CTRL. Therefore sub-group analysis was 
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performed on the primary outcome measure (KEMVC), CTRL participants were split into 
Young (aged 18-30, n= 8) and Old (aged 31-55, n= 8) subgroups, so they matched with DMD 
and FSHD, respectively. As this approach provided the same statistical outcomes as a 
combined CTRL group, only comparisons for a combined CTRL are presented. 
3.1.4 Control Participants 
As stated above, this thesis has utilised a single CTRL group for all of its cross-sectional 
comparisons, therefore it is important to identify if the CTRL group is reflective of the larger 
population. Therefore, using the main outcome measure that has been utilised through this 
thesis of KEMVC, the coefficient of variation of our CTRL KEMVC was 34%, which is 
comparative with the normative database for quantitative muscle testing (QMT)((Hogrel et 
al., 2007); n = 122, CV = 29%, mean difference = 4.3 N.m), and therefore deemed reflective of 
the larger population.  
3.1.5 Participant Information and Ethical Approval 
All MD participants were recruited from, and tested at, The Neuromuscular Centre (Winsford, 
UK). CTRL were tested at Manchester Metropolitan University, Cheshire Campus (Crewe, UK). 
Only males were recruited to allow cross-condition comparison, aged 18-55. CTRL participants 
were self-reported as being recreationally active (undertaking less than 2 hours of 
recreational physical activity per week), however were not undertaking any structured 
training programme. Similarly, no MD participants were taking part in a structured training 
programme, however all were receiving weekly, bi-weekly or monthly physiotherapy 
treatment, consisting of passive stretching, along with access to low intensity cardiovascular 
exercise equipment. Ethical approval was obtained through the Department of Exercise and 
Sport Science local Ethics Committee, and all participants signed informed consent forms 
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prior to participation (Appendix 3). All procedures complied with the World Medical 
Association Declaration of Helsinki (World Medical, 2013). 
3.2 Research Design 
This section provides an overview of the variables reported in each chapter, and how the 
testing was conducted, these are presented in Figure 3.1. Further identification of variables 
and methodologies are made in 3.5 Measures. An overview of participants relative to each 
Chapter is presented in Figure 3.1. The variables for each Chapter are identified below, and 
variations in sample sizes explained.  
 
Figure 3.1 Overview of data colleciton and relevant chapters. From left to right, the possible 
commitments and tests made by participants is identified, with data collection sessions at 
visit 1, 2 and 3.  
Participants testing was aligned with participant’s subsequent physiotherapy sessions. During 
Visit 1, variables for participant characteristics of body mass (BM), height, body fat % and LBM 
that are used to describe participants in every chapter, were recorded.  
Variables associated with Chapter 4 of GM ACSA, PFMVC and KEMVC were measured during 
Visit 1. Measures of PA reported in Chapter 4 were administered during visit 1 through the 
use of a wrist-worn accelerometer, and was returned during Visit 2. Reliability measures 
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reported in Chapter 4 were from repeat measures during Visit 2 of PFMVC and KEMVC. This 
chapter uses all 4 classifications of MD. One DMD participant refused to wear the wrist-worn 
accelerometer, therefore none of his data was used during this chapter, however in non-PA 
related chapters, this data was used in subsequent chapters. 
Chapter 5 consists of the KEMVC measured during Visit 1, and questionnaires administered 
during Visit 1. Some participants took the questionnaires home with them following Visit 1, 
and returned them during Visit 2. Due to the severe upper limb impairments associated with 
DMD, the principal investigator would tick the boxes chosen on questionnaires for 
participants. This chapter uses all 4 classifications of MD, however one participant with DMD 
and one with LGMD did not return their questionnaires, and were therefore not included in 
this chapter. 
Chapter 6 consisted of RoM and Stiffness measures of participants, these were measured 
during Visit 1. PFMVC reported in Chapter 4 is also used in this chapter. Reliability measures 
were reported from repeated measures from Visit 2. This chapter uses all 4 classifications of 
MD, however technical difficulties with the electro-goniometer and its outputs/readings 
reduced some participant numbers in BMD, LGMD and FSHD. 
Chapter 7 uses a prospective cohort design, whereby participants RoM, Stiffness and PFMVC 
from Visit 1 are repeated during Visit 2 to calculate Minimal Detectable Change (MDC). These 
variables were included for analysis following their differences and associations presented in 
Chapter 6. Participants would be tested for pre-physio measures, undergo a standard 
physiotherapy session, before repeating the testing measures. Effectiveness of physiotherapy 
is determined by statistical analysis and differences greater than MDC. Only DMD participants 
were reported for the acute responses to Physiotherapy. Due to the severe lower limb 
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impairment in DMD, it was deemed that by only including DMD participants, the principal 
investigator could assess specifically the intervention of Physiotherapy. Other forms of MD, 
which may contain ambulant individuals, could influence the stiffness properties of the lower 
limb dependant on the extent of PA achieved prior to their physiotherapy session. 
Chapter 8 is a repeated measures design using the participant characteristics, PFMVC, KEMVC 
and PA from visit 1, and those participants that were still available and willing to participate 
in a 12 month follow up. Only DMD and BMD participants were utilised for this Chapter, due 
to the similarities of their genetic impairment, and the typically linear progression of their 
conditions. Of the participants that completed all baseline testing during Visit 1, all DMD 
participants were tested at Visit 3 (12 months). While 12/18 BMD participants from baseline 
testing were available or willing to participate in Visit 3 testing (12 months). In addition, ROM 
measures were not recorded at 12 months due to technical issues with the electro-
goniometer. 
Please note, all data collection, data analysis and statistical analysis was performed by the 
principal investigator.  
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Table 3.2. Recruited participants utilised in each Chapter 
3.2.1 Protocol 
All participants completed the following testing during Visit 1, MD participants completed 
testing prior to their physiotherapy session. The testing protocol was completed in all 
participants using the same equipment, with the exception of seated scales for BM measures 
in non-ambulatory MD participants. Due to the high level of whole-body contractures present 
in some participants, testing was designed for the most severely affected participants to be 
tested in their own power-wheelchair, with all other participants then assessed in a seated 
position to ensure consistency. Bioelectrical Impedance (BIA) (Bodystat 1500, Bodystat Ltd., 
United Kingdom) and anthropometric measures were performed first, followed by B-mode 
ultrasound measures of the GM (MyLabGamma Portable Ultrasound, Esaote Biomedica, 
Genoa, Italy). Ultrasound recordings were taken of the participants’ self-reported dominant 
leg. If a participant was unable to distinguish a dominant leg, the right leg was measured. 
Goniometry assessment of ROM, mechanical properties and displacement through ROM were 
assessed on the self-reported dominant leg using an electro-goniometer (K100, Biometrics 
Ltd, UK) and the above-mentioned ultrasound. Quantitative muscle strength was then taken 
from the self-reported dominant leg using a load cell (Zemic, Eten-Leur, Netherlands) for 
 DMD BMD LGMD FSHD CTRL 
Total Recruited 16 18 13 14 16 
Chapter 4 15 18 13 14 16 
Chapter 5 15 18 12 14 16 
Chapter 6 16 17 10 13 16 
Chapter 7 14 - - - - 
Chapter 8 15 12 - - - 
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PFMVC, followed by KEMVC. Participants then performed a maximal handgrip strength test 
with their dominant hand. Those MD participants that were capable and confident then 
completed a 10 m walk. Following completion of physical measures, a wrist-worn 
accelerometer was attached to the wrist of the self-reported dominant arm, and worn for 
seven consecutive days (GENEActiv, Cambridge, United Kingdom). In addition, participants 
were given a pack of health related questionnaires to complete (participants were instructed 
to return both the questionnaires and accelerometer at their next physiotherapy 
appointment). For the questionnaires, the principal investigator was available to answer any 
queries, however participants were allowed to take the questionnaires home to reduce time 
commitments. In the case of DMD participants, the principal investigator was available to 
assist with completion, given their severe physical limitations.  
Only MD participants performed Visit 2. Visit 2 consisted of all physical measures reported 
above, with the exception of 10 m walk, and were completed Pre-Physio and Post-Physio. 
Visit 3 (12 months follow up) completed the physical measures of participant characteristics, 
PFMVC, KEMVC and PA.  
3.3 Measures 
3.3.1 Anthropometry 
CTRL participants’ BM was measured by digital scales (Seca model 873, Seca, Germany). 
Alternatively, all MD participants were weighed in a digital seated scales system (6875, 
Detecto, Webb City, Mo, USA). Slings, shoes, splints etc. were weighed separately and 
subtracted from the gross weight. All participants’ height was calculated as point-to-point of 
arm span (index finger, elbow, shoulder and across midline) to replicate the method used on 
non-ambulatory participants, consistent with previous MD research (Morse, 2016; Morse et 
al., 2018; Morse et al., 2015). A correction of 3.5% was applied to the raw data, consistent 
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with regression data from Caucasian males in order to account for the known discrepancy 
between height and arm span measures (Reeves et al., 1996).  
3.3.2 Body Composition 
Body composition measures of fat and lean LBM were measured using BIA in a fasted state, 
with adhesive electrodes placed on the right hand and foot. Two distal electrodes were placed 
on the dorsal surfaces of the metatarsals and metacarpals, and two proximal electrodes were 
placed between the medial and lateral malleoli of the right ankle, and between the styloid 
processes of the right ulna and radius. BIA has been commonly used as a quicker, cheaper and 
more easily accessible alternative to other body composition measures, such as Dual-Energy 
X-Ray Absorptiometry (DEXA). BIA has been shown to be valid and reliable in comparison to 
DEXA in adults of healthy weight (r=0.99) (Okasora et al., 1999) and in overweight populations 
(r=0.78) (Sun et al., 2005). In addition, BIA has been promoted as a measure for change in fat 
and LBM over time in a dystrophic population (Mok et al., 2010). 
LBM was determined by the following equation: 
𝐿𝐵𝑀 (𝐾𝑔) = 𝐵𝑜𝑑𝑦 𝑀𝑎𝑠𝑠 (𝐾𝑔) − 𝐹𝑎𝑡 𝑀𝑎𝑠𝑠 (𝐾𝑔) 
Body Mass Index (BMI) was calculated using the following equation (McCabe et al., 2013): 
𝐵𝑀𝐼 (
𝐾𝑔
𝑚2
) = 𝐵𝑜𝑑𝑦 𝑀𝑎𝑠𝑠 (𝐾𝑔) ÷ 𝐻𝑒𝑖𝑔ℎ𝑡2(𝑚2) 
3.3.3 Muscle Morphology 
The same B-mode real-time ultrasound (MyLab Gamma; Esaote, Reading, Berks, UK) with a 
7.5-MHz linear array probe was used to complete all measurements of Tibia Length (LTibia), 
Achilles Tendon Length (LTendon) and LGM. All measures took place with the participant seated, 
with knee and hip angles maintained at 90°. Non-ambulant participants remained seated 
within their manual/power wheelchair. All participants were measured with ankle angle as 
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close to 0° (neutral position) as possible, however, not all participants’ ankles were able to be 
mechanically moved into a neutral position, with ankles typically in a plantar-flexed position 
due to contractures, and so measures were taken from as close to neutral position as possible. 
3.3.3.1 Muscle-Tendon Unit Length 
LTibia was measured using a tape over the skin surface following identification of the medial 
condyle and medial malleolus. LGM was measured using tape over the skin surface following 
identification of the visible origin of the GM at the posterior aspect of the femur to the distal 
formation of the MTJ by use of sagittal plane ultrasonography. LTendon was measured as the 
distance from the GM MTJ to the insertion of the Achilles tendon into the calcaneus. MTU 
length (LMTU) was determined by the sum of LGM and LTendon. 
3.3.3.2 GM ACSA 
GM ACSA was measured using transverse ultrasound scans (7.5-MHz linear array probe) at 
50% of muscle length, consistent with the muscle length at which the largest ACSA occurs 
(Fukunaga et al., 1992). Muscle length was measured with a tape measure over the skin 
surface, following identification of the visible origin of the GM at the posterior aspect of the 
femur to the distal formation of the MTJ through ultrasonography. 
Echoabsorptive tape (Transpore, 3M, USA) was used to project shadows on the ultrasound 
image during recording to provide a positional reference. Strips of tape were placed 
longitudinally across the GM at 50% of muscle length, at approximately 3 cm intervals. The 
probe was moved in the transverse plane from the medial to the lateral borders of the muscle 
while digitally recording. Ultrasound transmission gel (Aquasonic 100, New Jersey, USA) was 
used to maximise image quality; minimal and consistent pressure was applied to avoid 
compression of the muscle. Ultrasound was recorded in real time (at 25 frames per second) 
and stored prior to digitising. Ultrasound recordings were exported into video editing 
44 
 
software (PowerDirector V6; Cyberlink Corporation, Tokyo, Japan), from which still images 
were captured. Images were captured at intervals consisting of two reference markers, as 
shown by shadows projected on the muscle from echoabsorptive tape. The entire GM ACSA 
was then recreated into a single image (Graphic Image Manipulation Program, GIMP 
Development) using the shadows from echoabsorptive tape, muscle markers and aponeurosis 
of the muscle. The ACSA was then measured using digitising software (ImageJ 1.45, National 
Institute of Health, USA). This method of ACSA measurement using ultrasound has been 
performed previously in dystrophic conditions (Morse et al., 2015; Jacques et al., 2017), and 
previously reported as a valid (0.998) and reliable (0.999) measure in comparison to magnetic 
resonance imaging (MRI) (Reeves et al., 2004). 
3.3.4 Ankle ROM 
An electro-goniometer (K100, Biometrics Ltd, UK) was attached to the self-reported dominant 
ankle, aligned with anatomical landmarks of the fibula and fifth metatarsal bone, and 
calibrated using a manual goniometer. The electro-goniometer was displayed in real-time on 
a laptop to provide feedback by a self-coded program using MyLabView (National 
Instruments, Berkshire, UK). All participants were tested in a seated position with hip and 
knee angles at 90°s, a 30 cm block was also placed under the knee of participants, ensuring 
foot clearance from the ground. For ROM presentation, goniometric data is presented with 
0° as a right angle to the tibia, with movement superiorly considered negative, and inferiorly 
considered positive, relative to 0° (see Figure 5.1). This presentation of ankle angle as positive 
and negative in consistent with previous work associated with ankle stiffness measurements 
(Morse, 2011; Morse et al., 2008; Ryan et al., 2008; Mizuno et al., 2013a; Mizuno et al., 
2013b). 
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3.3.4.1 Resting Angle 
A single measure of resting angle, defined as the angle in which the ankle rests at naturally 
without any force applied, was recorded.  
3.3.4.2 ROMActive 
Two trials were performed for total ROMActive, consisting of the participant moving their foot 
independently to its maximum ROM, with the principal investigator stabilising the ankle. 
Participants were instructed to “point your toes towards the floor as much as you can” to 
identify maximum active plantarflexion (Max PFActive), followed by “point your toes to the sky 
as much as you can”, to identify maximum active DF (Max DFActive). The maximum values were 
taken as Max DFActive and Max PFActive, respectively. ROMActive was determined by the absolute 
sum of Max PFActive and Max DFActive.  
3.3.4.3 ROMPassive 
To perform ROMPassive assessment the dominant foot of participants was securely fastened to 
a footplate, with a load cell attached underneath (see Force Measures below), (Note: the 
footplate was not attached for either Resting Angle or ROMActive measures, as the weight of 
the footplate could impact resting angle, or the participant’s ability to perform ROMActive). 
Two trials were performed to identify Max PFPassive and Max DFPassive, with the principal 
investigator moving the foot through ROM until participant discomfort, with maximal values 
used for analysis. ROMPassive was determined by the absolute sum of Max PFPassive and Max 
DFPassive.  
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Subsequently, two trials of ultrasound and stiffness assessment were then performed (see 
MTU and GM Stiffness below).  
Figure 3.2: Schematic diagram of MTU Morphology and ROM Measures. ROMPassive – Passive 
Range of Motion; ROMActive – Active Range of Motion; Max DFPassive – Maximum Passive 
Dorsi-Flexion; Max DFActive – Maximum Active Dorsi-Flexion; Max PFActive – Maximum Active 
Plantar-Flexion; Max PFPassive – Maximum Passive Plantar-Flexion; GM – Gastrocnemius 
Medialis; MTJ – Myotendinous Junction; MTU – Muscle-Tendon Unit.  
3.3.4.4 Reliability of ROM measurement 
Goniometry has been extensively used to monitor ROM in DMD (Archibald and Vignos Jr, 
1959; Johnson et al., 1992). In DMD high intra-tester reliability has been reported (ICC= 0.90), 
however lower reliability has been reported for inter-tester reliability (ICC= 0.73) (Pandya et 
al., 1985), therefore the Principal Investigator recorded all goniometric assessments. 
Reliability testing was performed across all four dystrophic conditions, with within-day 
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reliability performed with 1 minute breaks between trials, while between-day reliability was 
performed over 2 separate days, separated by 1-4 weeks, to coincide with participants’ 
physiotherapy appointment. The high between-day Intra-Class Correlations (ICC) (See Table 
5.1) are testament to the lack of condition progression in the short time period between 
assessments. 
Table 3.3. Intra-Class Correlations of Goniometry 
Condition n Between-Day ICC Within-Day ICC 
ROMPassive ROMActive ROMPassive ROMActive 
DMD  16 .962 .984 .965 .969 
BMD 17 .891 .932 .958 .964 
LGMD 10 .894 .841 .913 .932 
FSHD 13 .901 .912 .924 .949 
Table 3.3. Intra-Class Correlations of Goniometry. DMD = Duchenne Muscular Dystrophy, 
BMD = Beckers Muscular Dystrophy, LGMD = Limb-Girdle Muscular Dystrophy, FSHD = 
Facioscapulohumeral Muscular Dystrophy, ICC = Intra-Class Correlations, ROMPassive = Passive 
range of motion, ROMActive = Active range of motion. 
3.3.5 Muscle Properties through RoM 
Simultaneous recordings of MTJ Displacement, passive PF torque, and joint angle were 
recorded for the calculation of MTU and GM stiffness through ROMPassive, with one minute 
breaks between trials. The Principal Investigator moved the participant’s foot though 
ROMPassive from the previously identified Max PFPassive to Max DFPassive at a maximum rate 5°. s-
1 (Morse et al., 2008), measured by a live feedback system. Measures of MTJ Displacement 
and Max Passive PF Torque are presented relative to the resting angle, comparable with 
previous methods of GM stiffness in CTRLs (Blazevich et al., 2014), and consistent with 
methods used in cerebral palsy where participants feet typically remain in PF (Hussain, 2013). 
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3.3.5.1 MTJ Displacement 
During assessment of movement through ROMPassive, B-mode ultrasonography was used to 
track the distal displacement of the previously identified GM MTJ (See Muscle Morphology). 
The GM was chosen for analysis as it contributes significantly more to the contractile area of 
the triceps surae than the Gastrocnemius Lateralis (26% vs 12%, respectively) (Albracht et al., 
2008), hence contributes more to the passive properties of DF. In addition, although the 
Soleus contributes more (62%) to PFMVC, the deeper nature of the Soleus, along with the 
degradation of muscle tissue impairs ultrasound image quality (Jacques et al., 2017; Morse et 
al., 2015), making it difficult to accurately track in MD. Furthermore, tracking of the soleus 
requires participants to be laid prone, which the DMD participants would be unable to do. 
The ultrasound was time-locked with force and goniometer outputs. MTJ displacement was 
measured relative to an acoustically reflective marker (a thin strip of micro-pore tape) on the 
skin proximal to the MTJ, consistent with techniques used previously (Maganaris, 2005). 
Images were recorded online from Max PFPassive to Max DFPassive and analysed offline every 5° 
from resting angle to Max DFPassive, using digitising software (ImageJ 1.45, National Institute 
of Health, USA). 
3.3.5.2 Max Passive PF Torque 
Max Passive PF torque was calculated based on force measures recorded using a load cell 
attached underneath the footplate. The force produced was digitized using an analogue-to-
digital converter and displayed in real-time using a self-coded program using MyLabView 
(National Instruments, Berkshire, UK). Force (N) was converted to moment (N.m) by 
multiplying the force measurement by the moment arm, from the axis of rotation (ankle) to 
the point of the load cell on the footplate. Force measures were displayed in real-time, but 
analysed offline. Due to the severe level of contractures and difficulties with body mechanics, 
all strength testing protocols were designed for the most severely physically limited 
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participants, and replicated across all conditions and participants. The load cell was calibrated 
prior to every testing session in 500g increments, up to 5kg. 
Due to some passive PF torque being recorded even when at rest, attributed to the mass of 
foot and limitations of ROM, Max Passive PF torque was normalised to 0 N.m from the point 
of resting angle, and measured from this point to Max DFPassive. Two trials were performed 
with the Max Passive PF Torque taken for analysis. If more than 5% difference was found 
between the two trials for Max Passive PF Torque, a third trial was performed. Similar 
methods of passive PF torque assessment have been used previously in other clinical 
conditions (Rao et al., 2006).  
3.3.5.3 Stiffness Calculations 
MTU and GM stiffness are calculated as below (Morse, 2011; Morse et al., 2008): 
MTU stiffness (N.m.deg-1) = Max Passive PF Torque (N.m)/ Ankle Angle (deg)  
GM stiffness (N.m.cm-1) = Max Passive PF Torque (N.m)/MTJ Displacement (cm) 
3.3.6 Strength 
Due to the severe level of contractures and difficulties with body mechanics, all strength 
testing protocols were designed for the most severe participants, and replicated across all 
conditions and participants. Isometric PFMVC and KEMVC force was recorded using a load cell 
with the participants in a seated position. The load cell was calibrated prior to every strength 
testing session. Three trials were performed, with extended breaks of 1 minute between trials 
due to the increased fatigue associated with MD (Sharma et al., 1995). The highest measure 
of the three trials was used for analysis. The force produced was digitized using an analog-to-
digital converter, displayed by a self-displayed and coded program using MyLabView 
(National Instruments, Berkshire, UK). Force (N) was converted to moment (N·m) by 
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multiplying the force measurement by the moment arm from the axis of rotation (knee or 
ankle) to the point of force measurement (the strap height on the shin, or ball of the foot). 
PFMVC and KEMVC measures have been presented as torque (N.m) and normalised to BM 
(N.m/Kg) and presented as KEMVC/BM and PFMVC/BM respectively, while PFMVC is also 
normalised to GM ACSA (N.m/cm2) and presented as PFMVC/ACSA. 
3.3.6.1 MVC Protocol  
All MVC measures took place with the participant seated, with knee and hip angles 
maintained at 90°. Non-ambulant participants remained seated within their manual/power 
wheelchair. For KEMVC, straps were used to limit hip flexion during contractions. A strap was 
securely fastened around ankle and attached perpendicularly to the load cell, which was 
securely fastened to a weighted support bar. The strap length was shortened until the strap 
was taut between the load cell and limb, while maintaining limb position. All participants were 
verbally encouraged throughout their maximal effort. 
All participants PFMVC was measured with ankle angle at 0° (neutral position), however, not 
all participants’ ankles were able to be mechanically moved into a neutral position, with 
equinus deformity common in MD (Williams et al., 1984), and so measures were taken from 
as close to neutral position as possible. The participants’ foot was attached to a footplate, 
with the load cell attached underneath. The Principal Investigator produced the resistive force 
to ensure a static/isometric contraction occurred during MVC. Plantar-flexion forces were 
normalised for gravity. 
3.3.6.2 MVC Reliability  
Similar techniques to those used within this chapter have been common within 
neuromuscular research. The KEMVC protocol is similar to Quantitative Muscle Testing, and 
has been previously used within both clinical and non-clinical populations (Brussock et al., 
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1992; Hogrel et al., 2007; Narici et al., 1996). The plantar-flexion measures are restricted by 
the mechanical limitations previously mentioned within these conditions, namely capacity the 
put the leg into full extension due to contractures and remain self-supported; however similar 
techniques using a non-mechanical resistive force are common in dystrophic research (Willis 
et al., 2013; McDonald et al., 2013). Reliability testing was performed across all four 
dystrophic conditions, with within-day reliability performed with 1 minute breaks between 
trials, while between-day reliability was performed over 2 separate days, separated by 1-4 
weeks, to coincide with participants’ physiotherapy appointment. Intra-Class Correlations 
(ICC) (See Table 3.1) showed strong reliability for between-day and within-day reliability 
across all conditions for KEMVC and PFMVC, and were in fact comparative or even stronger 
than ICCs in previous quantitative muscle assessment studies (Personius et al., 1994; Escolar 
et al., 2001; Lewelt et al., 2015). 
Table 3.4 Intra-Class Coefficients for Muscle Strength 
Condition n Between-Day ICC Within-Day ICC 
Plantar-Flexion Knee Extension Plantar-Flexion Knee Extension 
DMD  15 0.984 0.987 0.985 0.991 
BMD 18 0.832 0.991 0.911 0.992 
LGMD 13 0.946 0.985 0.921 0.980 
FSHD 14 0.921 0.956 0.934 0.973 
Intra-Class Correlations for muscle strength in dystrophic conditions. DMD – Duchenne 
Muscular Dystrophy; BMD – Beckers Muscular Dystrophy; LGMD – Limb-Girdle Muscular 
Dystrophy; FSHD – Facioscapulohumeral Dystrophy. 
3.3.7 Handgrip 
A digital handgrip dynamometer (Jamar plus, Patterson Medical, USA) was used to assess grip 
strength. Of the participants able to produce a measureable grip strength (three DMD 
participants produced 0 kg grip strength), three maximal attempts were performed. Measures 
were taken in a seated position for all participants, on their self-reported dominant hand, 
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with the arm in an extended position to the side of the body. Extended one-minute rest 
periods were allowed between trials due to the previously mentioned high fatigability of 
these conditions. 
3.3.8 10m Walk Test 
A 10m walk test was performed by 20 out of 24 ambulant participants (8 BMD, 2 LGMD and 
10 FSHD). The 10m walk was performed on an even, carpeted surface, and is a common 
measure of function within neuromuscular conditions (McDonald et al., 2013; Fowler et al., 
2017). All participants started in a standing position and were instructed to walk as quickly 
and safely as they could, with the time recorded from the point of “Go” from the Principal 
Investigator, to the point of crossing the finish line. Walking aids were permitted if required. 
Given the limited numbers, these participants were pooled for analysis upon 10m walk time. 
Please note that the 10m walk time was used only for MD participants, this is a standard 
functional measure relevant to clinical groups, and was therefore not measured in CTRL. 
3.3.9 Physical Activity  
Daily PA was monitored over a consecutive 7-day period using a wrist-worn tri-axial 
accelerometer (GENEActiv, Kimbolton, Cambs, United Kingdom). Wrist worn accelerometers 
have previously been recommended as the best location for accelerometers for wheelchair 
users (Nightingale et al., 2015).  Furthermore, accelerometer attachment of mid-thigh was 
trialled on one participant, however had to be removed due to being uncomfortable once 
back their wheelchair. In addition, this thesis is focused on monitoring activity, rather than 
sitting time, therefor wrist-worn accelerometers other hip or mid-thigh accelerometer was 
deemed acceptable. Monitors were worn for 24 hours a day on the preferred wrist of 
participants and worn continuously for 7 days, which was deemed the minimum wear time 
(Dillon et al., 2016). Monitors remained on during sleep, with no participants, or collected 
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data, suggesting monitors removed during sleep, or during the 7 days of data collection. 
Monitors were initialised to collect data at 100 Hz and acceleration values, recorded in “g’s”, 
and recorded continuously on each axis (x, y, and z). Recorded total activity time has been 
previously validated against doubly labelled water (van Hees et al., 2011). In addition, 
GENEActiv validation studies for both PA and SB have shown strong correlations (Pearson’s 
r=0.79-0.98) (Phillips et al., 2013; Esliger et al., 2011). 
Once wrist-worn monitors were returned post 7-day period, data was downloaded from 
monitors into .bin files and converted into 60s epoch .csv files using the GENEActiv PC 
Software (Version 2.1). 60s epoch data files were entered in an open source Excel macro (v2, 
Activinsights Ltd.) (Esliger et al., 2011), which classified activity as sedentary (SB), light, 
moderate or vigorous intensity, dependant on the physical characteristics of participant age, 
height and weight. The PA intensity thresholds used within the macro were not designed for 
adults with MD, therefore rather than incorrectly allocating PA to intensity domains, activity 
will be presented as time as sedentary or total time spent physically active (TPA). TPA, the 
sum of light, moderate and vigorous PA time, is presented as average daily minutes (TPAmins), 
while SB is presented as percentage of waking hours (SB%). Both SB% and TPAmins will be used 
for comparisons, as well as correlations and regression analysis.  
3.3.10 Questionnaires 
3.3.10.1 Quality of Life 
All participants completed the SF-36v2 questionnaire (Appendix 4), a reliable and validated 
measure, with eight domains of QoL (Ware Jr and Sherbourne, 1992; Jenkinson et al., 1999). 
The constructs for the domains of QoL are Physical Functioning, Role-Functioning Physical, 
Role-Functioning Emotional, Social Functioning, Bodily Pain, Mental Health, Vitality and 
General Health (Ware et al., 2008). All measures are scored out of 100, with higher scores 
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representative of better health, better function and less pain. The SF-36v2 has been used and 
validated extensively in the general population; however, it has also been used extensively in 
Dystrophic populations (Simonds et al., 1998; Padua et al., 2009; Abresch et al., 2002; Kohler 
et al., 2005). In addition to the eight domains within the SF-36v2, data is also presented as 
Total Mental and Total Physical component scores, and SF6D, a total mean score derived from 
a selection of SF-36v2 items. All data was analysed using Health Outcomes Scoring Software 
4.5 (QualityMetric Health Outcomes™, Lincoln, United Kingdom). Furthermore, the SF-36v2 
allows for participants perspective on their lives generally, more recent neuromuscular 
disorder QoL assessments have very specific questions, consisting of “how does your 
condition affect….” (Vincent et al., 2007). These forms of assessment restrict CTRL 
comparisons, and similarly require participants to disassociate many aspects of their lives 
from their condition, which may or may not be affected them. 
3.3.10.2 Activities of Daily Living 
Activities of Daily Living (ADL) were assessed using the Nottingham Extended ADL Scale 
(NEADL; Appendix 5), a 22 item based measure of ADL covering four domains of activity 
(Mobility, Domestic, Kitchen and Leisure). Respondents record what they have actually done 
over the last few weeks, with possible answers “Not at all”, “With help”, “On your own with 
difficulty”, or “On your own”. To increase sensitivity, scores were allocated using a Likert scale 
“0-1-2-3” (Sveen et al., 2004; Ho et al., 2001), rather than “0-0-1-1” as typically used, 
therefore scores ranged from 0-66 with higher scores representing greater independence. 
The NEADL has been previously validated in other clinical conditions (Gladman et al., 1993; 
Harwood and Ebrahim, 2002).  
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3.3.10.3 Fatigue 
The Checklist Individual Strength (CIS; Appendix 6) is a 20-item self-report questionnaire 
originally developed for Chronic Fatigue Syndrome (Vercoulen et al., 1994). The CIS has 
domains of: Fatigue Severity (8 items), Concentration (5 items) Motivation (4 items) and 
physical activity level (3 items), as well as Total. Items are scored on a 7-point Likert scale. 
Higher scores indicate a higher degree of fatigue, concentration problems, reduced 
motivation or less activity, respectively. Reliability of CIS has been previously reported as good 
(α= 0.82-0.92) (Vercoulen et al., 1994) and has good discriminate validity (Vercoulen et al., 
1999). The Severity subscale of the CIS has been used previously to identify chronic fatigue in 
adults with FSHD (Kalkman et al., 2005; Voet et al., 2014). Therefore, for the purposes of the 
present study, while participants completed the whole 20-item questionnaire, only the 
Fatigue Severity scale (8 items) from the CIS has been used for analysis, and is hereafter 
referred to as CIS Severity, and is scored out of a possible 56, with scores over 35 deemed 
representative of chronic fatigue. 
3.3.10.4 Pain 
A Visual Analog Scale (Pain VAS) of pain was used to quantify the level of pain felt by 
participants over the 7 days preceding assessment (Appendix 7). VAS is a common method of 
pain assessment (Price et al., 1983) and used in many conditions (Padua et al., 2009; Douvillez 
et al.; Moulin et al., 1997). Participants were given a 10cm straight line, with at one end “No 
Pain”, and the other “Worst Possible Pain”, and instructed to mark where, on average, they 
felt their pain over the preceding 7 days was on the scale. The mark was then measured and 
presented as distance (cm) from the “No Pain” end.  
3.3.10.5 Self-Efficacy 
The General Self Efficacy Scale (Jerusalem and Schwarzer, 1979) is used as a measure of an 
individual’s perception of their ability to overcome problems and challenges (Appendix 8). 
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Most Self-Efficacy scales used clinically are rehabilitative, and focussed on improvements or 
return to physical status, and were deemed invalid for a degenerative muscle condition. 
Therefore, The General Self Efficacy Scale was used, a scale which focuses on overcoming 
problems rather than rehabilitation. The General Self Efficacy Scale is a 10-item scale, using a 
4-point Likert Scale for each question. Possible responses to questions are: not at all true (1), 
hardly true (2), moderately true (3), and exactly true (4), resulting in a total score between 10 
(lowest possible) and 40 (highest possible). High reliability, stability, and construct validity 
have been confirmed in various previous studies (Leganger et al., 2000; Schwarzer et al., 
1999), with strong Crohnbach Alpha levels ranging 0.87-0.95 across different clinical 
conditions (Luszczynska et al., 2005). 
3.3.11 Physiotherapy Intervention 
For the Physiotherapy intervention in Chapter 7, all participants received their standard 
physiotherapy treatment delivered by the same Chartered Physiotherapist with experience 
in managing long-term muscle conditions. Physiotherapy sessions consisted of 60 minutes of 
whole-body passive stretches and range of movement exercises. Consistent with participants’ 
standard treatment, particular focus was given to moving muscles and joints to their maximal 
length and end ROM respectively, with general focus given to typical areas of limited ROM, 
namely ankles, hips, shoulders and fingers (Bushby et al., 2010). While each individual’s 
treatment would be slightly different to target issues relevant to their own condition 
progression and presentation, relevant to the outcomes in the present chapter, a minimum 
of 5 minutes of DF stretching was administered. DF was the focus of the treatment, as limited 
DF is a recognised feature of DMD (Williams et al., 1984) and consistently limited across adults 
with DMD (Chapter 5). As this thesis is describing the current “service provision” of 
physiotherapy, rather than conducting a set number of stretches, it is not possible to outline 
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in further detail what was completed within each individual session. Normal practice for 
stretches tends to be limited by the participants’ volitional stretch tolerance. Despite the 
limited guidance for physiotherapists working with neuromuscular disorders, typical practice 
at The NMC for passive stretches consists of holding stretches at their maximal length for up 
to 30s, before a release of stretch, and then passively stretch to maximal length again. 
3.3.12 Minimal Detectable Change 
Consistent with previous research, the author deemed it unethical to deny any participants 
access to physiotherapy (Hyde et al., 2000), therefore no CTRL group was formed. MDC scores 
were however, calculated to determine the minimal change required beyond the error of 
measurements (Haley and Fragala-Pinkham, 2006). MDC was calculated using intra-class 
correlation coefficients (ICC) and standard error of measurements (SEM) from data collected 
at baseline and pre-physio (Hoch et al., 2012). MDC scores are presented in relevant tables, 
intervention changes are only deemed significant if they meet both statistical and MDC 
criterion. Calculations are as below: 
𝑆𝐸𝑀 = 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑆𝐷 𝑥 (√1 − 𝐼𝐶𝐶) 
𝑀𝐷𝐶 = 1.96 𝑥 𝑆𝐸𝑀 𝑥 √2 
Please note: adults with DMD are severely impaired (Chapter 4) and all participants use 
powered-wheelchairs, therefore no internal or external influences are likely to affect ROM, 
any effect identified in the present chapter is likely a direct result of the physiotherapy 
received. This is emphasised by the SB% times occupying 98% of their waking hours (Chapter 
4). 
Furthermore, please note that the principal investigator is aware of minimal clinically 
important difference (MCID). The use of MCID however for the effectiveness of physiotherapy 
58 
 
was deemed redundant in this case. While MCID may be relevant for conditions whereby a 
return to function is possible, given the extremely limited ROM in DMD, no possible return to 
function and a lack of previous data, MCID was not used during this thesis to assess 
physiotherapy.  
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Chapter 4 
Relationships between muscle size, 
strength and physical activity in adults 
with Muscular Dystrophy 
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4.1 Abstract 
Background 
Muscular Dystrophy (MD) is characterised by progressive muscle wasting and weakness, yet, 
few comparisons to non-MD controls (CTRL) of muscle strength and size in this adult 
population exist. Physical activity (PA) is promoted to maintain health and muscle strength 
within MD, however PA reporting in adults with MD is limited to recall data, and its impact on 
muscle strength is seldom explored. 
Methods 
This chapter included 76 participants 16 CTRL, 15 Duchenne (DMD), 18 Becker’s (BMD), 13 
Limb-Girdle (LGMD), 14 Facioscapulohumeral (FSHD)). Body fat (%) and lean body mass (LBM) 
were measured using bioelectrical-impedance. GM ACSA was determined using B-mode 
ultrasound. Isometric maximal voluntary contraction (MVC) was assessed during plantar-
flexion (PFMVC) and knee extension (KEMVC). Physical activity was measured for seven 
continuous days using tri-axial accelerometry, and was expressed as daily average minutes 
being physically active (TPAmins) or average daily percentage of waking hours being sedentary 
(Sedentary Behaviour). Additionally, 10m walk time was assessed. The Kruskal Wallis test with 
post-hoc Mann-Whitney U (Least Significant Difference) pairwise comparisons for non-
parametric comparisons and one-way analysis of variance (ANOVA), with Tukey’s used for 
post-hoc comparison, for parametric data. Kendall Tau correlations were used to identify 
associations and Bivariate linear regression were used to identify the best predictor of 10m 
walk from associated variables.  
Results 
MD groups had 34-46% higher body fat (%) than CTRL. Only DMD showed differences in LBM 
with 21-28% less LBM than all other groups. PFMVC and KEMVC were 36-75% and 24-92% 
lower respectively, in MD groups than CTRL. GM ACSA was 47% and 39% larger in BMD and 
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LGMD, respectively compared to CTRL. No other group differences in GM ACSA were 
observed. PFMVC was associated with GM ACSA in DMD (r= 0.429) and CTRL (r= 0.553). All 
MD groups were 14-38% more sedentary than CTRL groups, while DMD was more sedentary 
than BMD (14%), LGMD (8%) and FSHD (14%). Sedentary Behaviour was associated with LBM 
in DMD participants (r= -0.446). TPAmins was associated with KEMVC (r= 0.540) in BMD 
participants, while TPAmins was also the best predictor of 10m walk time (R2= 0.540) in 
ambulant participants, revealed by multiple linear regression.  
Conclusions 
The data from this chapter showed impaired muscle strength in adults with MD and impaired 
10m walking time, in ambulant adults with MD. These observations of weakness and 10m 
walk time were associated with lower levels of TPA in adults with MD. In addition, higher 
levels of sedentary behaviour were associated with reduced LBM in DMD. These findings 
suggest a need for investigations into patterns of physical activity behaviour, and relevant 
interventions to reduce Sedentary Behaviour and encourage PA in adults with MD regardless 
of impairment severity.  
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4.2 Introduction 
Relationships between muscle size and strength have long been recognised and reported in 
healthy and clinical populations (Fukunaga et al., 2001; Visser et al., 2000; Hussain et al., 
2014). Similarly, the importance of PA and exercise to maintain strength and health is 
commonly recognised (Goodpaster et al., 2006; Lauretani et al., 2003), these relationships 
however, have received little or no attention in adults with MD. Where reported in children, 
the applicability to adults may be limited due to the degenerative/heterogeneous nature of 
some classifications of MD (Huml, 2015). Despite an increasing volume of research supporting 
exercise interventions to maintain muscle function within this clinical population (Sveen et 
al., 2008; Van der Kooi et al., 2004), basic understanding of the relationship between muscle 
structure/function, and habitual levels of PA in adults with MD remains largely unexplored 
(Jimenez-Moreno et al., 2017). 
Decreased muscle strength has long been recognised within MD and attributed to progressive 
muscle wasting (Akima et al., 2012; Skalsky et al., 2008; Skalsky et al., 2009). Lower limb 
strength comparisons between adults with MD and age-matched CTRL have been made in 
adults with BMD (Løkken et al., 2016), LGMD (Løkken et al., 2016) and FSHD (Skalsky et al., 
2008; Bachasson et al., 2014). Of these comparisons, lower KEMVC was attributed to smaller 
lean mass in the KEMVC muscle group in FSHD (Skalsky et al., 2008). While Løkken et al. (2016) 
showed PFMVC was associated with cross-sectional area in adults with LGMD. Decreased 
muscle strength compared to CTRL has been reported in children and adolescents with DMD 
(Mathur et al., 2010; Akima et al., 2012). In children with DMD, pseudohypertrophy is evident, 
due to the inflammatory process associated with muscle degradation, resulting in apparent 
increased calf size compared to age-matched CTRL, however no relative increase in strength 
(Jones et al., 1983; Deconinck and Dan, 2007). The relationship between cross sectional area 
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with muscle strength remains unexplored in adults with DMD however, with Morse et al. 
(2015) reporting decreased cross-sectional area of the GM compared to CTRL, suggesting an 
end of pseudohypertrophy in adulthood, and muscle size possibly becoming more 
representative of muscle strength. 
Typically, in healthy adult populations, a combination of high habitual PA and medium 
intensity planned exercise sessions are recommended, in order to maintain and/or improve 
health, and muscle strength (Warburton et al., 2006; Nelson et al., 2007). Furthermore, within 
ageing populations, where sarcopenia and muscular atrophy can become evident, PA 
measures have been positively associated with muscle strength and functional measures 
(Morie et al., 2010). Similarly, Foong et al. (2015) reported a positive association between PA 
intensity and both, lower limb strength and lean mass in elderly participants. PA is promoted 
as a measure to maintain muscle mass and function within MD (Muscular Dystrophy 
Campaign, 2014). Jimenez-Moreno et al. (2017) however, recently presented a systematic 
review of habitual PA within neuromuscular disorders, highlighting the distinct lack of PA data 
currently reported. Subjective recall methods have been primarily used in MD research, 
namely the BPAQ (MD) (Morse, 2016; Jacques et al., 2017), Baecke Physical Activity 
Questionnaire (DMD) (Hawker et al., 2005) and a self-developed physical activity 
questionnaire (DMD) (Heutinck et al., 2015). Objective measures of PA levels in DMD include 
step count activity (McDonald et al., 2005; Davidson et al., 2015), accelerometry (Jeannet et 
al., 2011) and doubly labelled water (Elliott et al., 2015), but have only been used with 
children. Thus, all current research has shown reduced PA levels in MD compared to healthy 
CTRL, however, only two of the above mentioned papers have measured PA in adults with 
MD, both of which used recall methods, which lack objectivity (Jacques et al., 2017; Morse, 
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2016). Recall methods have been shown previously to over-estimate PA, and under-estimate 
SB (Dyrstad et al., 2014).  
In MD, PA may help to maintain muscle mass and strength, conversely, SB is likely to 
accelerate muscle atrophy through disuse, as well as promote other associated health risks 
such as increased fat mass, diabetes and heart disease (Shields and Tremblay, 2008; Tremblay 
et al., 2010; Dempsey et al., 2014; Wullems et al., 2016). Despite the lack of current 
knowledge and understanding of PA in MD, the importance of exercise and interventions are 
becoming more and more apparent within MD. Morse et al. (2016) highlighted the strong 
associations between bone health and lifetime PA in MD. While MD populations have also 
shown physiological improvements following aerobic exercise interventions (Sveen et al., 
2008). Ferguson et al. (2016) showed increased PA levels, through an aerobic training plan, 
decelerated muscle fat infiltration in adults with FSHD. Moreover, Jansen et al. (2013) showed 
assisted bicycle training delays functional deterioration in boys with DMD. Further 
understanding of the habitual PA of adults with MD, along with its relationships with other 
functional measures, may enhance and specify future interventions. 
This chapter aims to: 1) to investigate the relationship between muscle strength and size and 
2) establish the relationship between muscle size and strength with objective measures of 
physical activity, with implications for the maintenance of muscle function in MD. 
This chapter hypothesises that measures of KEMVC and PFMVC in MD will appear lower than 
CTRL, and DMD will be lower than all other MD. PA will similarly be lower in MD than CTRL, 
and lower in DMD than the other MD. GM ACSA will be associated with PFMVC in BMD and 
DMD. PA and SB% will be consistently associated with measures of LBM, PFMVC and KEMVC 
in FSHD, BMD and LGMD. 
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4.3 Methods 
For full details of methods see Chapter 3, in brief: this chapter included 76 participants (16 
CTRL, 15 DMD, 18 BMD, 13 LGMD, 14 FSHD). Body fat (%) and LBM were measured using 
bioelectrical-impedance. GM ACSA was determined using B-mode ultrasound. PFMVC and 
KEMVC were assessed using methods replicative of QMT. PA was measured for seven 
continuous days using tri-axial accelerometry, and was expressed as daily average minutes 
being physically active (TPAmins) or average daily percentage of waking hours being sedentary 
(Sedentary Behaviour). Additionally, 10m walk time was assessed. 
4.3.1 Statistical Analyses 
All analyses were performed using IBM Statistics 21 software. The critical level of statistical 
significance was set at 5%. Tests for parametricity (Shapiro-Wilks and Levenes) were 
performed upon all variables. All data, except for height and LBM, was non-parametric. 
Reliability of muscle strength measurements (KEMVC and PFMVC) within and between day 
was calculated using Intraclass Correlation Coefficients (absolute agreement) within the MD 
groups (See Table 3.1). The Kruskal Wallis test was used to compare between groups, with 
post-hoc Mann-Whitney U (Least Significant Difference) pairwise comparisons used where 
appropriate. Height and LBM was compared between groups using a one-way ANOVA, and 
Tukey’s used for post-hoc comparison. Kendall Tau correlations were used to identify 
associations of anthropometric variables, muscle size, muscle strength and physical activity. 
Significant associations with age were identified for KEMVC, KEMVC/BM and PFMBC/BM, 
therefore ANCOVAs were performed to determine whether differences remained when age 
was controlled for. Bivariate linear regression were used to identify the best predictor of 10m 
walk from muscle strength measures and TPAmins. Multiple linear regressions were used when 
two or more variables were associated. Post Hoc effect size was determined by Phi, using 
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PFMVC, KEMVC and TPAmins, with moderate-strong effect sizes shown (Phi = 0.75-0.85). 
Where relevant, comparisons are presented with P values, and the relative difference (%) 
from a named experimental group.  
4.4 Results 
4.4.1 Demographic, anthropometric and body composition measures 
DMD participants were younger than those with BMD (43%, P<0.001), LGMD (44%, P<0.001), 
FSHD (49%, P<0.001) and CTRL (32%, P=0.013) (Table 4.1). Furthermore, CTRL were younger 
than FSHD (25%, P=0.021) (Table 4.1). No other differences were found between groups for 
age (P>0.05). DMD participants were lighter than BMD (15%, P=0.032), LGMD (25%, P<0.001) 
and FSHD (15%, P=0.029) participants, while LGMD participants were heavier than CTRL (19%, 
P=0.012) (Table 4.1). There were no differences in stature between any groups (P>0.05). 
No differences were found between groups for BMI (P>0.05, Table 3.2). DMD (45%, P<0.001), 
BMD (38%, P<0.001), LGMD (56%, P<0.001) and FSHD (34%, P=0.002) participants had higher 
body fat% than CTRL participants (Table 3.2). DMD participants had less LBM compared to 
BMD (21%, P=0.001), LGMD (26%, P<.001), FSHD (22%, P=0.002) and CTRL (28%, P<0.001) 
participants (Table 3.2). No other differences were found between groups for LBM (P>0.05). 
BMD GM ACSA was larger than FSHD (40%, P=0.039) and CTRL (47%, P=0.001) participants, 
while LGMD participants’ GM ACSA was larger than CTRL (39%, P=0.015) participants (Table 
4.1). No other differences were found between groups for muscle size (P>0.05).  
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Table 4.1 Participant Characteristics and Anthropometrics 
 DMD BMD LGMD FSHD CTRL 
n 15 18 13 14 16 
Ambulant 0/15 10/18 4/13 10/14 16/16 
Age (years) 24.2 (6.1)B,LG,F 42.4 (13.5) 43.1 (124) 47.1 (11.1)C 35.4 (12.7) 
Mass (Kg) 73.1 (14.6)B,LG,F 86.5 (20.3) 96.9 (17.3)C 86.0 (11.2) 81.1 (18.2) 
Stature (cm) 172.0 (4.3) 177.4 (6.0) 179.5 (6.9) 178.6 (8.1) 177.5 (9.3) 
BMI (Kg/m2) 25.5 (4.1) 27.3 (6.2) 29.5 (4.8) 26.6 (3.4) 25.5 (3.7) 
Body Fat (%) 33.3 (6.7)C 29.2 (10.0)C 33.7 (4.7)C 27.6 (7.3)C 18.2 (4.5) 
Lean Body 
Mass (Kg) 
47.6 (7.7)B,LG,F,C 60.0 (9.1) 64.1 (9.3) 61.0 (8.6) 66.0 (13.2) 
GM ACSA 
(cm2) 
23.3 (16.5) 27.9 (15.9)C,F 23.9 (11.0)C 16.6 (4.5) 14.7 (4.5) 
Anthropometric measures. DMD = Duchenne Muscular Dystrophy, BMD = Beckers Muscular 
Dystrophy, LGMD = Limb-Girdle Muscular Dystrophy, FSHD = Facioscapulohumeral Muscular 
Dystrophy, CTRL = Control, BMI = Body Mass Index, GM = Gastrocnemius Medialis, ACSA = 
Anatomical Cross Sectional Area. B denotes significance from BMD, LG denotes significance 
from LGMD, F denotes significance from FSHD, C denotes significance from CTRL. 
4.4.2 Muscle Strength 
CTRL KEMVC was significantly stronger than DMD (92%, P<0.001), BMD (41%, P=0.010) and 
LGMD (53%, P=0.020) (Table 4.2). DMD participants had weaker KEMVC than BMD (87%, 
P=0.001), LGMD (87%, P=0.002) and FSHD (90%, P<0.001) (Table 4.2). No differences were 
found between other groups (P>0.05). All differences between groups remained for KEMVC 
when age was controlled for by an ANCOVA. DMD participants were also significantly weaker 
in KEMVC per BM than BMD (86%, P=0.001), LGMD (82%, P=0.001), FSHD (88%, P<0.001) and 
CTRL (92%, P<0.001) (Table 4.2). While CTRL participants were stronger than BMD (40%, 
P=0.009) and LGMD (53%, P=0.003) participants in KEMVC/BM (Table 4.2). No other 
differences between groups were found for KEMVC/BM (P>0.05). When age was controlled 
for, all differences remained, in addition FSHD were shown as stronger than LGMD (32%, 
P=0.032) (Table 4.2). 
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CTRL participants were significantly stronger in PFMVC than DMD (75%, P<0.001), BMD (51%, 
P<0.001) and LGMD (58%, P<0.001) participants, respectively (Table 4.2). FSHD (62%, 
P<0.001) and BMD (49%, P=0.007) participants were also stronger than DMD participants 
(Table 4.2). No other differences were found between conditions (P>0.05). PFMVC/BM in 
CTRL was significantly stronger than DMD (72%, P<0.001), BMD (53%, P<0.001), LGMD (63%, 
P<0.001) and FSHD (39%, P=0.006) (Table 4.2). Similarly, FSHD were stronger than DMD (55%, 
P=0.002) and LGMD (39%, P=0.042) participants for PFMVC/BM. BMD participants greater 
PFMVC/BM than DMD (42%, P=0.017) participants (Table 4.2). Once age had been controlled 
for statistically, all differences remained, in addition FSHD were stronger than BMD (23%, 
P=0.048) for PFMVC/BM (Table 4.2). 
CTRL participants had significantly greater PFMVC/ACSA than DMD (80%, P<0.001), BMD 
(68%, P<0.001), LGMD (72%, P<0.001) and FSHD (40%, P=0.049) participants (Table 4.2). FSHD 
participants had greater PFMVC/ACSA than DMD (66%, P<0.001), BMD (47%, P=0.009) and 
LGMD (53%, P=0.005) participants (Table 4.2). No other differences were found between 
conditions (P>0.05).  
4.4.3 Grip Strength 
DMD had significantly weaker handgrip strength than BMD (85%, P=0.001), LGMD (85%, 
P=0.001), FSHD (87%, P<0.001) and CTRL (94%, P<0.001) participants (Table 4.2). Compared 
to CTRL, grip strength was weaker in BMD (63%, P<0.001), LGMD (63%, P<0.001) and FSHD 
(55%, P=0.003) groups (Table 4.2). No other differences were found between groups (P>0.05). 
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Table 4.2 Muscle Strength in Adults with Muscular Dystrophy 
 DMD BMD LGMD FSHD CTRL 
KEMVC (N.m) 
12.6 
(8.8)B,LG,F,C 
96.6 (60.0)C 
93.5 (56.6) 
C 
123.6 (78.2) 164.6 (55.9) 
KEMVC/BM (N.m/Kg) 
0.17 
(0.1)B,LG,F,C 
1.23 (0.9)C 
0.97 
(0.6)F,C 
1.41 (0.8) 2.04 (0.6) 
PFMVC (N.m) 16.7 (6.8)B,F,C 32.7 (13.7)C 
28.2 
(15.4)C 
43.8 (20.3) 67.0 (13.1) 
PFMVC/BM (N.m/Kg) 
0.23 
(0.1)B,LG,F,C 
0.40 (0.2)F,C 
0.31 
(0.2)F,C 
0.51 (0.2)C 0.84 (0.1) 
PFMVC/ACSA 
(N.m/cm2) 
0.92 (0.5)F,C 1.46 (0.9)F,C 
1.29 
(0.8)F,C 
2.75 (1.3)C 4.58 (0.7) 
Handgrip (Kg) 3.0 (3.1)B,LG,F,C 19.5 (14.9)C 19.6 (9.5)C 24.1 (13.2)C 53.5 (10.0) 
Strength measures. DMD = Duchenne Muscular Dystrophy, BMD = Beckers Muscular 
Dystrophy, LGMD = Limb-Girdle Muscular Dystrophy, FSHD = Facioscapulohumeral Muscular 
Dystrophy, CTRL = Control, KEMVC = Knee Extension, PFMVC = Plantar-Flexion, N.m = Newton 
Metres, BM = Body Mass, Kg = Kilograms, ACSA =Anatomical Cross Sectional Area. B denotes 
significance from BMD, LG denotes significance from LGMD, F denotes significance from FSHD, 
C denotes significance from CTRL. 
4.4.4 Physical Activity 
Participants with DMD displayed higher SB% than BMD (14%, P<0.001), LGMD (8%, P=0.016), 
FSHD (14%, P<0.001) and CTRL (39%, P<0.001) participants (Table 4.3). Conversely, CTRL had 
lower SB% than BMD (29%, P<0.001), LGMD (33%, P<0.001) and FSHD (29%, P=0.004) 
participants (Table 4.3). No other differences were found between conditions for SB% 
(P>0.05). 
DMD participants had lower TPAmins than BMD (88%, P<0.001), LGMD (83%, P=0.010), FSHD 
(89%, P<0.001) and CTRL (96%, P<0.001) (Table 4.3). Furthermore, BMD (65%, P<0.001), 
LGMD (76%, P<0.001) and FSHD (64%, P=0.001) had lower TPAmins than CTRL (Table 4.3). 
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Table 4.3 Physical Activity and 10m Walk time. 
 DMD BMD LGMD FSHD CTRL 
TPAmins 
13.5 
(16.1)B,LG,F,C 
115.4 
(63.1)C 
80.3 
(34.6)F,C 
117.6 (58.2)C 
329.1 
(125.0) 
SB (%) 97.1 (3.3)B,LG,F,C 83.8 (8.8)C 88.9 (5.4)C 83.1 (6.4)C 59.3 (15.2) 
10m Walk (s)* n/a 11.8 (4.5) n/a 
Physical Activity and 10m Walk. DMD = Duchenne Muscular Dystrophy, BMD = Beckers 
Muscular Dystrophy, LGMD = Limb-Girdle Muscular Dystrophy, FSHD = Facioscapulohumeral 
Muscular Dystrophy, CTRL = Control, TPAmins = Total minutes being physically active, SB = 
Sedentary Behaviour, m = metre, s = second, * = performed by 20/24 ambulant participants, 
B denotes significance from BMD, LG denotes significance from LGMD, F denotes significance 
from FSHD, C denotes significance from CTRL, * = performed by 20/24 ambulant participants. 
4.4.5 Correlations 
Age was shown to be significantly associated with measures of PFMVC/BM (r= -0.408, 
P=0.026), KEMVC (r= -0.343, P=0.048) and KEMVC/BM (r= -0.384, P=0.030) in BMD. 
Anthropometric associations with muscle strength revealed significant associations between 
GM ACSA and PFMVC in CTRL (r= 0.553, P=0.003) and DMD (r= 0.429, P=0.026) participants, 
respectively. Other conditions showed positive, but non-significant associations between 
muscle size and PFMVC (P>0.05). No associations were identified between LBM and muscle 
strength measures in adults with MD (P>0.05).  
Sedentary Behaviour was negatively associated with LBM in participants with DMD (r= -0.446, 
P=0.021), but no other groups. Furthermore, Sedentary Behaviour was negatively associated 
with KEMVC (r= -0.477, P=0.006) and KEMVC/BM (r= -0.487, P=0.005) in BMD, with other 
dystrophic groups showing no correlation. Furthermore, TPAmins was associated with KEMVC 
in BMD (r= 0.407, P=0.020) participants. 
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Of the participants with the ability to ambulate, 20/24 recorded 10m walk times. Strength 
measures associated with 10m walk were KEMVC (r= 0.484, P=0.030) KEMVC/BM (r= 0.514, 
P=0.020), PFMVC (r= 0.502, P=0.024) and PFMVC/BM (r= 0.472, P=0.001). In addition, TPAmins 
was also associated with 10m walk (r= 0.735, P<0.001). Multiple linear regression identified 
TPAmins as the greatest predictor of 10m walk time (R2= 0.540, P<0.001), with all strength 
measures excluded. 
4.5 Discussion 
The present chapter showed cross-sectional findings of muscle weakness in adults across four 
MD classifications, with, as expected a direct relationship between muscle strength and 
muscle size observed in adults with DMD. In addition, objective measures of PA show 
increased levels of SB in all dystrophic conditions in comparison to CTRL, particularly within 
DMD participants who were more sedentary than BMD, LGMD and FSHD participants. 
Furthermore, relationships were identified between muscle strength, specifically KEMVC, and 
TPAmins in adults with BMD. Moreover, relationships were also identified between TPAmins and 
10m walk times in the 20, cross-condition, participants that completed the functional task. 
The present understanding of muscle strength in MD is primarily focussed in DMD paediatric 
populations (Mathur et al., 2010). Adults with DMD in the present chapter showed KEMVC 
92% less than CTRL participants, reflective of the degenerative nature of the condition, with 
previous paediatric studies reporting KEMVC as 72-86% less than CTRL (Akima et al., 2012; 
Lott et al., 2014; Mathur et al., 2010; Skalsky et al., 2009; Wokke et al., 2014; Lerario et al., 
2012). Similarly, the 75% lower PFMVC reported in the current chapter appears consistent 
with the progression of the condition, where previous studies have reported PFMVC in 
paediatric groups as 52-65% lower age-matched CTRL (Lott et al., 2014; Mathur et al., 2010; 
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Wokke et al., 2014; Vohra et al., 2015). More pronounced muscle weakness is predicted in 
adults with DMD, however this is likely exacerbated into adulthood by a lack of PA. The 
relative maintenance of muscle strength of plantar-flexors, compared to knee extensors, is 
consistent with the classical proximal-distal wasting (Emery, 2002); however may also be 
influenced by the long term impact of wheelchair-use. There is currently a lack of quality 
natural history reports using quantative measures of KE or PFMVC in adults with MD 
(McDonald et al., 2013), which will be described and assessed in Chapter 8. 
Despite weakness being a clinical diagnostic tool (McDonald et al., 2013; Griggs et al., 1993), 
there are limited quantitative measures of muscle strength in adults with MD compared to 
age matched CTRL. Differences from CTRL in the present chapter are similar to those reported 
previously. Of the other MDs measured (BMD, LGMD, FSHD), PFMVC in the present study was 
42-49% less than CTRL, compared to 48-61% reported in adults with BMD and LGMD (Løkken 
et al., 2016). Additionally KEMVC in the present study was 25% less than CTRL, compared to 
55-58% in previous studies of FSHD (Skalsky et al., 2008; Bachasson et al., 2014). The 
differences between the present and previous research can be attributed to the 
heterogeneity of conditions (Wicklund and Kissel, 2014), participant sex differences (present 
chapter contains all male participants) (Bachasson et al., 2014; Løkken et al., 2016), 
participants ages (Skalsky et al., 2008; Løkken et al., 2016), differences in strength assessment 
(Skalsky et al., 2008; Løkken et al., 2016) or condition severity in the participant groups (e.g. 
47% non-ambulant, excluding DMD, in the current chapter), with previous research typically 
all ambulant (Skalsky et al., 2008; Løkken et al., 2016). The presented data can be seen as a 
comparison to previously reported lower limb muscle strength in Figure 4.1. The present data 
is particularly novel in the objective assessment of SB and PA as contributing factors to the 
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differences between groups and participants with MD. 
 
Figure 4.1. Muscle strength of PFMVC and KEMVC in DMD, BMD, LGMD and FSHD, based on 
comparisons relative to CTRL participants from Chapter 3 (Bold) and previous reports (Not 
Bold). Data is presented as the mean age of participants groups (X axis) to show the lifespan 
comparisons, and muscle strength as percentage of CTRL (Y axis). PF = Plantar-flexion maximal 
voluntary contraction; KE = Knee-extension maximal voluntary contraction D = Duchenne 
muscular dystrophy; B = Becker’s muscular dystrophy; LG = Limb-Girdle muscular dystrophy; F 
= Facioscapulohumeral muscular dystrophy’ CTRL = Control. (Bachasson et al., 2014; Forbes 
et al., 2013; Lott et al., 2014; Akima et al., 2012; Mathur et al., 2010; Skalsky et al., 2008; 
Skalsky et al., 2009; Wilson et al., 2018; Lerario et al., 2012; Løkken et al., 2016; Vohra et al., 
2015; Wokke et al., 2014) 
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Previous PA data from dystrophic conditions has almost exclusively been presented from 
paediatric DMD populations (McDonald et al., 2005; Jeannet et al., 2011; Elliott et al., 2015). 
The only PA comparisons from adults with dystrophic conditions to CTRL have been presented 
in the form of self-reported PA history (Morse, 2016; Jacques et al., 2017). The use of 
quantitative measures of PA through tri-axial accelerometry allows for a much greater 
understanding of PA. Understandably, adults with DMD had the highest SB, however, the 
ability of some DMD participants to participate in forms of PA and the negative association 
between SB and LBM in the present chapter appears encouraging. Furthermore, these 
findings and recent work from Jansen et al. (2013), showing maintenance of function with the 
use or arm-cycle ergometers, suggests that PA should be encouraged through the use of 
adapted equipment and hydrotherapy.  
The significant relationship between PA and KEMVC in BMD is a key finding from the current 
chapter. The relationships identified between TPAmins and KEMVC in BMD is furthered by the 
stronger relationship of TPAmins with 10m walk time in ambulant MD participants, and is 
consistent with those relationships identified within elderly populations (Foong et al., 2015; 
Santos et al., 2012) and paediatric DMD populations (Fowler et al., 2017). Furthermore, these 
findings add substantial value to current PA guidance in MD (Muscular Dystrophy Campaign, 
2014). Future work is required to quantify activity thresholds relative to separate conditions, 
and between ambulant and non-ambulant individuals, in order to quantify PA intensities, and 
the relative intensities relationships with functional outcomes. 
4.6 Conclusions 
The present chapter quantifies lower limb muscle weakness (PFMVC and KEMVC) across four 
MD classifications, and can be used to add to the currently under-reported, yet clinically 
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observed, physiological understanding of conditions. Significant relationships were identified 
between muscle size and muscle strength of plantar-flexors in DMD adults. Furthermore, 
cross-sectional findings of PA in dystrophic conditions are presented, with significant 
increases in SB in all MD conditions compared to CTRL. Relationships have been identified 
between SB and reduced LBM, TPAMins and KEMVC in BMD, as well as TPAMins and 10m walk 
time in ambulant MD participants, suggesting PA should be encouraged, consistent with 
current MDUK guidelines. Future work however must quantify different PA intensities, as well 
as consider the safety and appropriateness of PA intensity relevant to MD classification. 
Chapter 5 will now focus on the self-perceived QoL in adults with MD, identifying the impact 
of muscle weakness on QoL, as well as a variety of previously identified variables (Chapter 2), 
such as pain and fatigue. 
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Chapter 5 
 
Quality of Life in Adults with Muscular 
Dystrophy 
 
 
 
 
 
 
 
 
 
This chapter is currently Under Review: Quality of Life in Adults with Muscular Dystrophy. 
Quality of Life and Health Outcomes.  
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5.1 Abstract 
Background 
Muscle weakness is a defining characteristic of Muscular Dystrophy (MD); however, its impact 
on QoL in adults with MD remains unreported. This chapter aims to quantify QoL across four 
classifications of MD, and the impact of muscle weakness on QoL, as well as other previously 
identified determinants on QoL, such as pain and fatigue. 
Methods  
75 adults’ males volunteered (15 DMD, 18 BMD, 12 LGMD, 14 FSHD and 15 CTRL). QoL 
measured by the SF36-v2 (8 domains); Knee Extension maximal voluntary contraction 
(KEMVC) measured by quantitative muscle testing; Fatigue measured by the Checklist 
Individual Strength Severity; Pain measured by a Visual Analog Scale (Pain VAS); ADLs 
measured by the Nottingham Extended Activities of Daily Living (NEADL); Self-Efficacy 
measured by The General Self-Efficacy Scale. Kruskal Wallis test was used to compare 
between groups, with post-hoc Mann-Whitney U pairwise comparisons used where 
appropriate. Stature was compared between groups using a one-way ANOVA, and Tukey’s 
used for post-hoc comparison. Spearman’s rank correlation analysis were used to identify 
associations between variables and domains of QoL 
Results 
QoL was lower across many domains in MD compared to CTRL. Within MD, FSHD scored lower 
than DMD for Role Physical, Vitality and Mental Health domains. KEMVC was only associated 
with Physical Function and Social Function domains for BMD. Pain, Self-Efficacy and ADLs 
associated with QoL domains in DMD, BMD and FSHD, with Fatigue the most consistently 
associated.  
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Conclusions  
The present study has identified differences in QoL between MD classifications, especially 
within self-perceptions of mental health. The present study indicates that whilst muscle 
strength may be a defining feature of MD, it does not define self-perceived QoL in adults with 
MD. Comparatively, ADLs (DMD), Self-Efficacy and Pain (MD) were all associated with QoL 
domains, while Fatigue (MD) was the most consistent associate of QoL domains. Suggesting 
greater understanding of mental wellbeing and independence, and management of fatigue 
and pain are required to improve QoL for adults with MD. 
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5.2 Introduction 
Irrespective of condition, all MDs typically present with muscle weakness (Chapter 4) and an 
eventual loss of ambulation, which are likely to reduce independence, and the self-perception 
of physical function (Gabriel and Bowling, 2004). The loss of muscle strength and function is 
commonly seen as a defining feature of MD and in Chapter 3 was associated with a) severity 
of the condition b) level of PA in ambulant adults, however its impact on perceived QoL 
remains unreported in adults with MD (McDonald et al., 2010). Therefore it is important to 
further understand the impact of declining muscle strength on QoL, but also in comparison to 
other variables such as pain and fatigue (Morís et al., 2017; Padua et al., 2009), that have 
previously been shown to impact QoL in MD. 
QoL represents an individual’s perception of their physical, mental and social functioning 
(Brazier et al., 1992), and is a meaningful measure of how a clinical condition may be 
impacting an individual. QoL has been reported previously in adults with MD, however, when 
multiple classifications of MD have been included within the same report classifications have 
been pooled (Grootenhuis et al., 2007; Ahlström and Gunnarsson, 1996; Abresch et al., 2002; 
Nätterlund and Ahlström, 2001). The variations in mutative-genetic cause (Emery, 2002), and 
clinical progression (Kilmer et al., 1995; C. M. McDonald et al., 1995; C. McDonald, R. Abresch, 
et al., 1995; C. McDonald, R. Johnson, et al., 1995), of each condition strongly suggest that 
each classification should be recognised and assessed independently, in order to detect 
possible differences in QoL between classifications of MD. In addition, greater understanding 
of the factors associated with QoL within different classifications of MD is required.  
Given the progressive loss of strength and function associated with MD (Mathur et al., 2010), 
much research to date has focussed on the physical aspects of individual’s lives, such as 
respiratory function (Kohler et al., 2005) and muscle strength (McDonald et al., 2010). 
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Associations between QoL and quantified muscle strength however remain unreported within 
adult populations with MD. By comparison, loss of muscle strength has previously been 
correlated with QoL in children with DMD (McDonald et al., 2010), and more broadly in MD a 
loss of muscle strength limits the ability to walk and perform functional tasks (Alfano et al., 
2013), which are both facets contributing to QoL. In addition, increased BMI has been 
reported previously in adults with MD, and shown to impact not only function (Littleton, 
2012), but also effect psychological well-being in CTRL (Taylor et al., 2013).  Alternatively, 
psychological aspects such as self-efficacy (Bandura and Wood, 1989), an individual’s 
confidence in their ability to overcome problems (Kohler et al., 2002),  may provide a greater 
insight into QoL than physical impairment alone, and has been shown to be positively 
associated with QoL in other clinical conditions (Motl et al., 2009; Cunningham et al., 1991). 
Other perceived measures, including fatigue and pain, are also likely to impact upon QoL in 
all MD groups, and have indeed previously been shown to impact QoL in adults with DMD and 
FSHD (Morís et al., 2017; Padua et al., 2009; Pangalila, Van Den Bos, Bartels, Bergen, Stam, et 
al., 2015), but are not reported in adults with BMD or LGMD.  
This study therefore, aimed to 1) compare the self-reported QoL of adults with DMD, BMD, 
LGMD and FSHD, and a non-MD CTRL group; 2) Present and compare between groups 
measures of Muscle Strength, Activities of Daily Living, Fatigue, Pain, Self-Efficacy and BMI 3) 
Identify associations between QoL domains and Muscle Strength, Activities of Daily Living, 
Fatigue, Pain, Self-Efficacy and BMI 
This chapter hypothesises that measure of QoL will be lower in adults with MD compared to 
CTRL, while QoL will be comparable across MD conditions, except for the Physical Function 
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domain. KEMVC, Pain and CIS Severity will all be consistently associated with domains of QoL 
across MD. 
5.3 Methods 
Full details of methods can be found in Chapter 3, however in brief: this chapter consists of 
75 adult males (15 DMD, 18 BMD, 12 LGMD, 14 FSHD and 15 CTRL). QoL measured by the 
SF36-v2 (8 domains); Body composition was assessed using BIA; KEMVC measured by 
quantitative muscle testing; Fatigue measured by the CIS Severity; Pain measured by the Pain 
VAS; ADLs measured by the NEADL; Self-Efficacy measured by The General Self-Efficacy Scale..  
5.3.1 Statistical Analysis 
All analysis was performed using IBM SPSS Statistics v21 software. The critical level of 
statistical significance was set at 5%. All data is presented as mean ±SD, unless stated 
otherwise in the table legend. Tests for parametricity (Shapiro-Wilks and Levenes) were 
performed upon participants’ anthropometrics and KEMVC, with all questionnaire data 
interpreted as non-parametric. All data, except for stature was parametric. Kruskal Wallis test 
was used to compare between groups, with post-hoc Mann-Whitney U pairwise comparisons 
used where appropriate. Stature was compared between groups using a one-way ANOVA, 
and Tukey’s used for post-hoc comparison. Spearman’s rank correlation analysis were used 
to identify associations between variables and domains of QoL with ±0.30-0.49 considered 
weak, ±0.50-0.69 considered moderate and ±0.70+ considered strong (Mukaka, 2012). 
Note: Due to the high volume of variables in this chapter, differences are reported in 
respective sections and statistical significance reported in respective tables. 
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5.4 Results 
5.4.1 Participant Characteristics  
Data detailing participant characteristics is summarised in Table 5.1. DMD were younger than 
all other groups, and FSHD were older than CTRL. No differences were found between groups 
for stature. DMD were lighter than other MD groups, and LGMD were heavier than CTRL. No 
differences were found between groups for BMI. 
Table 5.1 Participant Characteristics and Anthropometrics 
 DMD BMD LGMD FSHD CTRL 
n 15 18 12 14 16 
Age (Years) 24.2 ±6.1 
B***,LG***,F***,C* 
42.4 ±13.5 41.6 ±11.7 47.1 ±11.1 
C* 
35.4 ±12.7 
Stature (cm) 172.0 ±4.3 177.4 ±6.0 179.6 ±7.2 178.6 ±8.1 177.5 ±9.3 
Mass (Kg) 73.1 ±14.6 
B*,LG**,F* 
86.5 ±20.3 97.0 ±18.1 
C* 
86.0 ±11.2 81.1 ±18.2 
Ambulant 0/15 10/18 3/12 10/14 16/16 
BMI (kg/m2) 25.5 ±4.1 27.3 ±6.2 29.4 ±26.6 26.6 ±3.4 25.5 ±3.7 
Table 5.1. Participant’s anthropometric characteristics. DMD = Duchenne Muscular 
Dystrophy; BMD = Beckers Muscular Dystrophy; LGMD = Limb-Girdle Muscular Dystrophy; 
FSHD = Facioscapulohumeral Muscular Dystrophy; cm = centimetres; Kg = Kilograms; BMI = 
Body Mass Index; B denotes significant difference from BMD; LG denotes significant difference 
from LGMD; F denotes significant difference from FSHD; C denotes significant difference from 
CTRL; * denotes P<.05; ** denotes P<.01; *** denotes P<.001. 
5.4.2 Quality of life 
Data detailing QoL in the study sample is summarised in Table 5.2. For consistency across 
domains, higher scores are indicative of higher QoL, e.g. Bodily Pain domain was higher in 
CTRL than all MD i.e. all MD reported more pain, therefore scoring lower. 
The Physical Function and Role Physical domains were lower in all MD groups compared to 
CTRL. Within MD, the Physical Function domain was lower in DMD than BMD and FSHD. The 
83 
 
Role Physical domain was higher in DMD than FSHD. The Vitality domain was lower in BMD 
and FSHD compared to CTRL. In addition, DMD reported a higher Vitality domain than FSHD. 
No other differences were found between groups for Vitality.  
Within the Role Emotional domain, DMD, BMD and FSHD were lower than CTRL. The Role 
Emotional domain, was higher in LGMD than FSHD. No other differences were found between 
groups for the Role Emotional domain.  
The Bodily Pain, Social function and General Health domains were lower in all MDs compared 
to CTRL, with no differences found between MD groups. The Total Physical domain was lower 
in all MDs compared to CTRL. No other differences were found between groups for the Total 
Physical domain. No differences were found between groups for Total Mental domain. Total 
SF6D domain was lower in all MDs compared to CTRL. No other differences were found 
between groups for Total SF6D domain. 
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Table 5.2 SF-36v2 in MD 
 DMD BMD LGMD FSHD CTRL 
Physical Function 
1.3 ±3.5 
B**,F**,C*** 
18.4 ±18.2 
C*** 6.3 ±10.3
C*** 18.2 ±12.5 
C*** 95.9 ±9.3 
Role Physical 
72.1 ±26.1 
F*,C** 
53.8 ± 32.5 
C*** 
59.9 ±31.5 
C*** 
41.5 ±26.7 
C*** 99.2 ±2.1 
Bodily Pain 66.1 ±16.4C* 58.6 ±22.2C** 56.1 ±24.4C** 
48.1 
±28.6C*** 
87.1 ±15.8 
General Health 55.6 ±20.1 C** 
48.4 ±19.3 
C*** 
43.3± 22.5 
C*** 
44.1 ±24.2 
C*** 
81.7 ±11.2 
Vitality 63.3 ±18.0F*** 50.0 ±24.7C* 51.6 ±17.3 
37.9 
±16.9C*** 
72.3 ±19.2 
Social Function 84.1 ±41.9C* 
68.8 ±30.4 
C** 
76.0 ±27.4 C* 
67.9 ±29.7 
C** 
97.7 ±6.8 
Role Emotional 80.6 ±24.5C* 
66.2 ±32.6 
C** 
86.8 ±25.7 F* 
69.0 ±24.1 
C** 
98.4 ±4.5 
Mental Health 79.0 ±14.9 F* 74.2 ±16.0 C* 78.8 ±14.6 65.0 ±19.1C** 84.7 ±8.5 
Total Physical 
Score 
34.3 ±5.4 C*** 34.5 ±6.7 C*** 30.2 ±5.8 C*** 30.8 ±6.3 C*** 56.8 ±3.6 
Total Mental 
Score 
58.2 ±10.5 51.8 ±9.3 58.3 ±9.7 49.8 ±11.0 55.8 ±3.6 
Total SF6D 
.646 ±0.109 
C*** 
.643 ±0.118 
C*** 
.611 ±0.071 
C*** 
.589 ±0.122 
C*** 
.896 ±0.101 
Table 5.2 SF36-v2 outcomes. Presented as mean ± SD. DMD = Duchenne Muscular Dystrophy; 
BMD = Becker’s Muscular Dystrophy; LGMD = Limb-Girdle Muscular Dystrophy; FSHD = 
Facioscapulohumeral Muscular Dystrophy; B denotes significant difference from BMD; LG 
denotes significant difference from LGMD; F denotes significant difference from FSHD; C 
denotes significant difference from CTRL; * denotes significance <0.05; ** denotes 
significance <0.01; *** denotes significance <0.001. 
5.4.3 Strength 
The associations between QoL and impairment are detailed in Table 5.3. KEMVC was less in 
DMD, BMD, LGMD groups compared to CTRL. Similarly, DMD were weaker than BMD, LGMD 
and FSHD groups, respectively. No other KEMVC differences were found between groups. No 
other differences were found between groups.  
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5.4.4 Questionnaires 
The associations between QoL and perceptions are also detailed in Table 5.3. Thus, the 
reported severity of CIS Severity was higher in all MD groups compared to CTRL participants. 
Furthermore, FSHD participants scored higher on CIS Severity than DMD and BMD groups, 
respectively. No other differences were found between groups for CIS Severity. DMD 
participants reported lower than all other groups on the NEADL scale. No other differences 
were found between groups. Furthermore, CTRL participants scored higher than BMD, LGMD 
and FSHD, respectively. All MD groups reported higher levels of pain compared to CTRL 
participants. There were no differences in pain between MD groups. There were no 
differences between any groups for the General Self-Efficacy Scale.  
Table 5.3 Measures of Impairment and Perception 
 DMD BMD LGMD FSHD CTRL 
CIS Severity 34.4 ±8.7 F*,C*** 
33.2 ±10.5 
F**,C*** 
34.4 ±10.9 C*** 
43.0 ±5.3 
C*** 
14.1 ±6.1 
VAS Pain 2.5 ±1.6 C** 3.5 ±2.5 C*** 3.6 ±2.8 C*** 3.9 ±2.2 C*** 0.4 ±0.7 
KEMVC (N.m) 
12.6 ±8.8 B***, 
LG***,F***,C*** 96.6 ±60.0
 C** 98.2 ±56.4 C* 123.6 ±78.2 164.6 ±55.9 
NEADL 
13.9 ±6.0 
B***,LG*,F***,C*** 
36.7 
±14.4C*** 
29.3 ±7.1 C*** 
39.4 
±14.6C** 
63.6 ±3.1 
General Self-Efficacy 31.0 ±6.2 28.3 ±5.9 31.0 ±5.1 30.7 ±7.5 34.3 ±4.3 
Table 5.3 Measures of Impairment and Perception. DMD = Duchenne Muscular Dystrophy; 
BMD = Beckers Muscular Dystrophy; LGMD = Limb-Girdle Muscular Dystrophy; FSHD = 
Facioscapulohumeral Muscular Dystrophy; CIS = Checklist Individual Strength; VAS = Visual 
Analog Scale; KEMVC = Knee Extension Maximal Voluntary Contraction; N.m = Newton 
Metres; NEADL = Nottingham Extended Activities of Daily Living; B denotes significant 
difference from BMD; LG denotes significant difference from LGMD; F denotes significant 
difference from FSHD; C denotes significant difference from CTRL; * denotes significance 
P<0.05; ** denotes significance P<0.01; *** denotes P<0.001. 
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5.4.5 QoL Correlations  
The following brief description of associations (or lack therefore of), are summarised in Table 
5.4 below. 
5.4.5.1 BMI 
The Social Function domain was moderately associated with BMI, while the Vitality domain, 
Total Mental Score and SF6D were all strongly associated with BMI, in LGMD. No other 
associations were identified with BMI. 
5.4.5.2 Strength 
The Physical Function and Social Function domains were also moderately associated with 
KEMVC in BMD. No other associations were identified with strength. 
5.4.5.3 Perception 
Physical Function domain was associated with NEADL, moderately in DMD and BMD, and 
strongly in FSHD. The Role Physical domain was strongly associated with CIS Severity in DMD 
and FSHD. In addition, Role Physical domain was also moderately associated with Self-Efficacy 
in DMD. The Bodily Pain domain was associated with the VAS Pain scale in BMD (strong) and 
FSHD (moderate).  
The General Health domain was moderately associated with CIS Severity in DMD, BMD and 
LGMD, and VAS Pain in BMD. The Vitality, Bodily Pain and General Health domains were 
moderately associated with NEADL in DMD. 
The Vitality domain was moderately associated with CIS Severity in DMD. BMD moderately 
associated both CIS Severity and VAS Pain with the Vitality domain. While both Vitality and 
Social Function domains were moderately associated with CIS Severity in FSHD.  
The Role Emotional domain was moderately associated with Self-Efficacy in DMD and BMD, 
respectively. In addition, Role Emotional domain was associated with CIS Severity in DMD 
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(moderate) and FSHD (strong). The Mental Health domain was moderately associated with 
CIS Severity in both BMD and FSHD.  
Total Physical Score was moderately associated with CIS Severity in BMD, while VAS Pain was 
associated with Total Physical Score in both BMD (weak) and FSHD (moderate). Total Mental 
Score showed strong associations with CIS Severity in FSHD.  
SF6D was associated with CIS Severity in DMD (moderate) and FSHD (strong), respectively. 
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Table 5.4 Associations of SF-36v2 domains. 
SF-36v2 BMI KEMVC NEADL 
CIS 
Severity 
VAS 
Pain 
Self-
Efficacy 
Physical Function - 0.609B** 
0.595D* 
0.654B** 
0.751F** 
- - - 
Role Physical - - - 
-0.769 D** 
-0.759F** 
- 0.534D* 
Bodily Pain - - 0.613D* - 
-0.715B** 
-0.694F** 
- 
General Health - - 0.564D* 
-0.525D* 
-0.620B** 
-0.644LG* 
-0.602B** - 
Vitality 
-
0.800LG** 
- 0.533D* 
-0.548D* 
-0.533B* 
-0.668F** 
-0.558B* 
0.590D* 
0.541F* 
Social Function -0.643LG* 0.544B* - -0.594F* - - 
Role Emotional - - - 
-0.544D* 
-0.851F*** 
- 
0.570D* 
0.600B** 
Mental Health - - - 
-0.588B* 
-0.575F* 
- - 
Total Physical 
Score 
- - - -0.597B** 
-0.476B* 
-0.683F** 
- 
Total Mental 
Score 
-
0.748LG** 
- - -0.884F** - - 
SF6D 
-
0.720LG** 
- - 
-0.569D* 
-0.884F** 
- - 
Table 5.4 Associations of SF-36v2 domains. BMI = Body Mass Index; KEMVC = Knee Extension 
Maximal Voluntary Contraction; NEADL = Nottingham Extended Activities of Daily Living; CIS 
= Checklist Individual Strength; VAS = Visual Analog Scale; D denotes significant association in 
DMD; B denotes significant association in BMD; LG denotes significant association in LGMD; F 
denotes significant association in FSHD; - denotes no significant associations; * denotes 
association of <0.05; ** denotes association of <0.01; *** denotes association of <0.001. 
5.5 Discussion 
The present study assesses QoL across four separate classifications of adults with MD, as well 
as presenting a range of factors that are associated with QoL. The findings show that adults 
89 
 
with MD typically scored poorer QoL when compared with CTRL. Furthermore, the QoL of 
adults with different classifications of MD were largely comparable with the exception of the 
Physical Function domain, and domains associated with mental wellbeing. Furthermore, the 
findings from this study highlight that despite progressive muscle weakness being a clinical 
feature of MD, it is not consistently associated with QoL in adults with MD; specifically, 
KEMVC was associated with 2/11 domains in BMD only. By contrast, QoL domains were more 
frequently associated with ADLs (4/11 in DMD), pain (4/11 in BMD, 2/11 in FSHD), and self-
efficacy (4/11 in DMD, 1/11 in BMD and FSHD). Fatigue was the most consistent associate of 
QoL in adults with DMD (5/11 domains), BMD (4/11), LGMD (1/11) and FSHD (7/11 domains). 
In addition, higher BMI appeared a consistent negative associate of QoL in adults with LGMD 
(4/11).  
The poorer QoL observed in adults with MD is consistent with other reports of MD and in 
other conditions where physical function is impaired (Picavet and Hoeymans, 2004; Abresch 
et al., 2002; Ahlström and Gunnarsson, 1996; Grootenhuis et al., 2007). In the present study 
however, differences between the QoL of adults with different classifications of MD, in 
domains other than physical function were identified. Unsurprisingly, differences in Physical 
Function appeared consistent with the clinical progression of each individual condition 
(Emery, 2002), and the severity of weakness described in Chapter 3. As would be expected 
given the severity of the condition, DMD scored lowest for physical function (Bendixen et al., 
2014; Mathur et al., 2010). Despite the lower Physical Function score, adults with DMD scored 
higher than adults with FSHD across Vitality, Role Physical and Mental Health domains. It is 
possible that this could be attributed to better coping mechanisms within DMD, as has been 
suggested previously in adolescents with DMD (Uzark et al., 2012). Adults with FSHD may be 
less likely to have these coping mechanisms, possibly due to the later onset of the condition 
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(Padberg, 1982), leading to large changes in individual’s lives and possible comparisons to an 
individual’s pre-condition state. By comparison, DMD is a life-long condition (C. McDonald, R. 
Abresch, et al., 1995), therefore acceptance of the condition and limitations may be easier or 
occur earlier. Nonetheless, these assumptions are speculative and require greater 
investigation beyond the scope of this thesis, which identified impaired strength and ROM as 
clinical features of MD and therefore primary outcome measures (Chapters 1 and 2). 
Interestingly though, adults with FSHD also scored lower than adults with LGMD for Role 
Emotional and Mental Health domains, despite both conditions having a characteristically 
later onset (Huml, 2015).  
Within adults with MD, the level of physical impairment is typically seen as the defining 
characteristic of the condition (McDonald et al., 2013), and was therefore theorised as a key 
associate of QoL. Within the present study however, KEMVC was only associated with Physical 
Function and Social Function domains in adults with BMD. Similarly, previous research has 
shown no association between the Physical Function domain and respiratory function in 
adults with DMD (Kohler et al., 2005), however within ambulant children with DMD, KEMVC 
was shown as a good predictor of QoL determined Physical Function (McDonald et al., 2010). 
The Physical Function domain showed more consistent associations with ADL across 
conditions, which can be interpreted in two ways; firstly, that an individual’s level of 
independence, rather than just function, influences QoL; or, secondly, that the physical 
function assessment of the SF-36v2 is an assessment of physical independence, rather than 
function. This is further evidenced by the reflection of the Physical Function scores upon 
ambulatory status, suggesting the Physical Function domain of the SF-36v2 may be less 
appropriate for non-ambulant individuals (Haran et al., 2007). For example, all SF36-v2 
questions regarding physical function relate to walking (Appendix 4), which is limited within 
91 
 
the population and as evidenced in Chapter 4, significant differences can still be found 
between lower limb function between different populations that are both largely non-
ambulant (DMD vs BMD and LGMD). In comparison the NEADL does include so questions 
related to walking (Appendix 5), however also includes broader independent questions, such 
as those regarding controlling money and emails. Therefore, the results from the present 
chapter suggests further development and validation of the SF-36 walk-wheel (Lee et al., 
2009) may be required. The Walk-Wheel has further adapted the SF36-v2 by adding 3 further 
questions related to physical function, whereby questions 8-10 of the SF36-v2 are repeated, 
however the word “Walked” is replaced with the word “Wheeled” (Appendix 9). Furthermore, 
the use of a single strength measure of KEMVC, previously identified as relevant to ADLs of 
high intensity, are beyond the capacity of many adults with MD (Skelton and McLaughlin, 
1996). KEMVC may not be as relevant to QoL in adults with MD particularly those who are 
non-ambulatory. The associations of NEADL with QoL, especially in adults with DMD, signifies 
independence, ownership and being able to undertake broader aspects of daily life 
(potentially using adaptive measures), rather than lower limb function (i.e. KEMVC), has a 
positive influence on QoL in DMD. The provision of support to empower adults with DMD to 
be able to undertake daily tasks should therefore be considered essential for the maintenance 
of their QoL. 
Pain and fatigue levels are higher in MD groups than CTRL within the present study, consistent 
with those that have previously identified pain and fatigue in adults with FSHD and DMD 
(Abresch et al., 2002; Padua et al., 2009; Pangalila, Van Den Bos, Bartels, Bergen, Stam, et al., 
2015). The elevated pain and fatigue levels in BMD and LGMD adults are however, 
comparable to DMD and FSHD adults, suggesting that fatigue and pain may be symptomatic 
of MD, rather than specific conditions (Bushby et al., 1998). In addition, the elevated fatigue 
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of adults with FSHD in comparison to other MD groups, as well as CTRL, identifies a condition 
specific need for further investigation and condition specific interventions (Kalkman et al., 
2005). Furthermore, the consistent associations of fatigue and pain across the MD conditions 
with aspects of QoL highlights their impact on both physical and mental well-being (Kalkman 
et al., 2005). Similar associations between pain and fatigue have been identified in other 
clinical conditions (Rupp et al., 2004; Motl et al., 2009), as well as in adults with DMD and 
FSHD (Morís et al., 2017; Pangalila, Van Den Bos, Bartels, Bergen, Stam, et al., 2015). This 
finding suggests that there is the potential for interventions that are known to reduce pain 
and fatigue in other clinical conditions, such as acupuncture (Vickers et al., 2012), 
physiotherapy (Jansen et al., 2011; Smart et al., 2016), and where possible, PA (as has been 
applied in FSHD (Voet et al., 2014)), may be applicable in adults with MD and could possibly 
improve QoL. 
No differences between any of the present MD conditions and CTRL were observed for self-
efficacy, which would appear as a positive outcome, with physical manifestations of MD not 
influencing an individual’s confidence to overcome problems. Interestingly however, self-
efficacy was positively associated with QoL domains, particularly within the DMD group. The 
authors propose this could be attributed to the severe loss of physical function associated 
with DMD (Mathur et al., 2010), subsequently individuals may develop higher problem solving 
and coping capabilities, resulting in the higher Role Physical, Role Emotional and Vitality 
domains evidenced in the current study. Further interventions in the treatment strategy of 
those with DMD, and more broadly all of the MDs, should address the psychosocial issues 
identified in the present study, as they suggest possible improvements in the QoL of adults 
with MD. 
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Despite the wide variance in the physical manifestation of these MD conditions, as 
demonstrated in Chapter 3, the present chapter displays all adults with MD to have lower QoL 
compared to CTRL, with some specific differences between MD classifications in individual 
domains of QoL. The largest differences in QoL between MD classifications were between the 
Physical Function domain, consistent with the classical definitions of these conditions (Emery, 
2002), other differences were identified however, between classifications across domains 
associated with mental and psychological wellbeing. This finding suggests that classing these 
forms of MD together when examining QoL (Ahlström and Gunnarsson, 1996; Nätterlund and 
Ahlström, 2001), as seen previously, is not appropriate given the specific differences 
identified. Independently, a range of variables were associated with QoL domains, with the 
most frequent associations being found with activities of daily living, self-efficacy and pain; it 
was however, fatigue that was most consistently associated with multiple QoL domains, 
across all MD conditions.  
5.6 Conclusion 
Differences identified in domains of QoL in the present chapter suggests a greater focus is 
required, and further investigation is needed into mental health and wellbeing, particularly in 
conditions such as FSHD. It is proposed that later onset of this condition may have a large 
impact on psychosocial aspects associated with QoL. Furthermore, ADLs were only associated 
with QoL domains, other than Physical Function, in adults with DMD, highlighting the 
importance of independence in this condition. In addition, consistent associations of pain and 
fatigue across QoL domains, across MD classifications, indicates a need for future 
investigation into the management and treatment of pain and fatigue within adults with MD. 
While this chapter had identified QoL, coping mechanisms and measures of subjectivity as 
important, the description of physiological impairments in adults with MD remains lacking, as 
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identified in Chapter 2, therefore further understanding of the physical impairments 
associated with clinical features of MD is still required. Impaired RoM and its neuromuscular 
determinants will therefore be assessed in Chapter 6. 
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Chapter 6 
 
Neuromuscular Determinants of Range 
of Motion in Adults with Muscular 
Dystrophy 
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6.1 Abstract 
Background 
Limited passive ankle range of motion (ROMPassive) is commonly recognised in muscular 
dystrophy (MD), especially children with Duchenne MD (DMD), however the limitation of 
active ROM (ROMActive) remains to be reported. Similarly, the morphological and stiffness 
properties associated with ankle ROM that could limit ROM in adults with MD, are 
unreported. 
Methods 
This chapter included 72 participants including: 16 non-MD control (CTRL), 15 DMD, 17 
Beckers (BMD), 13 Limb- Girdle (LGMD), 16 Facioscapulohumeral (FSHD). Body fat (%) and 
lean body mass (LBM) were measured using bioelectrical-impedance. Ankle plantarflexion 
(PF)-dorsiflexion (DF) ROMPassive and ROMActive were measured using electro—goniometry. 
Muscle morphology, including displacement of the muscle-tendinous junction (MTJ) through 
ROMPassive, of the Gastrocnemius Medialis (GM) were determined by B-mode ultrasound. GM 
stiffness was calculated as passive plantar-flexor torque during a DFPassive movement, relative 
to the distal displacement of the MTJ. Muscle-tendon unit (MTU) stiffness was calculated as 
passive plantar-flexor torque during a DFPassive movement, relative to the ankle angle. 
Isometric maximal voluntary contraction (MVC) was assessed during plantar-flexion (PFMVC) 
using a load cell. The Kruskal Wallis test was used to compare between groups, with post-hoc 
Mann-Whitney U pairwise comparisons where appropriate. Parametric data was compared 
using a one-way ANOVA, and Tukey’s for post-hoc comparison. Kendall Tau correlations were 
used to identify associations of non-parametric data and Pearson’s correlation coefficient of 
parametric data, between age, LGM, strength and stiffness properties with ROMPassive and 
ROMActive measures 
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Results 
CTRL participants had 82%, 55%, 60% and 56% greater ROMActive than DMD, BMD, LGMD and 
FSHD, respectively. ROMPassive was 66%, 34%, 44% and 35% greater in CTRL compared to DMD, 
BMD, LGMD and FSHD, respectively. DMD had smaller ROMActive and ROMPassive than BMD 
(60%, 49%), LGMD (54%, 39%) and FSHD (58%, 48%). GM stiffness was 29%, 46%, 40% and 
55% higher in DMD than BMD, LGMD, FSHD and CTRL, respectively. In all MD, PFMVC was 
associated with ROMActive (r= 0.376-0.750). ROMPassive was associated with passive properties 
of MTU Stiffness (r= -0.464) and GM Stiffness (r= -0.391) in DMD and BMD, respectively. 
Conclusions 
In conclusion, the present chapter has quantified limited ankle DF/PF ROM in four 
classifications of adults with MD, identifying muscle weakness and increased stiffness as 
associations of ankle ROM. 
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6.2 Introduction 
While progressive muscle weakness is the most common characteristic of MD, and the focus 
of Chapters 4 and 5, ROM of joints has similarly long been recognised as limited with the 
progression of MD (Johnson et al., 1992). Particular focus has been given to the sagittal plane 
ROM of the ankle (Halar and Bell, 1988; Archibald and Vignos Jr, 1959), which is the focus of 
this chapter and unless otherwise stated, ROM is referring to the sagittal plane of the ankle. 
Limited ROM of the ankle has been described as a characteristic of DMD (Bushby et al., 2010). 
In milder forms of MD, such as those discussed in Chapter 1, limited ROM has also been 
reported, particularly following the loss of ambulation (Kilmer et al., 1995; C. M. McDonald et 
al., 1995; C. McDonald, R. Johnson, et al., 1995).  
The ROMPassive has been reported as limited in 78% of children with DMD (n=46, 14 years) and 
57%, 25% and 42% of adults with BMD (n=7, 21 years), LGMD (n= 12, 45 years) and FSHD 
(n=40, 49 years), respectively (Johnson et al., 1992). In addition, ROMPassive loss, in children 
with DMD, and adults with BMD, LGMD and FSHD, at the ankle was reported as between 15-
44° (where normal ROM would be ~60deg PF to DF) (Johnson et al., 1992). Limitations of 
ROMPassive will restrict the ROMActive in MD, however ROMActive in adults with MD, and 
ROMPassive in adults with DMD, have yet to be quantified, and more broadly, mechanisms of 
limited ROMPassive across MD remain to be quantified.  
A reduction in ankle ROMPassive within MD has previously been attributed to fibrotic changes 
to the muscle, reduced muscle strength (limiting the ability to actively maintain ROM), and 
static positioning of the ankle in PF resulting in equinus deformity (Dubowitz, 1964; Brooke et 
al., 1989; Hsu and Furumasu, 1993). There is however little, if any, experimental evidence 
describing the possible factors limiting ROM in adults with MD. Furthermore, current reports 
of ROM are restricted to ROMPassive (Archibald and Vignos Jr, 1959; Johnson et al., 1992), which 
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although representing the impairments to the passive flexibility of a joint, may not fully reflect 
functional impairments (Ross and Engsberg, 2007). In contrast, the ankle ROM achieved by 
an individual, independently, through ROMActive, reflects the ability to perform functional 
tasks and could be indicative of fall risk, as was identified in the elderly (Menz et al., 2006; 
Menz et al., 2005).  
Stiffness of the MTU can be assessed through the passive torque-angle relation of the muscle-
tendon joint under stretch and contributes to the ROMPassive (Sale et al., 1982; Nakamura, 
2011). Whereas the individual muscle stiffness can be assessed by tracking the distal 
displacement of the GM MTJ using ultrasonography whilst the MTU is stretched, hereafter 
referred to as GM stiffness (Morse, 2011; Morse et al., 2008). Increased GM stiffness in 
children with DMD has previously been determined through supersonic shear imaging at two 
muscle lengths, “shortened” and “stretched” (Lacourpaille et al., 2015). MTU and GM stiffness 
throughout the ROM in adults with DMD or other forms of MD remain unreported. 
Furthermore, no associations have been made between morphological characteristics of the 
muscle, MTU stiffness or GM stiffness, and ROMPassive.  
Although the MTU and GM stiffness are unreported in adults with MD, a potential mechanism 
by which ROM could also be limited in MD is through reductions in GM length (LGM) as has 
been described in adults with DMD and BMD (Jacques et al., 2017; Morse et al., 2015). 
Shortened LGM, possibly attributed to the atrophic processes of the condition and the static-
positioning/immobility when in a seated position, is likely to reduce ankle ROM by limiting 
length-tension properties of the GM (Spector et al., 1982), and by predisposing the joint to 
ankle equinus (Williams et al., 1984). To date however, no study has reported associations 
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between the stiffness, strength and muscle length properties identified, and ROM in adults 
with MD. 
The aim of the present chapter was to 1) compere ROMActive and ROMPassive in adults with MD 
and CTRL. 2) Compare levels of MTU and GM stiffness in adults with MD and CTRL. 3) Identify 
associations of ROM with measures of muscle weakness, stiffness and muscle length. 
This chapter hypothesises that measures of ROMActive and ROMPassive will be lower, while MTU 
stiffness and GM stiffness measures will both be increased, in MD groups compared to CTRL. 
MTU stiffness and GM stiffness will be associated with measures of ROMPassive and muscle 
weakness will be associated with measures of ROMActive. 
6.3. Methods 
Full details of methods can be found in Chapter 3, however in brief: this chapter included 72 
participants including: 16 CTRL, 15 DMD, 17 BMD, 13 LGMD, 16 FSHD. Body fat (%) and LBM 
were measured using bioelectrical-impedance. Ankle; PF, DF, ROMPassive and ROMActive were 
measured using electro—goniometry. Muscle morphology, including displacement of the GM 
MTJ through ROMPassive, were determined by B-mode ultrasound. GM stiffness was calculated 
as passive plantar-flexor torque during a DFPassive movement, relative to the distal 
displacement of the MTJ. MTU stiffness was calculated as passive plantar-flexor torque during 
a DFPassive movement, relative to the ankle angle. PFMVC was assessed using a load cell.. 
6.3.1 Statistical Analysis 
IBM Statistics 21 software was used to perform all analyses with a critical level of statistical 
significance set at 5%. Tests for parametricity (Shapiro-Wilks and Levenes) were performed 
upon all variables. All data, except for height, LTibia, LGM and ROMPassive, were non-parametric. 
The Kruskal Wallis test was used to compare between groups, with post-hoc Mann-Whitney 
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U pairwise comparisons where appropriate. Parametric data was compared using a one-way 
ANOVA, and Tukey’s for post-hoc comparison. Due to significant differences in LTibia, measures 
of LGM, LTendon and LMTU, ANCOVAs were performed to determine whether differences 
remained when LTibia was controlled for. Kendall Tau correlations were used to identify 
associations of non-parametric data and Pearson’s correlation coefficient of parametric data, 
between age, LGM, strength and stiffness properties with ROMPassive and ROMActive measures. 
Correlations of ±.30-.49 are considered weak, ±.50-.69 considered moderate and ±.70+ 
considered strong. Where relevant, comparisons are presented with P values and the relative 
difference (%) from a named experimental group. When values are both positive and 
negative, only P values have been presented.  
6.4 Results 
6.4.1 Anthropometrics, Body Composition and MTU Morphology 
DMD participants were younger than those with BMD (44%, P<0.001), LGMD (37%, P=0.003), 
FSHD (49%, P<0.001) and CTRL (33%, P=0.006). FSHD were also older than CTRL participants 
(24%, P=0.032). LGMD participants were heavier than both DMD (22%, P=0.002) and CTRL 
(P=0.017) groups. DMD participants had lower LBM than BMD (19%, P=0.002), LGMD (23%, 
P=0.001), FSHD (19%, P=0.011) and CTRL (26%, P<0.001). No other differences were identified 
between groups for any other anthropometric or body composition measures (P>0.05, Table 
6.1). 
DMD participants had shorter LTibia than BMD (15%, P<0.001), LGMD (14%, P<0.001), FSHD 
(15%, P<0.001) and CTRL (18%, P<0.001) participants. Initial differences were identified for 
LGM with DMD shorter than all other groups (P<0.05), however when LTibia was controlled for 
in an ANCOVA no differences were identified between any groups for LGM (P>0.05). DMD 
participants had shorter LTendon than BMD (17%, P=0.001), LGMD (17%, P=0.014), FSHD (18%, 
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P=0.001) and CTRL (23%, P<0.001) participants. All differences remained when LTibia was 
controlled for in an ANCOVA (P<0.05). LMTU was shorter in DMD participants than BMD (17%, 
P<0.001), LGMD (16%, P=0.002), FSHD (18%, P<0.001) and CTRL (22%, P<0.001) participants. 
In addition, BMD participants (7%, P=0.028) had a shorter LMTU than CTRL. All significances 
remained when LTibia was controlled for in an ANCOVA (P<0.05), in addition LGMD was shown 
to have a shorter LMTU than CTRL (8%, P=0.045). CTRL had a bigger LGM/LMTU ratio than DMD 
(P=0.021). No other differences were identified between groups for LTibia, LGM, LTendon, LMTU or 
LGM/LMTU (P>0.05, Table 6.1). 
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Table 6.1. Participant Characteristics, Care and Muscle Morphology 
 DMD BMD LGMD FSHD CTRL 
N 16 17 10 13 16 
Age (Years) 
23.8 (6.1) 
B,LG,F,C 
42.5 (14.0) 37.9 (8.4) 
46.3 
(11.2)C 
35.4 (12.7) 
Height (cm) 172.2 (4.2) 177.5 (6.1) 178.7 (7.6) 178.9 (8.4) 177.5 (9.3) 
Mass (Kg) 75.9 (18.1)LG 87.2 (18.3) 
97.3 
(18.0)C 
84.19 (9.4) 81.11 
(18.2) 
LBM (Kg) 
49.1 (9.5) 
B,LG,F,C 
60.3 (7.2) 63.6 (10.3) 60.2 (8.4) 66.0 (13.2) 
Ambulant 0/16 8/17 3/10 10/13 16/16 
Physiotherapy 
Monthly 
Frequency (Range) 
4 (1-4) 2 (1-2) 2 (1-2) 2 (1-2) 0 (-) 
Orthotics 5/16 0/17 0/10 4/13 0/16 
LTibia (cm) 33.1 (2.5)B,LG,F,C 38.8 (2.5) 38.6 (2.9) 38.8 (2.1) 40.4 (4.4) 
LGM (cm) 
17.3 (1.9) 
B,LG,F,C 
21.4 (3.1) 21.5 (2.9) 21.9 (2.5) 23.2 (3.1) 
LTendon (cm) 
17.1 (2.0) 
B,LG,F,C 
20.1 (2.0) 19.7 (2.2) 20.2 (1.7) 21.4 (3.0) 
LMTU (cm) 
34.6 (2.9) 
B,LG,F,C 
41.5 (3.2)C 41.2 (4.0)C 42.1 (2.3) 44.5 (4.0) 
LGM/LMTU (%) 50.3 (3.9)C 51.4 (5.0) 52.2 (4.2) 51.9 (4.1) 53.0 (5.4) 
Table 6.1. Participant Characteristics and Body Composition. DMD = Duchenne Muscular 
Dystrophy, BMD = Beckers Muscular Dystrophy, LGMD = Limb-Girdle Muscular Dystrophy, 
FSHD – Facioscapulohumeral Muscular Dystrophy, LBM = Lean Body Mass, cm = centimetres, 
Kg = Kilograms, LTibia = Tibia Length, LGM = Gastrocnemius Medialis Length, LMTU = Muscle 
Tendon Unit Length. B denotes significant difference from BMD, LG denotes significant 
difference from LGMD, F denotes significant difference from FSHD, C denotes significant 
difference from CTRL. 
6.4.2 Range of Motion 
DMD participants resting angle was more plantar-flexed than BMD (43%, P=0.002), LGMD 
(36%, P=0.013), FSHD (46%, P=0.001) and CTRL (44%, P=0.002) groups. There were no other 
differences between groups for resting angle (P>0.05, Table 6.2). 
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Max PFActive was and in greater PF in DMD than BMD (P=0.048) and FSHD (P=0.015) groups. 
CTRL participants Max PFActive was in greater PF than BMD (P=0.003), LGMD (P=0.034) and 
FSHD (P=0.001) groups. Max DFActive was lower in DMD participants than BMD (P<0.001), 
LGMD (P=0.037), FSHD (P=0.001) and CTRL (P<0.001) participants. CTRL participants had 
greater Max DFActive than BMD (P<0.001), LGMD (P<0.001) and FSHD (P=0.001) groups. No 
other differences were found between groups for Max PFActive or Max DFActive (P>0.05, Table 
6.2). 
No differences were found between groups for Max PFPassive (P>0.05). DMD participants had 
lower Max DFPassive than BMD (P<0.001), LGMD (P=0.040), FSHD (P<0.001) and CTRL (P<0.001) 
groups. CTRL participants had greater Max DFPassive than BMD (P<0.001), LGMD (P<0.001) and 
FSHD (P=0.006) groups. No other differences were found between groups for Max PFPassive or 
Max DFPassive (P>0.05, Table 6.2). 
ROMActive was 60%, 54%, 58% and 82% smaller in DMD compared to BMD (P=0.002), LGMD 
(P=0.041), FSHD (P=0.006) and CTRL (P<0.001), respectively. CTRL participants had 55%, 60% 
and 56% greater ROMActive than BMD (P<0.001), LGMD (P<0.001) and FSHD (P<0.001) groups, 
respectively. ROMPassive was 49%, 39%, 48% and 66% smaller in the DMD group compared to 
BMD (P<0.001), LGMD (P=0.026), FSHD (P<0.001) and CTRL (P<0.001) groups, respectively. 
ROMPassive was 34%, 44% and 35% larger in CTRL compared to BMD (P<0.001), LGMD 
(P<0.001) and FSHD (P<0.001), respectively. CTRL participants had 42%, 32%, 34% and 34% 
bigger ROMActive/ROMPassive than DMD (P<0.001), BMD (P<0.001), LGMD (P=0.001) and FSHD 
(P<0.001) groups, respectively. No other differences were found between groups for 
ROMActive, ROMPassive or ROMActive/ROMPassive (P>0.05, Table 6.2, Figure 6.1).  
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Figure 6.1. Presentation of reported ankle ROM and relative muscle morphology. Key is 
consistent with that presented in Figure 3.2. In brief ROM measures: Superior black dotted 
line (     ) = DFPassive; Inferior black dotted line (       ) = PFPassive; Superior grey dotted line (    ) = 
DFActive; Inferior grey dotted line (      ) – PFPassive; Black solid line (      ) = Resting Angle. In Brief 
MTU Morphology: Filled black rectangle (     ) = Tibia; Unfilled black rectangle (      ) = Achilles 
tendon; Striated half-moon (                       ) = Gastrocnemius medialis.  
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Table 6.2. Range of Motion Assessment 
 DMD BMD LGMD FSHD CTRL 
Resting Angle (°) 31.0 (8.3) 
B,LG,F,C 
17.7 (8.2) 19.8 (10.5) 16.9 (6.1) 17.4 (3.4) 
Max PFActive (°) 36.9 
(13.7)B,F 
27.3 
(10.9)C 
29.7 
(15.7)C 
25.3 (8.0)C 39.1 (8.3) 
Max DFActive (°) 26.3 
(14.4)B,LG,F,C 
1.06 
(11.8)C 
6.70 
(10.0)C 
-0.23 
(10.1)C 
-18.7 (2.3) 
Max PFPassive (°) 41.5 (14.3) 35.8 (11.4) 35.9 (13.2) 32.1 (9.4) 42.8 (8.9) 
Max DFPassive (°) 20.2 (14.2) 
B,LG,F,C 
-5.71 
(10.0)C 
0.90 
(10.2)C 
-8.69 (7.3)C -20.4 (2.5) 
ROMActive (°) 10.6 (4.92) 
B,LG,F,C 
26.2 (12.8) 
C 
23.0 (14.6) 
C 
25.5 (11.1) 
C 
57.8 (8.6) 
ROMPassive (°) 21.3 
(9.4)B,LG,F,C 
41.5 (13.1) 
C 
35.0 (14.4) 
C 
40.7 (9.2) C 63.1 (9.5) 
ROMActive/ROMPassive 
(%) 
52.8 (15.6) C 62.4 (21.8) 
C 
60.7 (28.0) 
C 
60.6 (16.4) 
C 
91.6 (4.9) 
Table 6.2. Range of Motion Assessment. DMD = Duchenne Muscular Dystrophy, BMD = 
Beckers Muscular Dystrophy, LGMD = Limb-Girdle Muscular Dystrophy, FSHD – 
Facioscapulohumeral Muscular Dystrophy, PFActive = Active Plantar-Flexion, DFActive = Active 
Dorsi-Flexion, PFPassive = Passive Plantar-Flexion, DFPassive = Passive Dorsi-Flexion, ROMActive = 
Active Range of Motion, ROMPassive = Passive Range of Motion. B denotes significant difference 
from BMD, LG denotes significant difference from LGMD, F denotes significant difference from 
FSHD, C denotes significant difference from CTRL. 
6.4.3 Muscle Properties 
DMD participants had weaker PFMVC than BMD (47%, P=0.011), FSHD (60%, P<0.001) and 
CTRL (73%, P<0.001) groups. In addition, CTRL had stronger PFMVC than BMD (50%, P<0.001), 
LGMD (58%, P<0.001) and FSHD (33%, P=0.016). No other differences were identified 
between groups for PFMVC (P>0.05; Table 6.3). 
Max Passive PF Torque was lower in DMD than BMD (52%, P=0.001), LGMD (43%, P=0.048), 
FSHD (59%, P<0.001) and CTRL (66%, P<0.001). CTRL had higher Max Passive PF Torque than 
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BMD (29%, P=0.019), LGMD (40%, P=0.003). DMD had reduced MTJ Displacement than BMD 
(67%, P=0.001), LGMD (67%, P=0.003), FSHD (75%, P<0.001) and CTRL (84%, P<0.001). CTRL 
had greater MTJ Displacement than BMD (52%, P<0.001), LGMD (52%, P=0.003) and FSHD 
(37%, P=0.025; Table 6.3).  
GM stiffness was higher in DMD than BMD (29%, P=0.008), LGMD (46%, P<0.001), FSHD (40%, 
P<0.001) and CTRL (55%, P<0.001). BMD had higher GM stiffness than LGMD (23%, P=0.035) 
and CTRL (37%, P<0.001). FSHD also had higher GM stiffness than CTRL (25%, P=0.019). No 
differences were identified between any group for MTU stiffness (P<0.05; Table 6.3). 
Table 6.3 Muscle properties 
 DMD BMD LGMD FSHD CTRL 
PFMVC (N.m) 17.8 (7.9) 
B,F,C 
33.4 (13.6)C 28.2 (16.5)C 45.0 (20.6)C 67.0 (13.1) 
Max Passive PF 
Torque (N.m) 
8.07 (3.64) 
B,LG,F,C 
16.8 (7.14) C 14.2 (3.25) 
C 
19.5 (7.10) 23.5 (6.08) 
MTJ Displacement 
(cm) 
0.25 (0.13) 
B,LG,F,C 
0.76 (0.46) C 0.76 (0.29) 
C 
0.99 (0.47) 
C 
1.57 (0.40) 
GM Stiffness 
(N.m.cm-1) 
34.6 (5.89) 
B,LG,F,C 
24.5 
(4.74)LG,C 
18.9 (1.68) 20.7 (3.51)C 15.5 (4.52) 
MTU Stiffness 
 (N.m.deg-1) 
0.81 (0.27) 0.74 (0.24) 0.85 (0.27) 0.75 (0.18) 0.65 (0.23) 
Table 6.3. Ultrasound and Torque Measures. DMD = Duchenne Muscular Dystrophy, BMD = 
Beckers Muscular Dystrophy, LGMD = Limb-Girdle Muscular Dystrophy, FSHD = 
Facioscapulohumeral Muscular Dystrophy, CTRL = Control MTJ = Musculotendinous Junction, 
PFMVC = Plantar-Flexion Maximal Voluntary Contraction, cm = centimetre, N.m = Newton 
Metres. B denotes significant difference from BMD, LG denotes significant difference from 
LGMD, F denotes significant difference from FSHD, C denotes significant difference from CTRL. 
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6.4.4 ROM Associations 
No associations were identified for any MD group between age or LGM and ROMPassive or 
ROMActive (P>0.05, Table 6.4). 
PFMVC was weakly associated with ROMPassive (r= 0.402, P=0.030) and ROMActive (r= 0.442, 
P=0.020) in DMD. PFMVC was weakly associated with ROMActive (r= 0.376, P=0.041) in BMD. 
PFMVC was strongly associated with ROMActive (r= 0.750, P=0.003) in LGMD. PFMVC was 
weakly associated with ROMActive (r= 0.484, P=0.023), and moderately associated with 
ROMPassive (r= 0.562, P=0.008) in FSHD (Table 6.4).  
MTJ Displacement was moderately associated with ROMActive (r= 0.566, P=0.003) in DMD. 
BMD showed weak associations of MTJ Displacement with ROMActive (r= 0.376, P=0.041) and 
ROMPassive (r= 0.487, P=0.007). MTJ Displacement was moderately associated with ROMPassive 
(r= 0.536, P=0.012) in FSHD (Table 6.4). 
Max Passive PF Torque was weakly associated with ROMActive (r= -0.376, P=0.041) and 
ROMPassive (r= -0.457, P=0.012) in BMD. Max Passive PF Torque was moderately associated 
with ROMPassive (r= -0.562, P=0.008) in FSHD (Table 6.4). 
GM stiffness was weakly associated with ROMActive in DMD (r= -0.407, P=0.032). GM stiffness 
was weakly associated with ROMActive (r= -0.408, P=0.027) and ROMPassive (r= -0.391, P=0.031) 
in BMD. MTU Stiffness was weakly associated with ROMActive in LGMD (r= -0.464, P=0.013) and 
ROMPassive in DMD (r= -0.464, P=0.048, Tale 6.4). 
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Table 6.4. Active and Passive ROM Associations 
 Age LGM PFMVC 
MTJ 
Displacement 
Max 
Passive 
PF 
Torque 
GM 
Stiffness 
MTU 
Stiffness 
ROMActive (°) - - 
0.442D 
0.376B 
0.750LG 
0.484F 
0.566D 
0.376B 
-0.376B 
-0.407D 
-0.408B 
 
-0.494LG 
ROMPassive (°) - - 
0.402D 
0.562F 
0.487B 
0.536F 
-0.457B 
-0.562F 
-0.391B -0.464D 
Table 6.4. Active and Passive ROM Associations. ROMActive = Active Range of Motion, 
ROMPassive = Passive Range of Motion, LGM = Gastrocnemius Medialis, PFMVC = Plantar-Flexion 
Maximal Voluntary Contraction, MTJ = Musculotendinous Junction. D denotes significant 
association in DMD; B denotes significant association in BMD; LG denotes significant 
association in LGMD; F denotes significant association in FSHD; - denotes no significant 
associations. 
6.5 Discussion 
This chapter assessed ROM in adults with MD compared to CTRL, and investigated previously 
speculated limiting factors of ROM in adults with MD. As expected, there was a comparative 
loss of ROMPassive and ROMActive in MD compared to CTRL, and DMD compared to BMD, LGMD 
and FSHD. Adults with DMD, BMD and FSHD all showed increased GM stiffness compared to 
CTRL, however interestingly no differences were identified between groups for MTU Stiffness. 
MTU stiffness, GM stiffness and muscle weakness were found to be associated with limited 
ROM across MD classifications, the weak-medium associations identified however suggests a 
combination of muscle properties limits ankle ROM in adults with MD. 
The presented ankle ROMPassive appear on the whole, consistent with previous research, with 
ROMPassive loss compared to CTRL in the present chapter -42°, -22°, -28° and -23° in DMD, 
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BMD, LGMD and FSHD respectively, compared to -44°, -15°, -47° and -28° reported previously 
(Johnson et al., 1992). Differences in loss of ROMPassive between the present chapter and that 
reported previously for LGMD participants, can be explained by the wide range of ages 
recruited previously 9-82 years (LGMD) (Johnson et al., 1992), in contrast to the homogenous 
sample in the present chapter of 28-50 years for LGMD. It is possible, particularly within LGMD 
that the higher reported loss of ROMPassive (-47°) in previous participants (9-82years) 
represents a much more severe progression of the condition into later life.  
The 55% higher GM stiffness in adults with DMD compared to CTRL in the present chapter is 
consistent with the progressive nature of DMD, where 34% higher GM stiffness was reported 
previously in children with DMD (Lacourpaille et al., 2015). Furthermore, in the present 
chapter, increased GM stiffness in adults with DMD, BMD and FSHD appear consistent with 
the understanding of non-contractile replacement of contractile tissue associated with each 
of these conditions (Mathur et al., 2010; Løkken et al., 2016). In animal models of DMD, 
associations have been identified between non-contractile tissue and limited ROM (Garlich et 
al., 2010), with the assumption that non-contractile tissue is collagenous and would therefore 
increase the tensile stiffness (Puxkandl et al., 2002). In adults with BMD the contractile 
properties of the triceps surae have however been shown to remain impaired even when 
corrected for non-contractile tissue, suggesting a possible change in contractile tissue 
properties (Løkken et al., 2016), however future investigations are required to quantify the 
implications of non-contractile tissue on ROM and stiffness in human models. In the present 
chapter, differences identified between groups for GM stiffness rather than MTU stiffness 
suggests the impaired movement of the MTJ is a major limitation of ROM in MD, however 
muscle weakness was associated with all MD for ROMActive, but also ROMPassive for DMD and 
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FSHD. Therefore, future studies are required to identify methods to maintain muscle strength, 
and reduce GM stiffness in order to maintain, or improve, ROM. 
Adults with BMD, LGMD and FSHD all appear relatively comparable across ROM measures, 
with limitations in Max DFActive the most prominent finding, despite relatively maintained Max 
DFPassive. Although not measured in the present chapter, DF strength (DFMVC) has been 
presented previously as a classic area of weakness in FSHD (Emery, 2002), while weaker 
PFMVC was a consistent association of limited ROM in the present chapter. Issues with ankle 
strength and Max DFActive are a real concern given reduced functional ability and associated 
increased fall risk (Spink et al., 2011; Menz et al., 2006). Orthotics can be used to aid DF during 
gait (Statland and Tawil, 2014), and while restricted, current evidence from exercise training 
suggests it is safe (Sveen et al., 2008; Sveen et al., 2007). Further studies are required to 
quantify the effectiveness of exercise training in MD (Voet et al., 2010), and implications on 
gait and fall risk. The present chapter has demonstrated reduced PFMVC to be associated with 
limited ROMActive, therefore methods to improve PFMVC, and most likely DFMVC, may help 
to improve ROMActive, which in turn may help to maintain ROMPassive, however future studies 
should explicitly study this. Only one previous study, in FSHD only, has targeted DFMVC with 
resistance training however, which reported negative impacts of resistance training on 
DFMVC (Van der Kooi et al., 2004). Training could alternatively target other lower limb 
muscles that may respond better to resistance training, thereby improving function and gait 
(Damiano et al., 2010).  
In CTRL populations passive stretching has been shown to reduce GM stiffness by increasing 
MTJ displacement (Morse et al., 2008), and passive stretching is actively encouraged in MD 
as a potential method of improving ROMPassive (UK, 2016). Passive stretching however has 
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previously been shown to be less effective than night splints in the long term maintenance of 
ROM in children with DMD (Hyde et al., 2000). No measure of ROM was reported however, 
nor was there a non-treatment group against which to compare passive stretching. The long-
term use of passive stretching may be beneficial to reduce progression of limited ROMPassive, 
there are however no reports of the effectiveness of stretching and physiotherapy in adults 
with MD. 
In DMD the resting ankle angle is a more PF position, consistent with equinus deformity and 
static positioning issues identified previously (Bushby et al., 2010; Williams et al., 1984), likely 
caused by long term immobilisation in a seated position resulting in shortening of LMTU 
(Herbert and Crosbie, 1997; Morse et al., 2015). In DMD difficulties in ROMActive and Max DF 
(active and passive) would appear consistent with muscle weakness (Chapter 3) and shorter 
LGM (Morse et al., 2015), although specific associations of DF ROM were not reported in this 
chapter. This highlights the necessity of good static positioning of the foot in adults with DMD 
in as neutral position as possible, as poor positioning in PF could further reduce LGM (Spector 
et al., 1982). Reductions in LGM from sustained static positioning in PF may also reduce the 
active and passive force-length properties of the GM (Maganaris, 2003), therefore further 
reducing the ability to actively move through ROM. 
6.6 Conclusion 
In conclusion, the present chapter has quantified limited ankle ROM in four classifications of 
adults with MD, identifying muscle weakness and increased GM stiffness as consistent 
associations of ROM. Further research is required to establish the mechanisms of increased 
GM stiffness in adults with MD, which would appear consistent with the understanding of 
non-contractile replacement of contractile tissue. Following the identification of ROM and its 
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associations with stiffness and weakness, methods to reduce stiffness and increase muscle 
strength associated with ankle ROM are required to reduce fall risk and the loss of 
independence in adults with MD. Therefore Chapter 7 will investigate the acute responses of 
physiotherapy on ROM and muscle stiffness properties in adults with DMD. 
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Chapter 7 
Physiotherapy in Adults with Duchenne 
Muscular Dystrophy: Acute Responses 
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7.1 Abstract 
Background 
Physiotherapy is currently a best-practice method of care to maintain function in Duchenne 
muscular dystrophy (DMD). Experimental data of the effectiveness of physiotherapy is 
however limited to children with DMD. Given the progressive nature of DMD and increases in 
life expectancy, it is important to quantify the effectiveness of physiotherapy in adults with 
DMD to improve measures of joint range of motion (ROM) without further decreasing muscle 
strength in the short term. 
Methods 
This chapter employed a prospective cohort design with a sample comprising of 14 adult 
males with DMD. Participants were tested at baseline (visit 1) and then pre and post 
physiotherapy (Pre physio and Post physio) on visit 2. Due to no CTRL sample, MDC was 
calculated, based on the SEM between baseline and pre-physio. Maximum active and passive 
measures were taken of dorsiflexion (Max DFActive and Max DFPassive), plantarflexion (Max 
PFActive and Max PFPassive) and total range of motion (ROMActive and ROMPassive). Displacement 
of the myotendinous junction (MTJ) through ROMPassive, of the gastrocnemius medialis (GM) 
were determined by B-mode ultrasound. GM stiffness was calculated as passive plantar-flexor 
torque during a DFPassive movement, relative to the distal displacement of the MTJ. Muscle-
tendon unit (MTU) stiffness was calculated as passive plantar-flexor torque during a DFPassive 
movement, relative to the ankle angle. Isometric maximal voluntary contraction (MVC) was 
assessed during plantar-flexion (PFMVC) using a load cell. Intraclass Correlation Coefficients 
were calculated between Visit 1 and Visit 2, and used to calculate SEM and MDC. Freidman’s 
test was used to assess differences from baseline, pre-physio and post-physio, with a 
Bonferroni correction. 
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Results 
Max DFPassive increased post-physio by 3.1° (15%) and exceeded the MDC criterion (2.24°). 
Post-Physio ROMActive showed no significant change from pre-physio. Post-physio ROMPassive 
increased by 4.8° (19%) from pre-physio and exceeded the MDC criterion (3.58°). Compared 
to pre-physio, post-physio MTU stiffness decreased by 0.23 N.m·deg-1 (27%) and exceeded 
the MDC criterion (0.10 N.m·deg-1). 
Conclusion 
Physiotherapy is an effective method to acutely increase ankle ROMPassive in adults with DMD, 
with no negative effects on muscle strength. The increase in ROMPassive and Max DFPassive was 
likely attributable to reduction in MTU stiffness, which has previously been shown to limit 
ROM in adults with DMD. Given the improvements in ROM it would appear daily passive 
stretching on the ankle would be beneficial for adults with DMD, and should form part of their 
multi-disciplinary care. 
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7.2 Introduction 
Chapter 5 quantified the limitations of ankle ROM, GM stiffness and MTU stiffness, 
specifically, in adults with DMD (hereafter ROM will refer to ankle DF-PF ROM only). Extensive 
research has assessed the impacts of pharmacological interventions, such as corticosteroid 
treatments, on delaying the onset and progression of such condition characteristics in 
children with DMD (Bonifati et al., 2000; Daftary et al., 2007; Escolar et al., 2011; Fenichel et 
al., 1991). Muscular Dystrophy UK (MDUK) emphasises the standing of the Chartered Society 
of Physiotherapists that long-term muscle function should be maintained to ensure mobility 
and QoL in adults with DMD (Campaign, 2008). In adults with DMD, best practice 
physiotherapy is limited to a combination of passive stretching and mobility exercises 
(hereafter referred to as physiotherapy) and is compatible in even the most severely affected 
individuals (Stockley et al., 2010). Despite physiotherapy being known to be effective for 
reducing the stiffness of the GM and MTU in cerebral palsy (Theis et al., 2013; Palmer et al., 
1988), there is no evidence for the effectiveness physiotherapy for improving ROM, or the 
viscoelastic properties of the MTU, in adults with DMD.  
Limited ROM has been historically reported in children with DMD (Johnson et al., 1992) and 
broad multi-component methods, including passive stretching and the use of orthotics and 
night-splints, have been widely recommended for maintaining ROM (Bushby et al., 2010; 
McDonald, 1998). The long-term use of these methods has been shown as effective for 
delaying the loss of ROM and maintaining ambulation in children with DMD (Vignos and 
Archibald, 1960; Vignos et al., 1963; Hyde et al., 2000). Given the progressive and 
degenerative nature of DMD, resulting in loss of ambulation in adolescents, it is important to 
assess the effectiveness of physiotherapy in adults with DMD, who have developed further 
limited ROM and weakness (Chapter 3 and 5). 
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While the outcomes of delaying the loss of ambulation and ROM following longitudinal 
passive stretching, have been previously reported in children with DMD (Vignos and 
Archibald, 1960; Vignos et al., 1963), maintained ambulation as an outcome measure is 
however redundant in adults with DMD (Morse et al., 2018), and the mechanisms associated 
with maintenance of ROM remain unreported. In Chapter 5, ROMActive was associated with 
muscle weakness, and ROM determined by a Principal Investigator passively moving their foot 
to its maximum (ROMPassive) was associated with MTU Stiffness. In adults without MD, passive 
stretching has previously been shown to reduce MTU stiffness (Morse et al., 2008) and 
increase ROMPassive (McNair and Stanley, 1996), however this response has not been 
investigated in adults with DMD. Decreases in MTU stiffness following stretching, have 
however, been associated with short-term compromises in muscle strength (Behm et al., 
2001; Cramer et al., 2005; Fowles et al., 2000). Given the known muscle weakness reported 
in adults with DMD (Chapter 3), it is also important to determine whether physiotherapy can 
lead to further short-term decrements in muscle strength. 
This chapter aims to quantify the acute effect of physiotherapy on 1) Range of Motion 
Measures, 2) Stiffness Properties Associated with the ankle as identified in Chapter 6and 3) 
Muscle Strength, in adults with DMD.  
This chapter hypothesises that ROMPassive and DFPassive will both increase following 
Physiotherapy, and be attributable to reductions in GM Stiffness and MTU Stiffness. In 
addition, this chapter hypothesises that PFMVC will also be reduced following Physiotherapy. 
7.3 Methods 
Full details of methods can be found in Chapter 3, in brief: This chapter employed a 
prospective cohort design with a sample comprising of 14 adult males with DMD. Participants 
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were tested at baseline (visit 1) and then pre and post physiotherapy (Pre physio and Post 
physio) on visit 2. Due to no CTRL sample, MDC was calculated, based on the SEM between 
baseline and pre-physio. Maximum active and passive measures were taken of DF (Max 
DFActive and Max DFPassive), PF (Max PFActive and Max PFPassive) and total ROM (ROMActive and 
ROMPassive). Displacement of the GM MTJ through ROMPassive, of the gastrocnemius mediali 
was determined by B-mode ultrasound. GM stiffness was calculated as passive plantar-flexor 
torque during a DFPassive movement, relative to the distal displacement of the MTJ. MTU 
stiffness was calculated as passive plantar-flexor torque during a DFPassive movement, relative 
to the ankle angle. PFMVC was measured using a load cell. 
7.3.1 Statistical Analysis 
All analyses were performed using IBM SPSS Statistics v21 software with a critical level of 
statistical significance set at 5%. Test for parametricity (Shapiro-Wilks and Levenes) were 
performed upon all variables. For repeated measures analysis of ROM and muscle properties, 
all variables were revealed as non-parametric. All data is presented as mean (SD) except for 
physio frequency which is presented as median (range). 
Ambulatory status and physiotherapy frequency are presented for descriptive purposes. ICC 
were calculated between Visit 1 and Visit 2, and used to calculate SEM and MDC (See above 
equations). Freidman’s test was used to assess differences from baseline, pre-physio and 
post-physio, with a Bonferroni correction. Where relevant, comparisons are presented with 
P values, with changes in DF and PF expressed in degrees from pre-physio, with changes in 
ROM (active and passive) and muscle properties expressed as relative change (%) from pre-
physio. 
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7.4 Results 
Participant characteristics are presented below in Table 7.1. 
Table 7.1. Participant Characteristics, Anthropometrics, Body Composition and Care 
Table 7.1. Participant Characteristics, Anthropometrics, Body Composition and Care. DMD = 
Duchenne Muscular Dystrophy, LBM = Lean Body Mass, cm = centimetres, Kg = Kilograms. 
7.4.1 Range of Motion 
MDC criteria was met and statistically significant changes observed pre-physio to post-physio 
for an increased resting angle (P<0.001), an increased Max DFPassive (P<0.001) and an increased 
ROMPassive (P<0.001, Table 7.2). 
MDC criteria was not met, albeit statistical significance was observed, from pre-physio to 
post-physio for Max PFPassive (Table 7.2). 
MDC criteria was met, however statistical significance was not observed, from pre-physio to 
post-physio for Max PFActive (Table 7.2). 
Neither MDC criteria nor statistical significance was met from pre-physio to post-physio for 
Max DFActive and ROMActive (Table 7.2). 
 
 
 
 DMD 
n 14 
Age (years) 23.7 (6.1) 
Body Mass (Kg) 76.3 (19.2) 
Height (cm) 172.5 (4.4) 
LBM (Kg) 49.8 (9.9) 
Ambulatory 0/14 
Physiotherapy Frequency (visits per month) 3 (1-4) 
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Table 7.2. Range of Motion measures at Baseline and Pre Physio and Post Physio 
Range of Motion measures at Baseline, Pre-Physio and Post-Physio. DMD = Duchenne 
Muscular Dystrophy, Max PFActive = Maximum Active Plantar-Flexion, Max DFActive = Maximum 
Active Dorsi-Flexion, Max PFPassive = Maximum Passive Plantar-Flexion, Max DFPassive = 
Maximum Passive Dorsi-Flexion, ROMActive = Active Range of Motion, ROMPassive = Passive 
Range of Motion. ‡ denotes P<0.05 at Pre-Physio from Baseline.* denotes P<0.05 difference 
at Post-Physio from Pre-Physio. † denotes the Post-Physio change from Pre-Physio is greater 
than the MDC.  
7.4.2 Muscle Properties  
MDC criteria was met and statistically significant changes observed pre-physio to post-physio 
for decreased MTU Stiffness (P<0.001, Table 7.3). 
MDC criteria was not met, albeit statistical significance was observed, from pre-physio to 
post-physio for PFMVC, MTJ Displacement and GM Stiffness (Table 7.3). 
Neither MDC criteria nor statistical significance was met from pre-physio to post-physio for 
Max Passive PF Torque (Table 7.3). 
 
 
 
  DMD 
 Baseline 
Pre-
Physio 
Post-Physio 
Δ Pre- Physio 
Post-Physio 
MDC ICC 
Resting Angle (°) 30.9 (13.9) 30.8 (13.7) 34.8 (12.6)* 4.0 1.21† .999 
Max PFActive (°) 37.1 (14.6) 37.5 (14.6) 39.3 (13.0) 1.8 1.28† .999 
Max DFActive (°) 26.9 (14.6) 27.6 (14.0) 28.7 (14.3) 1.1 2.56 .996 
Max PFPassive (°) 41.4 (15.3) 41.2 (15.5) 42.8 (15.3)* 1.6 2.32 .997 
Max DFPassive (°) 20.9 (14.7) 20.9 (14.6) 17.8 (14.6)* 3.1 2.24† .997 
ROMActive (°) 10.1 (4.5) 9.93 (8.7) 10.6 (5.2) 0.67 2.10 .972 
ROMPassive (°) 20.5 (9.4) 20.3 (8.7) 25.1 (9.0)* 4.8 3.58† .981 
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Table 7.3. Muscle Properties at Baseline, Pre-Physio and Post-Physio. 
Muscle Properties at Baseline, Pre-Physio and Post-Physio. DMD = Duchenne Muscular 
Dystrophy, MTJ = Myotendinous Junction, PFMVC = Plantar-Flexion Maximal Voluntary 
Contraction, cm = centimetre, N.m = Newton Metres. ‡ denotes P<.05 at Pre-Physio from 
Baseline.* denotes P<.05 difference at Post-Physio from Pre-Physio. † denotes the Post-
Physio change from Pre-Physio is greater than the MDC.  
7.5 Discussion 
The main findings of the present chapter is that physiotherapy appears an effective method 
to acutely increase ankle ROMPassive in adults with DMD. This increased ROMPassive is likely 
attributable to the observed decreases in MTU stiffness following physiotherapy. In addition, 
no negative impacts of physiotherapy on muscle strength were identified in the present 
chapter.  
The outcomes from the present chapter suggests that physiotherapy is an effective method 
to acutely increase ROMPassive in adults with DMD, with no negative effects on PFMVC or 
ROMActive. Increases in ROMPassive post-physio are consistent with increases in ROMPassive 
reported previously in clinical and non-clinical populations following physiotherapy 
  DMD 
 Baseline Pre-Physio Post-Physio 
Δ Pre- Physio 
Post-Physio 
MDC ICC 
PFMVC (N.m) 17.4 (7.7) 17.5 (8.0) 16.2 (7.5)* 1.3 2.81 .984 
Max Passive 
PF Torque 
(N.m) 
7.59 (3.5) 7.68 (3.6) 7.97 (3.4) 0.29 1.07 .988 
MTJ 
Displacement 
(cm) 
0.23 (0.13) 0.23 (0.13) 0.26 (0.12)* 0.03 0.06 .975 
GM Stiffness 
(N.m·cm-1) 
35.2 (6.6) 35.6 (6.3) 32.3 (4.7)* 3.3 5.4 .914 
MTU 
Stiffness 
(N.m·deg-1) 
0.83 (0.28) 0.84 (0.32) 0.61 (0.18)* 0.23 0.10† .984 
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interventions (Radford et al., 2006; Wiktorsson-Moller et al., 1983; Theis et al., 2013; Gao et 
al., 2011). The 15% increase in Max DFPassive in the present chapter is comparable to other 
acute responses to passive interventions presented previously in adults without MD (9-26%) 
(Morse et al., 2008; Wiktorsson-Moller et al., 1983). Furthermore, the present chapter shows 
physiotherapy as an effective method to reduce MTU stiffness consistent with previous 
research (Morse et al., 2008), which is evidenced in the outcome measure itself, but also in 
the increase in ROMPassive and shift of resting angle into greater PF.  
The decrease in MTU stiffness  observed in the present chapter (a correlate of DF ROM in 
Chapter 6), is consistent with previous studies on the impact of passive interventions in CTRL 
groups (Morse et al., 2008). These decreases in MTU stiffness are normally attributable to 
decreases in GM and tendon stiffness, with previous research showing acute increases in 
tendon stiffness and reduction in GM stiffness following passive interventions (Nakamura, 
2011; Morse et al., 2008). In the present chapter, post-physio GM stiffness did not decrease 
sufficiently from pre-physio to meet the MDC criterion, while tendon stiffness could not be 
calculated, as previous methods use cadaveric equations which are incomparable with adults 
with DMD (Grieve, 1978). Given that the impairments of DMD are associated with 
degradation of muscle quality, whereby contractile tissue is replaced with non-contractile 
tissue, therefore it is deemed that tendon stiffness may be less relevant in this population. 
The observed decrease in MTU stiffness were however, apparent with no change in Max 
Passive PF Torque, changes could therefore be attributed to an increase in stretch tolerance 
(Magnusson et al., 1997), rather than necessarily changes in muscle properties (Magnusson 
et al., 2000). It is important to acknowledge however, that small decreases in both muscle 
and tendon stiffness may have contributed to the increased ROM, but did not reach MDC 
criteria. Future work is required to determine the respective GM stiffness and tendon stiffness 
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properties and their change in response to physiotherapy, these may be more apparent and 
methodologically measurable in BMD, a comparably milder condition (Huml, 2015). 
The present chapter has focussed on the acute responses of limited ankle ROM in adults with 
DMD to physiotherapy, given its presentation as a characteristic of DMD (Archibald and 
Vignos Jr, 1959; Vignos et al., 1963). The improvement in ROMPassive is consistent with current 
guidelines for care of adults with DMD (MDUK), that physiotherapy can improve ROM, and 
should be part of the multi-disciplinary approach to maintaining function and potentially 
limiting the progressive loss of passive mobility described in adults with DMD (Bushby et al., 
2010; McDonald, 1998). While limited ROM of the ankle may be a characteristic of DMD 
(Archibald and Vignos Jr, 1959), future work should assess the impact of physiotherapy on 
upper limb function, which could have a greater impact on activities of daily living in this 
population given their non-ambulant nature (Bartels et al., 2011). Similarly, the effects of 
physiotherapy on milder or more functional forms of MD such as BMD and FSHD are required 
given the limitations in ROMPassive identified in Chapter 5, as it may be able to delay functional 
impairments and loss of ambulation (Brooke et al., 1989; Vignos and Archibald, 1960). 
7.6 Conclusion 
To conclude, physiotherapy is an effective method to acutely increase ankle ROM in adults 
with DMD, with no negative effects on muscle function, however further work is required to 
quantify its long-term effects. The increases in ROMPassive in the current chapter are attributed 
to reductions in MTU stiffness from physiotherapy, which was identified as an associate of 
limited ankle ROMPassive in Chapter 5. Given the improvements in ROM it would appear daily 
passive stretching on the ankle would be beneficial and should form part of the multi-
disciplinary care for adults with MD.  
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Chapter 8 
Muscle Size, Strength and Physical 
Activity in Adults with Muscular 
Dystrophy: A One Year Follow Up 
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8.1 Abstract 
Background 
Muscular dystrophy (MD) is characterised by progressive muscle wasting and weakness, few 
studies however, have assessed longitudinal changes in lower limb function and body 
compositions in adult MD populations. Physical activity (PA) is encouraged in MD to maintain 
health and function; however, its association with longitudinal changes also remains 
unreported. 
Methods 
This Chapter included 15 adults with Duchenne MD (DMD) and 11 adults with Becker’s MD 
(BMD). Participants were assessed at baseline and at 12 months. Body fat (%) and lean body 
mass (LBM) were measured using bioelectrical-impedance. Gastrocnemius medialis (GM) 
anatomical cross-sectional area (ACSA) was determined using B-mode ultrasound. Isometric 
maximal voluntary contraction (MVC) was assessed during plantar-flexion (PFMVC) and knee 
extension (KEMVC). Physical activity was measured for seven continuous days using tri-axial 
accelerometry, and was expressed as daily average minutes being physically active (TPAmins) 
or average daily percentage of waking hours being sedentary (Sedentary Behaviour). 
Additionally, 10m walk time was assessed. For repeated measures Paired T-tests and 
Wilcoxon signed rank tests, for parametric and non-parametric respectively, were used to 
identify changes, with a Bonferroni correction. Linear, Quadratic and Cubic regressions are 
used to best model changes in body composition and muscle strength in relation to age and 
changes in TPAmins, with the best fit model presented. 
Results 
Compared to baseline, 12 month LBM decreased by -5% in DMD and Body Fat% increased by 
4% in BMD. No other changes were identified for body composition. One BMD participant lost 
ambulation between baseline and 12 months. Compared to baseline, PFMVC and KEMVC 
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decreased in DMD by -19% and -14%. No differences were identified in KEMVC or PFMVC at 
12 months compared to baseline in BMD. Compared to baseline 10m walk time increased in 
ambulant BMD by 13% (P=0.005). In BMD quadratic polynomial regressions best identified 
relationships for TPAmins change with PFMVC change (R2=0.585) and KEMVC change 
(R2=0.532). 
Conclusions 
Changes in DMD appear consistent with the progressive nature of the condition, with -14% 
and -19% weaker PFMVC and KEMVC after 12 months, respectively. Within BMD, 12 month 
changes in PFMVC and KEMVC although not significant, were best explained by changes 
physical activity. Changes in LBM in DMD and Body Fat% in BMD were both masked by non-
significant changes in body mass, furthering the need for specific monitoring of body 
composition. 
8.2 Introduction 
Chapters 4-6 have focussed on cross-sectional relationships of clinical features associated 
with MD, the present Chapter will assess the longitudinal changes in muscle weakness, muscle 
morphology and body characteristics. The progressive nature of DMD means it has been a 
focus of a wide range of cross-sectional and longitudinal studies quantifying the progression 
of the condition (hereafter termed “natural history”), and evaluating the impact of steroid 
treatment (Akima et al., 2012; Bendixen et al., 2014; Elliott et al., 2012; Jansen et al., 2013; 
Kohler et al., 2005; C. McDonald, R. Abresch, et al., 1995).  
‘Clinical endpoints’ are used to describe natural history, such as the 6-minute walk test 
(6MWT) which has shown declines in function with age (Mayhew et al., 2007; Henricson et 
al., 2013; McDonald et al., 2010). The scope of functional tasks such as the 6MWT are however 
limited, as children with DMD typically lose ambulation by the age of 12, rendering the 6MWT 
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and other functional measures redundant from this point as a clinical outcome measure 
(Morse et al., 2018).  
Broad conclusions can be drawn on the natural history of strength in DMD through the use of 
the MRC% and MMT (Florence et al., 1992; Mendell and Florence, 1990). These subjective, 
manual assessment methods have previously been identified as lacking sensitivity to quantify 
changes (Florence et al., 1992). Indeed, when using MMT or MRC%, annual declines of KEMVC 
are reported as -5% in children with DMD (5-13 years) (C. McDonald, R. Abresch, et al., 1995), 
and 1.2-2% in non-ambulant DMD (13-24 years) (C. McDonald, R. Abresch, et al., 1995; 
Steffensen et al., 2002), whereas when using more sensitive measures of strength assessment 
such as dynamometers, annual declines of KEMVC are reported as -15% in children with DMD 
(8-12 years) (Henricson et al., 2013). The use of more stringent measures of strength 
assessment, such as dynamometers, however are largely inaccessible given the severe muscle 
weakness and contractures associated with adults with DMD as discussed in Chapter 2. 
Despite DMD being progressive in nature, natural history descriptions of quantified lower 
limb muscle strength in adults with DMD are yet to be reported. Given the improvements in 
health care, particularly cardiac and respiratory, life expectancy is increasing in DMD, with 
many now living well into adulthood (Bettolo et al., 2016). It is therefore essential for greater 
understanding of the progression of DMD in this older age group, and to provide comparative 
norms, using relevant and accessible methods, for future longitudinal assessments of steroid 
therapy or other intervention studies which may be relevant to this population (Bettolo et al., 
2016; Rahbek et al., 2005). 
In comparison to DMD, BMD is perceived as a milder, yet more variable condition (Emery, 
2002). The loss of ambulation sometimes does not occur in BMD until middle age (C. M. 
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McDonald et al., 1995), and the maintenance of physical function is related to the amount of 
dystrophin present (Bello et al., 2016), with lower limb muscle strength previously associated 
with physical function ((Alfano et al., 2013)Chapter 3). In terms of natural history in BMD, a 
single MMT assessment of KEMVC has been conducted, with annual declines reported of -
1.2% (C. M. McDonald et al., 1995), no studies however have quantified the progression of 
lower limb muscle strength in adults with BMD using sensitive methods.  
The focus of natural history studies in DMD and BMD has understandably been muscle 
strength (Henricson et al., 2013), with limited description of changes in body composition or 
muscle size. LBM have been identified as a determinant of strength and function in children 
with DMD (Palmieri et al., 1996; Skalsky et al., 2009) and adults with BMD (Chapter 3). While 
pseudohypertrophy (increased muscle size without relative increase in strength) is well 
documented in children with DMD (Beenakker et al., 2002; Vohra et al., 2015; Wokke et al., 
2014), the limited investigations into muscle size in adults with DMD suggest it may not persist 
in adulthood (Morse et al., 2015); longitudinal changes in muscle size and LBM remain 
unreported however, in adults with DMD and BMD. Similarly, increased fat mass has 
previously been cited as a common co-morbidity in MD (Zanardi et al., 2003), and noted as 
higher in non-ambulant adults with BMD in a recent paper (Jacques et al., 2017). Continual 
assessment, and understanding, of body composition changes of both lean and fat mass is 
essential for not only their implications on function, but also the much broader impacts on 
health and wellbeing (Hogan, 2008; Davidson and Truby, 2009). 
Despite shortcomings in natural history studies reporting subjective strength measures in 
children with DMD and adults with BMD, both conditions certainly progressive in nature (C. 
M. McDonald et al., 1995; C. McDonald, R. Abresch, et al., 1995). Previous cross sectional 
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studies (in children with DMD) and Chapter 3 (in adults with BMD) have shown associations 
between age and strength (Mathur et al., 2010; Bello et al., 2016), with lower muscle strength 
leading to a loss of function (Alfano et al., 2013; Bendixen et al., 2014). The rate of this decline 
may however be influenced by PA. Lower levels of PA in adults with BMD, FSHD and LGMD 
has been linked to lower levels of bone health and grip strength (Morse, 2016). In adults with 
BMD, Chapter 3 showed group variance in KEMVC could be explained by PA, while 
adolescents with DMD taking part in structured assisted cycling have previously been shown 
to maintain function compared to those that did not (Jansen et al., 2013). In addition, adults 
with FSHD have shown that increased PA (steps) maintained contractile tissue more than 
those who did not increase PA (Ferguson et al., 2016). It is therefore possible that PA levels 
may be a determinant of the rate of the decline in KEMVC in adults with BMD. 
This chapter aims to: 1) To quantify changes, from a one year follow up, in body composition, 
muscle morphology, muscle strength and physical activity levels in adults with Duchenne and 
Becker’s MD 2) Identify the impact of changes in physical activity on body composition and 
muscle strength. 
It is hypothesised that 1) declines will be significant in both DMD and BMD, for lower limb 
strength, GM ACSA and LBM; and 2) PA may account for some of the variance in lower limb 
strength change in BMD. 
8.3 Methods 
Full details of methods can be found in Chapter 3, in brief: this Chapter included 15 adults 
with DMD and 11 adults with BMD. Participants were assessed at baseline and at 12 months. 
Body fat (%) and LBM were measured using bioelectrical-impedance. GM ACSA was 
determined using B-mode ultrasound. KEMVC and PFMVC were measured using methods 
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replicative of QMT. PA was measured for seven continuous days using tri-axial accelerometry, 
and was expressed as daily average minutes being physically active (TPAmins) or average daily 
percentage of waking hours being sedentary (Sedentary Behaviour). Additionally, 10m walk 
time was assessed. 
8.3.1 Statistical Analyses 
All analyses were performed using IBM SPSS Statistics v21 software with a critical level of 
statistical significance set at 5% and all data presented as mean (SD). Between group 
differences for baseline measures have been described previously (Chapter 3), with the 
present chapter interested in differences from baseline-12 months, therefore statistical 
analysis has been performed on baseline to 12month changes only (within group), with 
baseline values presented for clarity. Test for parametricity (Shapiro-Wilks and Levenes)  were 
performed upon all variables, for repeated measures DMD BM, height, BMI, LBM and PFMVC 
were parametric, while for BMD height, body fat%, Lean Mass, GM ACSA, PFMVC, SB% and 
TPAmins were parametric, all other variables were non-parametric. Ambulatory status is 
presented as a characteristic and no statistical analysis was performed on it.  
For repeated measures Paired T-tests and Wilcoxon signed rank tests, for parametric and non-
parametric respectively, were used to identify changes, with a Bonferroni correction. Where 
relevant, comparisons are presented with P values, and the relative change (%) baseline. 
Stepwise Multiple Linear Regression was used to identify the best predictors of PFMVC 
change from GM ACSA Change, LBM Change and Baseline PFMVC. Linear, Quadratic and Cubic 
regressions are used to best model changes in body composition and muscle strength in 
relation to age and changes in TPAmins, with the best fit model presented. 
133 
 
8.4 Results 
8.4.1 12 Month Changes  
Comparisons have only been made between baseline and 12 months data, as differences 
between DMD and BMD were systematically addressed in Chapter 4. Compared to baseline, 
12 month LBM and GM ACSA decreased by -5% (P=0.002) and -8% (P=0.012) respectively, in 
DMD. There was no significant change in GM ACSA or LBM in BMD (P>0.05). In BMD, 
compared to baseline, Body Fat% increased by 4% (P=0.009) after 12 months. One BMD 
participant lost ambulation between baseline and 12 months. No other differences were 
identified between baseline and 12 months for measures of anthropometric, body 
composition or muscle size for DMD or BMD (Table 8.1, P>0.05). 
Compared to baseline, PFMVC and KEMVC decreased in DMD by -19% and -14%, respectively 
(P=0.002; P=0.003). There was no difference in KEMVC or PFMVC compared to baseline in 
BMD. Compared to baseline 10m walk time increased in ambulant BMD by 13% (P=0.005). No 
other differences were identified between baseline and 12 months for any other measures 
(Table 8.1, P<0.05). 
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Table 8.1. 12 Month changes in body composition, muscle size, lower limb strength and 
physical activity 
 DMD BMD 
 Baseline 12-Months %Change Baseline 12-Months %Change 
N 15 12 
Age (years) 24.2 (6.1) 25.2 (6.1) - 44.1 (12.6) 45.1 (12.6) - 
Stature (cm) 
172.0 
(4.3) 
172.0 (4.3) - 178.9 (6.2) 178.9 (6.2) - 
Body Mass 
(Kg) 
73.1 
(14.6) 
71.4 (14.5) -2% 84.4 (15.1) 85.1 (16.4) 0% 
BMI (Kg/m2) 25.5 (4.1) 22.7 (7.5) -11% 26.4 (4.9) 26.6 (5.4) 0% 
Body Fat (%) 33.3 (6.7) 33.0 (7.0) -1% 28.8 (8.8) 29.8 (8.9)* 3% 
LBM (Kg) 47.6 (7.7) 45.0 (6.4)* -5 59.3 (7.8) 58.8 (8.1) -1% 
Ambulatory 0/15 0/15 - 9/12 8/12 - 
GM ACSA 
(cm2) 
23.3 
(16.5) 
21.4 
(16.3)* 
-8% 29.7 (18.4) 26.6 (14.4) -10% 
PFMVC 
(N.m) 
16.7 (6.8) 13.6 (6.3)* -19% 35.7 (11.3) 33.2 (12.2) -7% 
KEMVC 
(N.m) 
12.6 (8.8) 10.8 (7.0)* -14% 97.7 (64.3) 83.9 (56.2) 14% 
SB% 96.4 (4.5) 98.5 2% 83.4 (7.2) 83.9 (6.3) 0% 
TPAmins 
13.5 
(16.1) 
7.17 (8.9) -47% 
123.1 
(57.6) 
120.4 
(50.7) 
-2% 
10m Walk 
(s)† 
- 11.0 (2.9) 12.7 (3.9)* 15% 
Table 8.1. One year changes in MD strength, physical activity and function. DMD = Duchenne 
Muscular Dystrophy; BMD = Beckers Muscular Dystrophy; PFMVC = Plantar-Flexion Maximum 
Voluntary Contraction; KEMVC = Knee Extension maximum Voluntary Contraction; SB% = 
Percentage of waking hours in Sedentary Behaviour; TPAmins = Minutes of Total Physical 
Activity; m = metres; s = seconds; † Ambulant BMD only (n=8); *denotes significant changes 
from baseline. 
8.4.2 Regressions 
Stepwise Multiple Linear Regression identified a model containing baseline PFMVC, GM ACSA 
change and LBM change best predicted PFMVC Change in DMD (R2=0.582, P=0.019). 
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No relationship was identified for DMD using any regression model for age or TPAmins change 
with change in PFMVC, KEMVC, LBM or body fat% (P>0.05). No relationships were identified 
for either DMD or BMD using any regression model for age with change in PFMVC, KEMVC, 
LBM or body fat%, or TPAmins change with change in LBM or body fat % (P>0.05). 
In BMD quadratic polynomial regressions best identified relationships for TPAmins change with 
PFMVC change (R2= 0.585, P=0.019, Figure 8.1A) and KEMVC change (R2= 0.532, P=0.033, 
Figure 8.1B). No relationships were identified DMD using any regression model for TPAmins 
PFMVC change or KEMVC change (P>0.05). 
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Figure 8.1. BMD strength change and physical activity change relationships; A. PFMVC change 
and TPAmins change in BMD; B. KEMVC change and TPAmins change in BMD. PFMVC = Plantar 
Flexion Maximal Voluntary Contraction, N.m = Newton Metres, TPA = Total Physical Activity, 
KEMVC = Knee Extension Maximal Voluntary Contraction. 
8.5 Discussion 
The progression of DMD is well described in children (C. McDonald, R. Abresch, et al., 1995; 
Henricson et al., 2013), while in Chapter 3 cross-sectional muscle strength was presented in 
adults with DMD and BMD; the present chapter however presents longitudinal changes in 
lower limb muscle strength, muscle size and body composition in adults with BMD and DMD. 
A 
B 
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In the present chapter, after 12 months, LBM, GM ACSA, PFMVC and KEMVC decreased in 
DMD, whereas in BMD there was no change in any measure, other than body fat (%) which 
was increased. Although there was no significant decrease in strength within BMD, the 
variance in the 12-month change of PFMVC and KEMVC was attributable to the variance in 
PA change.  
The -14% decline in KEMVC in adults with DMD in the present chapter is consistent with the 
-15% decline previous reported over a similar timeframe in children with DMD (Henricson et 
al., 2013). These declines in KEMVC are in contrast to the -2% and -1.2% reported in non-
ambulant children and adolescents with DMD, respectively (Steffensen et al., 2002; Henricson 
et al., 2013). This discrepancy can be attributed to the greater sensitivity of the methods used 
in the present chapter to quantify changes in KEMVC, rather than subjective measures of 
MMT or MRC% (Hogrel et al., 2007; Cuthbert and Goodheart, 2007). In adults with BMD we 
observed no significant change in KEMVC or PFMVC, likely due to greater variance, however 
the quantified declines of -14% KEMVC and -7% PFMVC remain noteworthy and statistical 
trends of decline were still evident (P<0.1). Previous research has utilised MMT to monitor 
changes in strength over a 10 year period (C. M. McDonald et al., 1995), reporting -1.2% 
annual declines in KEMVC per year. Despite the declines of PFMVC and KEMVC in the present 
BMD participants being higher than those reported previously, the fact that they did not reach 
significance reflects the large variability of the condition progression (C. M. McDonald et al., 
1995).  
Decreases in LBM and GM ACSA in DMD, but not in BMD, appear to be consistent with the 
classical definition of DMD being the more progressive condition (Huml, 2015), and likely 
reflects the greater dystrophin protein defect in DMD compared to BMD (Bello et al., 2016). 
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The non-ambulatory nature and high SB% recognised in this population (Chapter 3) may also 
contribute to the increased progression. The reductions in GM ACSA appear consistent with 
findings that pseudohypertrophy (increased calf size) is primarily a paediatric characteristic 
(Beenakker et al., 2002; Jones et al., 1983), and that muscle size in the calf region decreases 
in adulthood (Morse et al., 2015). This is furthered by the inclusion of GM ACSA, LBM change 
and baseline PFMVC in the multiple linear regression model for change in PFMVC, further 
evidence for the relationships between body composition and muscle function. 
The increase in body fat% in BMD (+4%) in the present chapter after 12 months appears 
consistent with previous research in which the author previously identified excess weight gain 
as an issue in BMD, especially in non-ambulant individuals (Jacques et al., 2017). The relative 
increase in body fat% in BMD compared to DMD may be due to the fact that BMD remain 
relatively functional with a greater level of physical independence (Lue et al., 2009), compared 
DMD (Morse et al., 2018), who require assistance in the preparation and consumption of 
food, therefore BMD may maintain nutritional control, and a possible poor diet. Monitoring 
and management of food intake may be easier and more structured in DMD (Pane et al., 
2006). The stable BM did however, mask changes in body composition with decreased LBM 
decreased in DMD and increased Body Fat% in BMD; reaffirming the need for body 
composition monitoring in these conditions. 
BMD participants that maintained or increased PA levels showed a relative increase or 
maintenance of muscle strength compared to those that decreased PA levels. Increased PA 
has previously been attributed to decelerating fatty infiltration of muscles in FSHD (Ferguson 
et al., 2016). Based on the present relationship between PA and declines in muscle strength, 
it seems reasonable to suggest interventions that increase PA (equivalent to > 1.5 METs) in 
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adults with BMD may benefit muscle strength, and mitigate some of the declines associated 
with the condition. Future work needs to investigate the benefits of increasing PA, and to 
further identify psycho-somatic and/or social barriers and facilitators of PA and patterns of 
SB in this population (Phillips et al., 2009). 
8.6 Conclusion 
In conclusion, the present data describes natural history changes in body composition, 
strength and PA in adults with DMD and BMD. Changes in DMD appear consistent with the 
understanding of the condition, with -14-19% weaker PFMVC and KEMVC, consistent with 
previous research (Mok et al., 2010; Morse et al., 2015; Henricson et al., 2013). Change in 
DMD PFMVC was best explained by changes in LBM, GM ACSA and Baseline PFMVC. Within 
BMD 12 month changes in PFMVC and KEMVC although not significant, were be best 
explained by change in TPAMins. Changes in LBM in DMD and Body Fat% in BMD were both 
masked by non-significant changes in BM, furthering the need for specific monitoring of body 
composition. 
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Chapter 9 
General Discussion 
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9.1 Overview 
As described in Chapter 1, there is extensive literature into the genetics of MD (Angelini, 2013; 
Deconinck and Dan, 2007; Huml, 2015), as well as the health, function and pharmacological 
interventions in children with DMD (Guglieri et al., 2008; Angelini, 2007; C. McDonald, R. 
Abresch, et al., 1995). The understanding of health and function in adults with MD is by 
comparison, poorly reported (Pandya et al., 2018; Kilmer et al., 1995; C. M. McDonald et al., 
1995). The advances in cardiac and respiratory care have improved life expectancy in DMD 
(Eagle et al., 2002) and revealed a lack of descriptive data on the physical function of adults 
with DMD (McDonald and Mercuri, 2018; Rahbek et al., 2005). Similarly, in milder conditions 
such as BMD, LGMD and FSHD, the limited research has typically focussed on ambulant and 
relatively functional participants, which while valuable, does not reflect the large numbers 
that are non-ambulant (Løkken et al., 2016; Skalsky et al., 2008). The present thesis aimed to 
address the following in adults with MD: 
Chapter 4:  To investigate the relationship between muscle strength and size; Establish the 
relationship between muscle size and strength with objective measures of physical activity, 
with implications for the maintenance of muscle function in MD. 
Chapter 5: Compare the self-reported QoL of adults with DMD, BMD, LGMD and FSHD, and a 
non-MD CTRL group; Present and compare between groups measures of Muscle Strength, 
Activities of Daily Living, Fatigue, Pain, Self-Efficacy and BMI; Identify associations between 
QoL domains and Muscle Strength, Activities of Daily Living, Fatigue, Pain, Self-Efficacy and 
BMI. 
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Chapter 6: Compere ROMActive and ROMPassive in adults with MD and CTRL; Compare levels of 
MTU and GM stiffness in adults with MD and CTRL; Identify associations of ROM with 
measures of muscle weakness, stiffness and muscle length. 
Chapter 7: Quantify the acute effect of physiotherapy on 1) Range of Motion Measures, 2) 
Stiffness Properties Associated with the ankle as identified in Chapter 7 and 3) Muscle 
Strength, in adults with DMD.  
Chapter 8: Quantify changes, from a one year follow up, in body composition, muscle 
morphology, muscle strength and physical activity levels in adults with DMF and BMD; Identify 
the impact of changes in physical activity on body composition and muscle strength in adults 
with BMD and DMD. 
9.2 Main Findings 
Progressive muscle weakness and limited ROM are clinical features associated with MD 
(Huml, 2015; Emery, 2002), but have been limited in their presentation in adults with MD, 
with much focus in children with DMD (Brooke et al., 1989; Bakker et al., 2002). These two 
clinical features of MD have been quantified in this thesis, and identified as the main themes 
for discussion, for which their associations and implications are discussed below, with an 
overview presented in Appendix 10.  
This thesis has presented cross-sectional comparisons of lower limb muscle strength in adults 
with MD (Chapter 4), and 12 month changes in lower limb strength in DMD (-14-19%) and 
BMD (Chapter 8). The presented findings appear largely consistent with the previous findings 
from children with DMD (Mathur et al., 2010; Lott et al., 2014; Vohra et al., 2015) and the 
limited reports in adults with BMD, LGMD and FSHD (Skalsky et al., 2008; Løkken et al., 2016). 
The importance of lower limb muscle strength is evident by the respective associations 
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identified with 10m walk time in ambulant adults with MD (Chapter 4), QoL domains of 
Physical Function and Social Function in BMD (Chapter 5), and ROMActive measures consistent 
across adults with MD (Chapter 6).  
 Where the work in this thesis is particularly novel, is that PA, measured over 7 days with an 
accelerometer, and could explain variance in muscle weakness in both the cross-sectional 
presentation (Chapter 4) and longitudinal changes, in adults with BMD (Chapter 8). In 
addition, while functional performance of 10m walk could be predicted by lower limb 
strength, PA was the best predictor of 10m walk time in ambulant adults with MD (Chapter 
4). These findings suggest that PA is important for maintaining muscle function in adults with 
MD, consistent with the recommendations from MDUK (2014). Furthermore, the increased 
SB presented in this thesis, in addition with increased body fat % reported in adults with MD, 
and negative associations between BMI and domains of QoL, has further raised concerns of 
negative implications of SB on physical and mental health and wellbeing in adults with MD 
(Chapter 4 and 5). 
Progressive muscle weakness is a defining clinical feature of MD (Huml, 2015) and has 
previously been associated with QoL in children with DMD (McDonald et al., 2010), however, 
prior to this thesis muscle weakness had not been associated with measures of QoL in adults 
with MD. Within adults with MD, despite KEMVC being associated with the performance of 
functional tasks (10m walk time) in ambulant adults with MD in Chapter 4 and reported 
previously in adults with BMD (Alfano et al., 2013), in Chapter 5 KEMVC was only associated 
with the Physical Function and Social Function domains of QoL in BMD. By comparison, the 
Physical Function domain was associated with ADL in DMD, BMD and FSHD, suggesting 
independence and ownership of activities is of greater importance to adults with MD, possibly 
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due to the high proportion of non-ambulant adults with MD in this thesis (Chapter 3). 
Furthermore, while muscle weakness had limited associations with domains of QoL, BMI 
(LGMD), Pain (BMD and FSHD) and Self-Efficacy (DMD) were all consistent associates of QoL 
domains, while Fatigue (DMD, BMD and FSHD) was the most consistent associate of QoL 
(Chapter 5). These findings suggest a shift in focus is required in adults with MD, particularly 
given the largely non-ambulant sample in the present thesis, from impairment to perceptions, 
to improve QoL. 
Ankle ROMPassive in Chapter 6 appears consistent with that previously reported in adults with 
MD (Johnson et al., 1992), where this thesis is novel is in the presentation of ROMPassive in 
adults with DMD, and the quantification of ROMActive in adults with DMD, BMD, LGMD and 
FSHD. Adults with DMD are extremely limited in their ROMPassive, with evidenced equinus 
deformity, while adults with BMD, LGMD and FSHD all appear relatively comparable across 
ROM measures, however, limited DFActive is the most prominent finding, despite relatively 
maintained DFPassive. The limitations identified in DFActive have raised concerns of potential 
increased fall risk (Menz et al., 2006). In addition, Chapter 6 identified possible contributing 
factors of limited ankle ROM, with PFMVC associated with ROMActive, while GM stiffness and 
MTU stiffness were associated with limited ROMPassive, however the mild associations 
evidenced suggest it is a combination of factors that limit ROM in adults with MD. 
Physiotherapy however, appears to be an effective method to acutely increase ROMPassive in 
adults with DMD (Chapter 7). Chapter 7 showed no negative effects were identified from 
physiotherapy on ROMActive or PFMVC, however decreases in MTU Stiffness were identified, 
and attributed for the increase in ROMPassive. 
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9.3 Clinical Implications 
Progressive muscle weakness is arguably the most prominent clinical feature of MD (Emery, 
2002; Huml, 2015). This thesis has identified that the variance in progressive muscle 
weakness, and in particular functional measures, in ambulant adults with MD has been shown 
to be partly explainable PA (Chapter 4). In addition, the longitudinal changes in muscle 
strength in BMD were also explainable in changes of PA (Chapter 8). Maintenance of muscle 
strength in MD appears important in ambulant adults with MD: In BMD, KEMVC was 
associated with domains of QoL (Chapter 5), while PFMVC was associated consistently across 
MD with ROMActive (Chapter 6). Maintenance of lower limb muscle strength may help to 
maintain ambulation, and reduce the possible fall risk associated with lower muscle strength 
and limited DFActive (Campbell et al., 1989). Furthermore, in adults with LGMD, BMI was a 
consistent associate of QoL (Chapter 5), therefore methods to reduce body fat (Tremblay et 
al., 1990; Tremblay et al., 2010), such as PA, would likely improve BMI and may improve QoL. 
Therefore, this thesis provides support, consistent with MDUK (Campaign, 2014), for the 
encouragement of PA when possible, particularly in ambulant adults with MD in order to 
maintain lower limb function and health. 
In non-ambulant adults with MD, adults with DMD showed a negative association between 
SB% and LBM (Chapter 4), suggesting any method of physical movement, and interrupting 
prolonged bouts of SB, is important for this population. This builds on previous work from 
Jansen et al. (2013), who showed maintenance of function through assisted exercise 
protocols, and suggests similar methods of assisted arm ergometry and passive exercise could 
prove important to maintain LBM in adults with DMD. Beyond physical function, Chapter 5 
suggests a shift in focus is required in non-ambulant adults with MD, and adults with DMD in 
particular, from physical function to measures of perception. For example, in adults with DMD 
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no associations with QoL were identified using KEMVC, however ADLs were associated with 
domains of QoL, suggesting independence and ownership of activities and social behaviours, 
such as being able to use a phone, becomes much more important. Furthermore, 
identification of pain and fatigue as consistent measures associated with QoL (Chapter 5), 
across MD, but likely influenced by the largely non-ambulatory nature of the sample in this 
thesis, furthers this suggested shift in focus, and that pain and fatigue should be consistently 
monitored, and a focus of condition progression. Potential interventions that are known to 
reduce pain and fatigue in other clinical conditions include acupuncture (Vickers et al., 2012), 
physiotherapy (Jansen et al., 2011; Smart et al., 2016), and where possible, PA (as has been 
applied in FSHD (Voet et al., 2014)) may be applied in adults with MD and could possibly 
improve QoL. While unlikely to impact a non-ambulant individual with MDs QoL, evidence in 
Chapter 6 also suggests physiotherapy is an effective measure to acutely improve the clinical 
feature of limited ROMPassive in adults with DMD. Although speculative, the effectiveness of 
physiotherapy measured in Chapter 6 suggests physiotherapy should be encouraged regularly 
in adults with MD, as a method of ROM maintenance in non-ambulant individuals, and as a 
method of maintaining ankle properties for ambulation in ambulant individuals with MD. 
9.4 Limitations 
A wide range of techniques have previously been used to describe muscle strength, body 
composition and muscle size in clinical populations (Martone et al., 2017; Blauwhoff‐
Buskermolen et al., 2017; Yang et al., 2017). Limitations of previous methods used for muscle 
strength assessment have been systematically described in Chapter 2, however in brief; the 
most stringent methods of strength assessment are limited to the most functional 
participants, while the least stringent (MMT and MRC%) which are commonly used, to assess 
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the most physically impaired, lack objectivity and sensitivity (Cuthbert and Goodheart, 2007; 
Escolar et al., 2001; Løkken et al., 2016). By comparison, the methods of QMT in the present 
thesis are shown to be reliable within MD (Chapter 1: PFMVC - Between day ICC 0.832-.984, 
Within day ICC 0.911-.985; KEMVC – Between day ICC 0.956-.991, Within day ICC 0.973-.992). 
In addition, the coefficient of variation of the CTRL KEMVC was 34%, which is comparative 
with the normative database for quantitative muscle testing ((Hogrel et al., 2007); n = 122, 
CV = 29%, mean difference = 4.3 N.m).  
Similarly, BIA is necessary as an alternative to more stringent measures of body composition 
in MD where mobility is limited (Mok et al., 2010). BIA has been used extensively in sarcopenia 
research (Makizako et al., 2017; Heber et al., 1996) and shown as valid in obese and 
underweight individuals (Pateyjohns et al., 2006; Sun et al., 2005; Lupoli et al., 2004), a degree 
of error is however likely to be introduced within MD given the fat infiltration of muscle tissue 
(Sun et al., 2005). Based on previous validity data, BIA would underestimate the body fat 
percentage (BF%) in the present overweight MD participants and underestimate BF% in 
normal weight CTRL participants (Sun et al., 2005). When corrected, based on the values in 
Chapter 4, previously established, BF% would be 18% in CTRL (measured = 18.2%), and 33.8% 
in MD (measured = 30.8%). Therefore, despite the error associated with comparing BF% when 
using BIA, there is no meaningful impact on the conclusions drawn from the presented results. 
Similarly, the use of ultrasound for assessment of ACSA, although consistent with those 
previously reported, is likely to be overestimated in those individuals with high levels of 
muscle fat fraction (FF%)(Løkken et al., 2016). Based on the work of Løkken et al. (2016), the 
actual GM contractile area of ambulant BMD participants is ~23% less than the measured 
ACSA, in contrast the GM contractile area of the CTRL is 11% less than the measured ACSA. 
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Based on this estimated value the contractile area in ambulant BMD (n= 10) is 15.7 cm2 and 
CTRL is 13.0 cm2 in the present study, consistent with the comparisons made by (Løkken et 
al., 2016). It is therefore likely that the present GM ACSA is higher in the MD participants due 
to the presence of pseudohypertrophy (Jones et al., 1983). Future work is required to 
determine whether the measurement of muscle area is meaningful within adults with MD as 
it may not reflect any functional measure due to the level of non-contractile material 
contained within the muscle compartment (as observed within the lack of correlation 
between ACSA and strength in the present study, and previously by Løkken et al. (2016)). 
Although there are shortcomings to some methodologies used in this thesis, the use of 
transportable and adaptable equipment has allowed for 60 adults with MD encompassing a 
wide range of functional ability to be assessed. Up to 60% of MD participants in this thesis 
would have been unable to participate had DEXA or MRI been used for body composition and 
non-contractile muscle percentage, commonly referred to as FF%, assessment. The present 
authors suggest the use of adaptable equipment to encompass wide functional ranges in 
future studies, with the use of methods such as MRI to assess muscle FF% in sample subsets 
when possible and practical. 
As stated consistently throughout this thesis, and above, all testing was designed for the most 
severely impaired (adults with DMD), and then replicated on more functional and less 
impaired participants for consistency and to allow comparisons. The GM however, studied in 
the thesis, is bi-articular and therefore is influenced by the joint angle of both the knee and 
ankle (van Ingen Schenau et al., 1987). The use of a seated position for testing in this thesis, 
consistent with the body position of adults with DMD in power wheelchairs, with hip and knee 
angles at 90°, will predispose the GM to a shortened position (Maïsetti et al., 2012; Gao et al., 
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2009). This long-term seated position, and its predisposition of a shortened LGM, has been 
attributed to the shortening of LGM noted in adults with DMD (Spector et al., 1982; Morse et 
al., 2015). This shortened LGM, likely alters the length-tension relation of the non-ambulatory 
MD participants, compared to those who are ambulatory. For consistency, PFMVC should be 
measured at optimum angles in all participants given the shift in ROM observed in Chapter 6. 
The implications for the data presented here are likely minimal, as the actual force produced 
in the most severely affected, non-ambulatory participants was negligible, and measurement 
of PFMVC at optimum angle would accentuate differences between the most-to-least 
impaired. In addition, the ROM of the ambulatory participants were similar, meaning that the 
PFMVC measured at 90°, would reflect the same region of their ankle force-length relation. 
Chapter 7 was unable to use a CTRL comparison of no intervention, as it was deemed 
unethical to remove or reduce care for participants (Johnson et al., 1992). Therefore, the use 
of MDC was used in adjunction with statistical analysis to determine changes in ankle ROM 
and muscle properties (Hoch et al., 2012; Ries et al., 2009; Steffen and Seney, 2008; Fulk and 
Echternach, 2008). Participants of BMD, LGMD and FSHD were excluded from this chapter 
and analysis as their comparatively increased lower limb muscle strength, and some 
participants’ maintained ambulation, could increase the SEM of assessments techniques, 
therefore increasing MDC. By comparison, the lower limbs of adults with DMD are severely 
impaired, and all participants are long-term wheelchair users; therefore, there is likely no 
internal or external influences on the relevant variables. 
9.5 Future Research 
This thesis has presented data in adults with MD broadly, adults with DMD specifically have 
been identified as a population for being under-reported (McDonald and Mercuri, 2018). 
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Further research is required to understand and document the health and implications within 
this population (Pandya et al., 2018). Collaborations are required between research 
institutions and clinicians to improve the understanding and care for this population 
(Birnkrant et al., 2018). 
This thesis has identified limited PA in adults with MD, and presented implications on health 
and function, future research needs to build on these findings to identify methods of 
improving and facilitating PA (Chapter 4). The identified cross sectional relationships between 
muscle strength and PA in ambulant adults with MD, and PA influencing the progression of 
muscle weakness in BMD, identified in Chapter 4, suggests PA is a viable method to maintain 
physical function. Future research is required to identify dose-response relationships and 
implications on condition progression (Ferguson et al., 2016), SB behaviours, barriers to PA, 
and impacts of PA interventions on health, such as body fat%. Furthermore, BMI was 
associated with QoL in LGMD, therefore in conjunction with PA, greater nutritional 
management systems are required to reduce weight gain following loss of ambulation. 
Beyond the implications of PA on physical health, PA has previously been shown to reduce 
perceived fatigue in adults with FSHD (Voet et al., 2014), future work is required to identify 
other methods of alleviating fatigue, but also other associates of QoL identified in the present 
thesis (Chapter 5). This thesis has shown pain to be consistently reported in adults with MD, 
however evidence of effective interventions to reduce pain in MD remains limited. 
Physiotherapy and acupuncture are two proposed methods (Morís et al., 2017; Urtizberea et 
al., 2003), and have been shown effective in other conditions (Vickers et al., 2012), however 
their effectiveness for reducing pain remains unreported in MD.  
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ROM assessment for BMD, LGMD and FSHD evidenced limited DFActive, even when DFPassive was 
relatively maintained. The limited DFActive raises concerns of increased fall risk (Menz et al., 
2006). Future research is required to identify methods to maintain and improve functionality 
of DF in adults with MD, but also the implications on fall risk in these populations. A 
comprehensive battery of functional measures on reported falls and balance would help to 
determine effective future interventions. 
9.6 Conclusions 
This thesis has provided a wide range of health and function data in adults with MD. In 
particular, this thesis has expanded understanding of muscle strength in adults with MD, with 
what appears to be the first quantified measures of lower limb muscle strength in adults with 
DMD, as well as the first CTRL compared PFMVC in adults with FSHD, and KEMVC in adults 
with BMD and LGMD, respectively. The presentation, association and progression of lower 
limb muscle strength measures have been made in respective chapters.  
This thesis should aid clinicians and researchers working as a reference point of function and 
health in adults with MD, from cross-sectional understanding of strength, body composition 
and PA, to the progression and implications of these measures. Similarly, this thesis has 
provided evidence for focussed future interventions, identifying methods to improve PA in 
adults with MD, reduce pain and fatigue while maintaining independence to improve QoL; 
while also presenting physiotherapy as an effective acute method to improve ankle ROMPassive 
in adults with DMD.  
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Appendix 2 – Control Recruitment Poster 
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Appendix 3 – Participant Consent Form 
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Appendix 4 – SF-36v2
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Appendix 5 – Nottingham Extended Activities of Daily Living
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Appendix 6 – Checklist Individual Strength 
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Appendix 7 – Pain Visual Analog Scale 
 
Appendix 8 – General Self Efficacy Scale 
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Appendix 9 – SF-36 Walk-Wheel 
 
Appendix 10 – Overview of Thesis Findings 
 
Overview of Thesis findings presented with the main themes of impaired muscle strength and 
range of motion. SB% = Percentage of waking hours in sedentary behaviour, PA = Physical 
Activity, KEMVC = Knee extension maximal voluntary contraction, PFMVC = Plantar-flexion 
maximal voluntary contraction, QoL = Quality of Life, ROM = Range of Motion, ROMPassive = 
Passive range of motion, ROMActive = Active range of motion, DFPassive = Passive dorsi-flexion, 
DMD = Duchenne muscular dystrophy, BMD = Becker’s muscular dystrophy, LGMD = Limb-
girdle muscular dystrophy, FSHD = Facioscapulohumeral muscular dystrophy. ROM 
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presentation is consistent with that presented in Figure 3.2: Superior black dotted line (     ) = 
DFPassive; Inferior black dotted line (       ) = PFPassive; Superior grey dotted line (    ) = DFActive; 
Inferior grey dotted line (      ) – PFPassive; Black solid line (      ) = Resting Angle. In Brief MTU 
Morphology: Filled black rectangle (     ) = Tibia; Unfilled black rectangle (      ) = Achilles tendon; 
Striated half-moon (                       ) = Gastrocnemius medialis.  
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